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ABSTRACT OF DISSERTATION

THE ROLE OF BATF2 IN LPS/IFNγ POLARIZED MACROPHAGES
Transcription factors regulate distinct macrophage functions by regulating gene
expression in response to micro-environmental cues. This functional plasticity is critical
for regulating innate and adaptive immune responses during infection and during chronic
disease processes including inflammatory diseases and cancer. Microarray analysis of
macrophages polarized to a pro-inflammatory (M1) phenotype with LPS and IFNγ revealed
that basic leucine zipper transcription factor ATF-like 2 (Batf2), a member of the AP1
transcription factors, is selectively upregulated in M1 macrophages compared to antiinflammatory IL-4-polarized (M2) macrophages. The initial hypothesis was that Batf2 is
a master regulator of gene expression that orchestrates M1 polarization. To investigate a
potential role of Batf2 during macrophage polarization, its expression in M1 polarized
macrophages was examined. Batf2 mRNA appears within 60 minutes following LPS/ IFNγ
treatment and is sustained for at least 48 hours. To address the hypothesis that Batf2 acts
as a master transcriptional factor driving a functional M1 phenotype, we have established
macrophage cell lines that constitutively express Batf2. Batf2 overexpression did not
enhance key M1-associated genes, including iNOS and H2-Aa, but did enhance LPS/IFNγdriven Cxcl10. Batf2 overexpression also failed to suppress key M2-associated genes
including Fizz1 and Mrc1. Batf2 overexpression also failed to alter multiple nonimmunity-related genes established or predicted to be downstream of Batf2 in macrophages
or other cells. Overall, contrary to our initial hypothesis, constitutive Batf2 expression by
itself does not appear to broadly induce M1 gene expression; rather, it appears to enhance
only select genes. Since other Batf family members interact with members of the IRF
family, I discuss the possibility that Batf2 works in conjunction with a limiting cofactor,
possibly Irf family members and/or other regulatory proteins.
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Chapter I
INTRODUCTION
1.1.

Purpose
This study aims to examine the function of the transcription factor basic leucine

zipper transcription factor, ATF-like 2 (Batf2) in the context of macrophage polarization.
Master transcription factors commonly control transcriptional repertoires during
development and polarization, and such a factor or even the major factors for macrophage
polarization to the LPS/IFNγ activated macrophages (herein termed M1 macrophages)
remains unclear. Batf2, a member of the Batf subset of AP-1 transcription factors
involved in polarizing immune cells, was proposed as a master transcription factor for
macrophage polarization. A series of studies were designed and carried out to
demonstrate a role for Batf2 as master regulator. However, we found that Batf2 by itself
did not induce M1 polarization.

1.2.

Importance
Immune function plays a major role in the health of an individual. Appropriate

inflammatory responses kill pathogens and tumor cells. Inappropriate inflammation, or
lack of inflammation, contributes to many diseases including sepsis, atherosclerosis,
meningitis, cancer, AIDS, etc. For this reason, we seek to understand and control the
inflammatory processes: first, to understand which responses are appropriate in which
situation; second, to initiate these responses at the correct time or dampen them when
they are detrimental. This project focuses on the first goal by identifying transcription
factors regulating multiple genes during M1 polarization of macrophages.
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Although such transcription factors have been discovered for other cells, the study
of macrophages has been complicated by their plasticity and sensitivity. Macrophages
express polarization-associated genes in response to a large variety of common
endogenous stimuli, mechanical stresses, and media components such as cholesterol, etc.
Moreover, primary macrophage responses may be skewed by epigenetic programming in
vivo. Prior studies have uncovered several transcription factors, but until recently no
factor that acts similarly to master transcription factors in other cell types. This study
makes use of a reductionist, highly controllable model to study gene expression control.
We use a macrophage cell line isolated in an early myeloid precursor stage, genetically
engineered to differentiate in vitro in response to a non-polarizing stimulus. Thus, we can
detect gene changes upregulated or downregulated in the inflammatory state more clearly
than other systems due to the minimal M1/M2 polarization in the resting state.

1.3.

Results and analysis
In the context of the PUER macrophage cell system, we describe a recently

discovered M1-associated transcription factor, Batf2. Batf2 belongs to the AP-1 group of
bZIP transcription factors, and it was recently discovered that knockdown of Batf2 alters
a variety of M1-assicated genes1. Contrary to expectations, we demonstrate that
constitutive high expression of Batf2 alone in PUER cells did not induce most of the
hallmark M1-associated genes or suppress most of the hallmark M2-associated genes, nor
did it induce or suppress non-immune genes downstream of Batf2 or closely related Batf
and Batf3 in other cells. However, it did appear to enhance LPS/IFNγ-induced
expression of the M1-associated chemokine Cxcl10 and suppress expression the IL-4-

2

induced M2-associated enzyme Arg1. We further begin to explore the mechanisms of
Batf2 activity by analyzing potentially limiting binding partners and cofactors and the
genes they control. Binding partners required for Batf2 activity are present in PUER
cells but not associated with polarization. On the other hand, potential cofactor Irfs, are
expressed in M1-polarized cells and may be required for Batf2 activity.
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Chapter II
BACKGROUND
2.1.

Macrophages: Non-specific cells of the immune system with diverse function
2.1.1. Macrophages
Transcription factors serve a critical role in dictating macrophage differentiation

from a myeloid precursor, as well as functional polarization and activation of monocytes
and macrophages2. Macrophages arise from a precursor for all immune cells of myeloid
lineage3. This highly heterogeneous group plays critical roles in non-specific defense and
assists the adaptive defense against a variety of pathogens. It fulfills many homeostatic
functions such as tissue repair, muscle regeneration, and iron transport3. These cells arise
from a common myeloid progenitor, as opposed to the other lymphocytes that arise from
a common lymphoid progenitor. This common myeloid progenitor differentiates, under
the guidance of the key transcription factors that shape the chromatin landscape and
initiate transcription of lineage-specific proteins, into macrophages and their cerebral
counterpart microglia, dendritic cells, neutrophils, eosinophils, and basophils, and the
more distantly related mast cells, megakaryocytes, and erythrocytes2.
Macrophages play critical roles initiating and resolving infection-induced or
sterile inflammation as well as maintaining tissue homeostasis. Here transcription factors
also guide the translation of environmental cues into cellular activity2. Appropriate
activation of transcription factors by signaling pathways orchestrates an appropriate
response, such as generation of reactive oxygen species to damage an invading pathogen.
Inappropriate activation of these pathways, however, can lead to the generation of
detrimental responses, such as the generation of tissue-damaging inflammation in the

4

absence of infection in chronic inflammatory diseases4,5. Preventing and manipulating
such inappropriate responses requires an understanding of the signaling pathways and
transcription factors involved in each response. Therefore, we are investigating key
transcription factors for specific macrophage functions.

2.1.2. Transcription factors integrate environmental cues during macrophage
development
Each step in commitment to a lineage and thus to a function is under the control
of a specific combination of chromatin remodeling and transcription factors6. The first
stages of differentiation from a common stem cell occur during embryogenesis.
Microglial and some resident tissue macrophages, notable for their self-renewal capacity,
arise from the yolk sac hematopoietic stem cell (HSC) population78. Some HSCs,
destined to become microglia, migrate to the brain region. Transcription factors direct
microglia-specific marker expression around embryonic day 9 in mice78. Others migrate
to various tissues of the embryo and become tissue macrophages residing long-term in
the liver (Kupffer cells), kidney, spleen, lung, and skin (Langerhans cells). A second
wave of myeloid cells develops later in the fetal liver from HSCs. This HSC pool
differentiates into a common myeloid precursor, then macrophage and dendritic cell
progenitor, then monocytic cell, then fully differentiated macrophage cells3,8. These fetal
liver derived macrophages have two distinct types: those bound to be resident
homeostatic tissue macrophages similar to the yolk-sac derived microglia and tissue
macrophages, and those bound for immune-related activities such as fighting infection or
healing wounds (“inflammatory” macrophages)3,8.
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In spite of the differences in environment and origin, these macrophage
populations share some similar transcription factor requirements guiding their
development. Some of the unique factors required for macrophage and microglial
development have been defined. Early stages of differentiation require Runt-related
transcription factor 1 (Runx1) and high levels of PU.18,9. PU.1 and Runx1 recruit factors
that modify histones and DNA, beginning to shape the epigenetic landscape so that
available genes are hematopoietic cell specific10,11. Interferon regulatory factor 8 (Irf8)
activity is required as well as PU.1 and Runx1 for the development of macrophages and
microglia, likely in part as a cofactor with PU.17. More recently, transcription factor EC
3 (Tcef3), CCAAT/enhancer binding protein-alpha (C/EBP-alpha), BTB and CNC
homology 1 (Bach1), and cellular repressor of E1A-stimulated genes 1 (Creg-1) have
been associated with macrophage core gene expression, although their importance for
polarization requires further investigation12. However, there may also be differences
between the development of yolk sac and fetal liver populations and differences in
transcription factors required for macrophage types within these two lineages. Only
peritoneal macrophages, for example, expressed high levels of transcription factor GATA
binding protein 6 (GATA6) compared to splenic or lung macrophages or microglia in a
murine transcriptome analysis12,13.
Each macrophage subset likely responds in a unique manner to the environment in
which it develops and expresses a unique signature of transcription factors, resulting in
the wide variety of phenotypes in resting macrophages. Differentiation to these various
tissue associated macrophages has been extensively studied and has been reviewed by
Gautier et al. and Okabe and Medzhitov12,13. In summary, microglia and macrophages

6

share similar developmental pathways guided by transcription factors including PU.1,
Runx1, and Irf8.

2.1.3. Polarization of macrophages
After development, transcription factor-guided polarization allows resting
macrophage cells to respond uniquely to environmental cytokines. Often, this is
accomplished through a few “master” transcription factors2,14. These transcription factors
were first described as factors sufficient for determining cell type. T cells provide well
described examples of immune cells controlled by master transcription factors. Tbet
transduction drives helper T cell type 1 (Th1) cell differentiation, forkhead Box P3
(Foxp3) drives regulatory T cell (Treg) development, B cell CLL/lymphoma 6 (Bcl6)
drives follicular helper T cell (Tfh) differentiation, GATA3 drives helper T cell type 2
(Th2) differentiation, and RORγt (encoded by RAR-related orphan receptor C gene
[Rorc]) drives Helper T cell type 17 (Th17) differentiation14–20. These master
transcription factors accomplish this by driving expression of key lineage- and functionspecific genes and other transcription factors, thus controlling a specific transcriptional
program of multiple effector proteins. For example, as reviewed in Lazarevic et al., Tbet
induces interleukin 12 (IL-12) receptor beta 2 (IL-12RB2), Runx3, chemokine (C-X-C
motif) receptor 3 (Cxcr3), H2.0-like homeobox (Hlx), CC chemokine ligand 3 Ccl3,
Ccl4, and IFNγ, and suppresses Rorc, IL-17A, IL-4, IL5, and IL-1321. Master
transcription factors for macrophage polarization remain unclear, however, and this study
contributes to current work on this topic.
Initially, macrophage function consisted of two categories: “classically activated”
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(M1) or “alternatively activated” (M2)22. Bacterial cell wall component
lipopolysaccharide (LPS) and cytokine interferon gamma (IFNγ) induce polarization to
the “classically activated/inflammatory/M1” phenotype, promoting inflammation and
infection clearance through production of Th1-associated responses, such as production
of chemokine (C-X-C motif) ligand 10 (Cxcl10)23,24. In contrast, IL-4 induced an
“alternative/M2” phenotype associated with Th2 responses and suppression of
inflammatory responses, such as shunting L-arginine from nitric oxide (NO) production
to ornithine and urea production by increased Arginase 1 (Arg1). These two
classifications and the correlating gene expression, discussed below, are shown in Figure
2.1, page 46. Over time, however, more sensitive studies have continued to push the
model of macrophage polarization away from this binary model and towards a spectrum
of responses, even switching polarization states8,22,25. Still, four broad classifications
have emerged that prove useful for simplification of discussion of macrophage
polarization: M1 (classically activated or LPS/IFNγ activated), three alternative subsets
M2a, M2b, and M2c, and the M2d/tumor associated macrophages (TAMs) 26.
Predominantly, LPS and/or IFNγ remain representative stimuli for inducing the
M1, classically activated, phenotype, so named to correspond to the IFNγ-centered Th1 T
cell response23. IL-1β, tumor necrosis factor alpha (TNFα), and IFNs also influence M1
macrophage polarization. LPS (through its receptor toll-like receptor 4 [TLR4]), IFNγ,
IL-1β, and TNFα activate major adaptor protein MyD88 in the main mechanism of signal
transduction. This adaptor in turn signals through inhibitor of kappa light polypeptide
gene enhancer in B cells (IKKB) and mitogen activated protein kinase (MAPK) pathways
to activate transcription factors nuclear factor kappa B (NF-κB) and Activator Protein 1
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(AP-1), leading to expression of specific effector genes27. IFNs influence gene
expression through Janus activated kinase/signal transducer and activator of transcription
(JAK/Stat) pathways. Complete polarization is much more complex than simply
activating Stat, however. Transcription factors induced by M1-polarizing stimuli
important for inflammatory gene expression include Stat1, Stat2, NF-κB, AP-1, Irf3, Irf5
and HIF-1α (Figure 2.1)2,8,12,28. These each control multiple genes, but a unique 'master
transcription factor' that governs polarization such as exists in other immune cells
remains unclear2,8. Some studies have suggested Irf5 for this role, but recent evidence
suggests that Batf2 and Irf1 may also broadly induce gene M1-associated gene expression
in macrophages1. Mediated by genes induced by these transcription factors, M1polarized macrophages participate in pathogen phagocytosis and pathogen destruction via
iron restriction, phagosome acidification, nitric oxide production, and reactive oxygen
species release, as well as releasing inflammatory cytokines such as IFNs, IL-12, IL-1β,
and Cxcl10 to recruit and activate other inflammatory cells. Most macrophage studies
agree on the characteristic M1-polarized macrophage markers and functions, which are
described in several recent reviews2,8,22. In addition to the functions driven by the M1
transcriptional program, it also suppresses gene expression of alternative functions such
as regulatory T cell recruitment and IL-10 secretion. All of these genes contains multiple
transcription factor binding sites. Therefore, the various stimuli can have additive or
synergistic effects, and opposing stimuli can attenuate expression. This allows a finetuning of the macrophage role in an inflammatory response, critical for avoiding an
insufficiently weak or overly destructive response or for different environments.
In contrast to the M1 macrophages, the phenotypes of M2 macrophages range
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widely enough to require multiple subsets to simplify discussion. To complicate the
discussion, reviews from different authors rarely completely agree on M2 markers and
phenotype. All M2 subsets tend to overlap in transcriptional repertoires, however, and all
exert immunosuppressive activity when they affect the immune response. Mantovani et
al. described the most commonly used classification schemes, defining M2a, M2b, and
M2c subsets which reflect phenotypes alternatively activated macrophages, defined by
polarizing cytokines26. The “M2a” subset, IL-4/IL13 activated, associates with Th2
cytokines and provides the best contrast to the M1 macrophages. IL-4/IL13 activation is
most often used when comparing classical and alternative activation, with IL-10
providing another common alternative stimulus29. IL-4 and IL-10 elicit many of the same
responses, but also have some differences; IL-4 stimulates the IL-4 receptor and activates
both Stat3 and Stat6, while IL-10 stimulates the IL-10 receptor and activates Stat326,30–33.
IL-4 induces IL-10, while IL-10 induces Fc fragment of IgE, low affinity II (FcR/Fcer2),
and both induce mannose receptor C (Mrc1) and a key M2 enzyme Arg1. Importantly for
our study, IL-10 also induces Batf2 (discussed in section 4.2 page 76). Genes strongly
correlating with IL-4/IL13-activated M2a phenotype include Arg1, Ym1, Mrc1,
transglutaminase (Tgm2) and Fizz126. They counter the effects of M1 macrophages and
play a role in protection against parasites, Th2 cell recruitment, tissue repair, and growth
stimulation. Cytokines secreted by these cells include IL-10, TGF-β, and IL-1 receptor
antagonist (IL-1RA)22. The Arg1 enzyme, a key M2 marker, provides important antiparasitic, anti-inflammatory, and wound-repair function (described below). It is not
unique to IL-4-polarized macrophages, since it is also induced by IL-10 and active in the
M2b subset.
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Other subset classifications may be used depending on the purpose of a given
study, and designations differ between research groups. The subset designated M2b,
activated by immune complexes (ICs), LPS, and viral long terminal repeats (LTR)/IL1R,
parallels a memory immune response with B cell class switching and regulatory T cell
recruitment. This subset produces high amounts of IL-10 and expresses major
histocompatibility complex II (MHCII) and CD8634,35. The subset designated M2c,
activated by IL-10, TGF-β, and glucocorticoids, serves as scavengers for cell debris and
serves roles in the healing process. These express Arg1 like the M2a subset, but also
CD163 and CD20626. Finally, another subset designated M2d but more commonly called
tumor associated macrophages (TAMs) has been found in the context of tumors. This
phenotype can be induced with IL-6, leukocyte inhibitory factor (LIF), and monocytecolony stimulating factor (M-CSF). These produce some inflammatory and antiinflammatory cytokines and chemokines, as well as vascular endothelial growth factor,
and aid in tumor growth.
In summary, macrophages polarize to multiple functional states in response to
various stimuli. These states include a Th1-cytokine-associated M1 state, a Th2associted “M2a” state, and a variety of alternative M2 states functioning in wound repair,
tissue homeostasis, tumor growth, and more. Based on control of functional states in
other cells, it is reasonable to expect macrophages to be guided by master transcription
factors governing broad gene expression. The master transcription factors for M1
polarization are unclear. The purpose of this study is to determine the function of one
candidate for a master transcription factor, Batf2, and to identify Batf2-controlled M1associated genes.
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2.1.4. M1-associated gene Cxcl10
One of the genes influenced by the M1-associated transcription factor Batf2 is
Cxcl10, previously known as interferon-inducible protein 10 (IP-10) or Crg-2 (cytokine
responsive gene 2). Cxcl10 belongs to the small, inducible, secreted protein family
classified as chemokines36. These proteins share structural and functional similarities:
similar secondary structure with four similarly spaced cysteines, and the ability to attract
other cells to the origin of chemokine production. “CXC” chemokines belong to the
subfamily of chemokines characterized by having cys-x-cys as the first two cysteines22.
Other subfamilies include CC, C, and CX3C36. Chemokines may promote inflammation,
homeostasis, or both22. Cxcl10 is typically induced by pro-inflammatory stimuli37–40. In
our study, Batf2 enhances Cxcl10 message induction, as demonstrated in Chapter 4 (see
Figure 4.14) and discussed in Chapter 5 (see section 5.3).
Various stimuli generated during a pro-inflammatory state including IFNs, LPS,
and TNFα with IFNγ rapidly stimulate Cxcl10 production from a variety of cells
including macrophages, keratinocytes, fibroblasts, endothelial cells , mesangial cells,
astrocytes, monocytes and neutrophils41–44. Indeed, the Cxcl10 promoter region contains
sites for Irf1 (activated by interferon, IL6, leukemia inhibitory factor (LIF) or TLR
signaling), Stat1 (activated by IFNβ or IFNγ), NF-κB (activated by TNFα, TLR ligands,
or IL1), and AP-1 sites27,37,42,45–47. The importance of AP-1 in Cxcl10 induction remains
unclear. Mutating the AP-1 site did not impact TNF-induced Cxcl10 in human airway
smooth muscle cells, but decreased HCV infection-induced Cxcl10 in a separate study in
human hepatoma cells38,39. In mice, deficiency of AP-1 inhibitory subunit JunB
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decreased Cxcl1048. In contrast, expression is inhibited by Stat3 (activated by IL-1049.
As a general rule, pro-inflammatory stimuli upregulate Cxcl10 expression in
macrophages.
Cells responsive to Cxcl10 through the receptor CXCR3 are mainly polarized Th1
cells and natural killer (NK) cells but also macrophages, microglia, and dendritic cells
(reviewed in Mantovani et al. and Liu et al.)22,50. These cells have cytotoxic activity to
kill infected cells, or can produce inflammatory cytokines and chemokines to propagate
an immune response. Unlike other CXC chemokines, Cxcl10 does not activate
neutrophils22,50. Activation by Cxcl10 stimulates cells to migrate up the concentration
gradient to the area of its origin. Once arrived, the recruited cells exert their protective
functions such as resistance to intracellular pathogens and tumor cells51. In a typical
scenario, IFNs from an infected cell may stimulate macrophages in the surrounding area
to produce Cxcl10 that attracts Th1 and NK cells. These have the ability to destroy the
infected cell and halt the viral production in that cell.
Besides chemotaxis, Cxcl10 has less well-characterized functions in immune and
non-immune cells. Thymic or splenic Cxcl10 may play a role in T cell development and
function, can stimulate adhesion of mature T cells to endothelial cells, and enhance antitumor activity36,51,52. Cxcl10 enhances T cell and NK cell development and function
independently of chemotaxis, and may contribute to accessibility at sites of production.
Cxcl10 may also enhance NK cell migration and cytolysis. Other cells that do not
participate in the immune response may also be influenced by Cxcl10. Vascular smooth
muscle cells’ migration and proliferation may be enhanced, and angiogenesis is
inhibited51. Cxcl10 may also contribute to apoptosis and regulate cell growth in some
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cells50. The extent of these non-chemotactic functions in vivo are currently not well
understood.
Cxcl10 production is important for protective responses to a variety of pathogens.
Decreased Cxcl10 leads to increased susceptibility to Legionella pneumophilia and
increased pathogenesis of cutaneous candidiasis50. Further, increased Cxcl10 is
protective for in Leishmania amazonesis in mice, and Cxcl10 is protective during
Pneumocystis carinii and Cryptococcus neoformans in brains of immunized mice50 53. In
general, Cxcl10 is a chemokine induced by multiple M1 stimuli and promotes M1associated responses. Despite its role in T cell and NK cell development and effector
activity, the major role of Cxcl10 remains as a chemotactic signal for T and NK cells.

2.1.5. M2-associated gene Arginase 1 (Arg1)
Arginase 1 contrasts with Cxcl10 by association with M2 responses. Arginase 1
is a manganese metalloenzyme that catalyzes the conversion of L-arginine into ornithine
and urea. In the liver, this is the final step in the urea cycle. In IL-4 or IL-13 polarized
macrophages, it is considered a defining marker for alternative versus M1 polarization54.
In our study, the M1-associated transcription factor Batf2 mildly suppresses IL-4-induced
Arg1 expression.
Arginase 1 plays a critical role in immune function by promoting M2 responses
and suppressing M1 responses that may damage tissue. One major consequence of
arginase activity is decreased inflammation. By converting L-arginine to urea and
ornithine, it sequesters the pool of L-arginine available for nitric oxide synthase, an M1associated enzyme that produces the inflammatory and reactive nitric oxide to combat
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pathogens55–57. Further, decreased L-arginine availability decreases Th2 cell responses56.
Arginase activity also plays multiple roles in homeostasis and tissue repair. During
homeostasis, the production of polyamines from L-ornithine by L-ornithine
decarboxylase promotes cell growth58. Alternatively, L-ornithine aminotransferase
converts ornithine to collagen in tissue repair.
Multiple studies confirm in vitro effects with roles for arginase activity during
certain infections. Deficiency of Arg1 in myeloid cells worsens inflammation during
Schistosoma mansonii infection due to hyperactive inflammation beyond the point of
protection, thus hastening mortality56. Additionally, the decreased arginine availability
may affect growth of pathogens. For example, Toxoplasma gondii lacks arginine
synthesis ability, and arginine deficiency triggers conversion to the slow-growing
bradyzoite stage58,59. Through these mechanisms, Arg1 impacts some infections.
Notably, some evidence suggests arginase undergoes multiple layers of regulation.
Concentrations of polyamines may influence activity, as well as L-arginine (regulated in
part by activity of the cationic amino acid transporter 2)60. Thus, arginase activity may be
controlled independently of transcription.
In summary, arginase is a highly controlled enzyme that serves anti-inflammatory,
anti-pathogen, and homeostatic functions. The main importance of arginase to our study
is as a marker of IL-4-induced M2 macrophage polarization antagonizing M1 function.

2.2.

Transcription factors: Dictating the functions of myeloid cells
2.2.1. Transcription factors bind DNA and dictate gene expression patterns
Differentiation, polarization, and function rely on specific transcription factors
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that undergo regulation by a combination of multiple extracellular and intracellular
signals and modifications. Transcription factors enhance or suppress transcription by
altering the stability of the transcriptional apparatus61. They recognize and bind
consensus elements: short, unique nucleotide sequences. These sequences are located
within a gene's regulatory regions, reaching to a couple thousand base pairs upstream of
the transcription start site, or at distant sites that loop around to contact the transcription
apparatus. Binding often requires dimerization and/or ternary complex formation with
other transcription factors and non DNA-binding cofactors61,62. The structure of the
transcription factors promotes binding to specific DNA sequences, and transcription
factors cluster into families by structure of the DNA-binding domain. The four most
abundant are C2H2 zinc finger, homeodomain, helix-loop-helix (HLH), and basic leucine
zipper (bZIP)61. Family groupings can be useful since transcription factor families tend
to control genes with similar function. However, even transcription factors in the same
family differ in function. Moreover, activity of any transcription factor may differ
between cells.
Cell specificity and environmental specificity of transcription factors arises from
both regulation at the transcription factor level and consensus element level61. At the
transcription factor level, regulatory mechanisms include altering mRNA expression
levels of any given transcription factor, altering mRNA stability, alternative splicing of
that mRNA, post-translational modifications, and relative levels of opposing or
consensus-modifying transcription factors61. Thus, any given transcription factor's
mRNA message may be present only in some cells (at a low level for high specificity or a
high level for increased/broader activity), spliced to an isoform with lesser or greater
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activity, rapidly marked for degradation by ubiquitination, glycosylated for altered
function, phosphorylated for enhanced/inhibited activity, in competition with an opposing
transcription factor, and much more. PU.1, an important transcription factor for
macrophage differentiation, provides an example of a cell-specific transcription factor
with multiple levels of regulation. PU.1 mRNA levels are specifically induced in cells of
hematopoietic lineage9. High levels of PU.1 differentiate CMPs to macrophages,
overwhelming the effects of the antagonistic GATA3 that promotes mast cell
differentiation. AP-1 homo- and heterodimers demonstrate multiple levels of regulation
as well and also rely on a greater concentration of transcription-promoting subunits
versus inhibiting subunits62,63. Additionally, AP-1 exemplifies transcription factor
regulation by post-translational modifications, with cJun and cFos activity well
characterized as dependent on appropriate phosphorylation63–66. Thus, cells generate and
activate a specific set of active transcription factors for a given type and environment by
regulating expression, alternative splicing, post-translational modification, and
concentration of transcription factors.
At the consensus element levels, regulatory mechanisms involve altering
accessibility via epigenetic modifications. The current model for cell development
postulates early “pioneering” transcription factors that create a specific epigenetic
landscape for each cell type, allowing any given set of transcription factors access to a
unique set of genes67. PU.1, a pioneering transcription factor, again provides an
important example in macrophages. PU.1 facilitates H2K4me1 deposition via
remodeling enzymes11,68,69, allowing access of and activation by transcription factors
including NF-κB (activated by LPS, for example), Irf4 (role in M2 polarization), Irf5
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(M1-associated cytokines including IL-12p40, IL-12p35, and IL23p19)70, and Irf8 (M1associated cytokines including IFNβ, IL-12p40, and iNOS, reviewed in Günthner et al.4).
With these mechanisms, cells can achieve unique responses with a select set of active
transcription factors.
Previous studies on other immune cells have discovered “master transcription
factors” that are sufficient to drive broad transcriptional programs and commit to a
functional state. For T cells such master transcription factors include Tbet transduction
driving Th1 cell differentiation, Foxp3 driving Treg development, Bcl6 driving Tfh
differentiation, GATA3 driving Th2 differentiation, and RORγt driving Th17
differentiation14–20. Since the initial studies, the overall story has become somewhat more
complicated with discoveries that cofactors act in concert with these master factors
(Batf/Irf complexes being necessary for key Th2 genes along with GATA3, for
example)71. For a discussion on the master regulators in T cells, refer to Oestreich and
Weinmann, et al 72. Still, broadly-acting master factors orchestrate the majority of T cell
responses. Previous studies on master transcription factors in M1 macrophage
polarization have been inconsistent due to variation in the highly plastic macrophages
across different model systems. Recent studies have proposed Batf2 in combination with
Irf1 as a complex governing M1 gene expression1. This project focuses on Batf2 and its
role in regulating M1 gene expression.
In summary, specific cells produce specific responses via transcription factor
activity regulated in multiple ways. Each contains a specific set of transcription factor
mRNA and protein repertoire, with specific isoforms. Translation produces proteins
which may be activated or suppressed by modification. Active transcription factors then
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have access to specific gene regulatory regions, and master transcription factors can
induce multiple genes in a transcriptional program.

2.2.2. AP-1 Transcription factors
The activator protein 1 (AP-1) group of transcription factors belong to the bZIP
transcription factor family. One of the four most abundant transcription factor families,
as reviewed in Vaquerizas et al.61, AP-1 family members consist of a positively charged
segment (basic region) mediating DNA interactions and leucine repeats (leucine zipper)
mediating protein interactions. Two members must dimerize to bind DNA. Common
functions of bZIP factors include mitogen signaling, stress responses, cytokine
stimulation, brain and ocular development, development of dendritic cells, and
differentiation of myeloid cells65. Importantly, bZIP factors are also involved in
activation of macrophage cells.
AP-1 homo- or hetero-dimers recognize two similar consensus sequences: the AP1 site, also known as a tetradecanoyl phorbol acetate-responsive element (TRE), and the
cAMP responsive element (CRE). Several proteins of this group mix and match, forming
activating and inhibitory complexes: Jun, cFos, cFos-related antigen 1 (Fra1), Fra2, FosB,
JunB, and JunD62,65,73. Some sources divide these proteins into cFos and Jun families,
with the cFos family consisting of cFos, Fra1, Fra2, and FosB and Jun family consisting
of cJun, JunB, and JunD (refer to Foletta et al. for an excellent review of AP-1 factors)74.
The Jun family members can form homo- or hetero-dimers with cFos family members,
while cFos family members cannot homodimerize. More recently, the bZIP transcription
factor ATF-like (Batf) family members Batf, Batf2, and Batf3, were found to have similar
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structures, dimerization, and DNA-binding activities, and can be considered part of this
group (Figure 2.2), reviewed in Murphy et al65,75.
The cFos/Jun and Batf proteins, as basic leucine zipper (bZIP) transcription
factors, contain leucine residues that form a 'zipper' connecting two dimerizing factors.
Most members, such as cFos and cJun, contain a known transactivation domain at one
end, a basic region for protein-protein interactions, and a DNA-binding region at the
other end. Some members have two transactivation domains (cFos and FosB), while
others lack the transactivation domain (Fra1 and Fra2), which can affect transcription
rates65,75. The Batf family members Batf and Batf3 are truncated to the bZIP region and
rely on dimerization to a partner with a transactivation domain, while Batf2 contains an
N-terminus of unknown transactivation activity76.

2.2.2.1. Regulation of AP-1 proteins
AP-1 proteins are regulated by complex and multifactorial mechanisms to provide
differential gene expression in different cells and environments in light of the ubiquity of
the dimers and their target sites62. Protein-protein interactions and phosphorylation of
multiple residues provides the strongest regulatory mechanism. The consequences of
dysregulation can be severe. The growth dysregulation and epithelial-mesenchymal
transition of many cancers depends on dysregulation, for example. AP-1 activating
stimuli include growth factors, mitogens, toxins, cytokines, stress signals, and pathogens;
functional outcomes include cell development, proliferation, differentiation, and
survival74,77. Regulation of activity takes place on multiple levels such as changes in
transcription of AP-1 subunits (some subunits being inhibitory), mRNA stability, posttranslational processing, turnover of pre-existing or newly synthesized subunits, and
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specific interactions between the AP-1 dimers and other transcription factors or cofactors
(reviewed in Foletta et al. 1996 and Hess et al 2004)77,78.
Protein-protein interactions provide a critical point of regulation for both
transactivation and DNA recognition (Table B2.1). These include 1) hetero- or homodimerization with related family members63,73,75,79–83, 2) heterodimerization with other
bZIP transcription factors, 3) ternary complex formation with other transcription factors,
4) ternary complex formation with other activators or coactivators. Closely related AP-1
members include cJun, JunB, JunD, cFos, FosB, Fra1, and Fra2; more distant bZIP
transcription factors include V-Maf avian musculoaponeurotic fibrosarcoma oncogene
(Maf), C/EBP, activating transcription factors (ATFs), upstream stimulatory factors
(USFs), nuclear respiratory factor (NRF) and nuclear factor erythroid 2 (NF-E2); and
known ternary complex-forming factors include SMADs, E26 transformations-specific
(Ets) (of which the critical macrophage differentiation factor PU.1 is a part),
glucocorticoid receptor, NFκB, CREB-binding protein, TATA-binding protein and
nuclear factor of activated T cells (Nfat)65. Other cofactors include ring-domain
containing protein (Raco)84. The members of the complex determine the gene to which
the complex binds and its activity, allowing a high context specificity. For example, cJun
homodimers can directly bind and negatively regulate the promoter region of matrix
metalloproteinase 12 (Mmp12) and Mmp13, while cJun/cFos hereodimers positively
regulate the same genes63. The complex formed also determines the preferred consensus
sequence. While dimers of the closely related AP-1 family members usually prefer the
TRE (5'-TGA(C/G)TCA-3') over the CRE (5'-TGACGTCA-3'), preference depends upon
the members of the dimer62,85. Batf proteins complex with Irf4/Irf8 prefer the AP-1-Irf
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element (AICE) 5'-TTTCnnnnTGACTAA-3' or 5'-GAAAATGAnTCA-3'86. Ternary
complexes may also allow AP-1 proteins to activate gene expression without binding
DNA at all; in the case of IL-1β, PU.1-C/EBP β complex binds Jun at its DNA-binding
residues, preventing Jun from binding DNA directly, but still allowing its required
transactivating activity80. To further add to the regulation through complex formation, at
least some of the complexes formed change with changes in concentrations of AP-1
members present at any given time. For example, overexpression of cFos, which does
not bind the AP-1 consensus sequence except as a heterodimer with Jun, blocks
transactivation of the M-CSF receptor Csf1r presumably by saturating available AP-1
sites87.
A second, critical level of AP-1 regulation involves post-translational
modification. Hyperphosphorylation by MAPKs is a main regulatory mechanism of cJun
and cFos activation, but can also suppress activity64–66. Typically, JNKs phosphorylate
Jun proteins, and ERKs phosphorylate Fos proteins65. Mitogens or cell stress induce the
MAPK, which travels to the nucleus and hyperphosphorylates pre-existing Jun or Fos
proteins64,80. cJun then forms homodimers or heterodimers with cFos or other members
and then binds to DNA to enhance transcription88. Mmp13 provides an example of the
importance of phosphorylation. Unphosphorylated Jun/Jun homodimers act as repressors
by recruiting nuclear receptor co-repressor 1 (NCoR1), a repressor that recruits DNAmodifying enzymes leading to transcriptional repression63. Phosphorylation allows
dissolution of the complex and thus transcription. cFos is also regulated by
phosphorylation89. In some cases, a member may have a phosphorylation site but no
docking site for the kinase, and can only be phosphorylated when dimerized to a partner
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with a docking site65. In contrast, ubiquitination and SUMOylation can repress
transcriptional activity, specifically studied in the case of cJun and cFos, respectively90,91.
Finally, redox state in the cell also controls the activity of AP-1 by reducing residues on
the proteins, enabling the cell to respond appropriately92,93.
In summary, the regulation of AP-1 activity is critical for correct cell function.
Mechanisms include changes to levels of mRNA and AP-1 and non-AP-1 proteins and
post-translational modifications. Relative levels of interacting proteins alter the
transactivation activity and the DNA-binding location and ability of the AP-1-containing
complexes.

2.2.2.2. Function of AP-1 proteins
AP-1 has a broad range of functions in all cell types. Activities include regulating
stress response, tumor promotion, cell death, differentiation, immune cell function, and
much more. Expression of many members is constitutive with activity induced rapidly
after stimulus by post-translational modification such as hyperphosphorylation, as
discussed above. Dimerization and subsequent phosphorylation allows DNA binding at
TRE, CRE, or in complex formation with cofactors at variant sites. AP-1 can also
regulate genes with alternative consensus elements and weak AP-1 sites by forming a
ternary complex with other transcription factors. Occasionally, these complexes may
regulate genes entirely independently of AP-1 DNA binding62,80.
AP-1 is strongly implicated in tumorigenesis. Several of the AP-1 proteins,
including cFos, FosB, and cJun, transform cells in vitro, and cJun and cFos are both viral
oncoproteins94. AP-1 activity induces transcription of tumorigenic proteins including
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Cyclin D, GM-CSF, and Kgf/Fgf7, and suppresses anti-tumor proteins such as p5395,96.
On the other hand, AP-1 proteins in other contexts hinders tumor growth. JunB and JunD
tend to have anti-tumor effects in vivo, possibly by inhibiting cJun. Moreover,
suppression of JunB promotes spontaneous tumor formation independently of cJun94.
Batf2 also exhibits tumor suppression activity in multiple cell types, largely by inhibiting
cJun activity at various genes95. Specifically, this suppression results in decreased celladhesion molecule E-cadherin and decreased growth-promoting Cyclin E, among others.
cJun/cFos heterodimers also regulate genes involved in tumor invasiveness, such as
Mmp12, Mmp13, Mmp1, and Mmp363,94. AP-1, therefore, has important roles for growth
and differentiation in diverse cell types.
In addition to growth, AP-1 proteins promote the differentiation and function of
many cell types including immune cells. In macrophages, cJun can interact with the
major hematopoietic cell transcription factor PU.1, an important transcription factor for
the differentiation of multiple cell lineages including macrophages and B cells. AP1/PU.1 complexes are required for expression of a macrophage Fc receptor expressed
during monocyte to macrophage differentiation 97. Monocytic expression of Csf1r,
receptor for the growth factor M-CSF and part of an essential pathway for growth,
proliferation, and differentiation, also relies on AP-1/PU.187. Indeed, cJun/cFos
heterodimers promote expression of pro-inflammatory proteins including Mmp1463,98.
Further, the cJun/Irf1/NF-κB complex serves as an 'enhanceosome' for inflammatory
gene expression4,99–101. cFos and JunB play a non-essential but nevertheless influential
role in monocytic differentiation. This effect was demonstrated in myeloblastic leukemic
cells, in which expression of cFos or JunB increases their tendency to differentiate74,102–
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104

. The Batf members have a more essential role in non-monocytic cells. Batf, for

example, is required for differentiation of multiple immune cells including Th17 and Tfh
CD4 T cells76. The Batf subfamily is rapidly gaining appreciation for its role in
differentiation and function of multiple cell types, discussed more in depth below.
Clearly, AP-1 proteins play complex roles in a vast variety of cell types.
Regulation of these proteins includes transcription, post-translational modification,
dimerization, and ternary complex formation. Activity is highly dependent on cell type,
epigenetic history, and environment. Because of this, Batf2’s functions in macrophages
cannot be extrapolated from studies of other AP-1 family members or even Batf2
functions in other cell types.

2.2.2.3. Batf subgroup: AP-1 proteins important for B, T, and cDC subset
development and function
The Batf subgroup is composed of Batf (SFA2), Batf2 (SARI), and Batf3
(JDP/p21). Batf members, their function, and their interchangeability were recently
reviewed in Murphy et al76. As mentioned above, this subgroup belongs to the bZIP
family of transcription factors and falls into the category of AP-1 proteins based on
homology to and dimerization with classical members such as cJun and cFos. Batf2 also
recognizes the AP-1 TRE consensus and the similar AP-1 half of the AICE consensus
(Figure 2.3). Notably, however, murine Batf and Batf3 proteins are significantly smaller
than either cJun or cFos, with truncated C-terminal domains, and lack any likely
transactivation domains76. Batf2 does contain a C-terminal domain, but does not contain
known transactivation domains.
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Batf and Batf3 are expressed in hematopoietic cells, and Batf2 is more broadly
expressed in multiple cell types. Batf and Batf3 have roles in several cell types: Th1 and
Th17 cells express both Batf2 and Batf3, Th2 cells express Batf and low amounts of
Batf3, Tfh express Batf, and B cells, CD103+CD11b- conventional dendritic cells (cDCs),
and CD8α+ cDCs all express Batf376,83,105–107. Recently, cap analysis gene expression
(CAGE) also detected high expression of Batf in natural helper cells and macrophages,
and Batf3 in macrophages108. Expression of Batf, Batf2, and Batf3 in macrophages have
been confirmed in our studies and by others1,109. At this time, expression of Batf2 has
two notable patterns: suppressed expression in cancer cells and induced expression in
hematopoietic cells. Cancer cells downregulate or lose entirely expression of Batf2
compared to normal counterparts or adjacent tissues. M1 stimuli (IFNβ, IFNγ, and LPS)
in vitro induce Batf2 expression in macrophages, and IL-12 treatment in vivo or
Toxoplasma gondii infection in vivo (which induces IL-12 production) induces Batf2
expression in CD103+ CD11b- cDCs and CD8α+cDCs1,83,95.
In spite of the lack of transactivation domain, the Batf members clearly serve
critical roles in transcription. Batf and Batf3 not only bind to TREs as heterodimers with
another AP-1 protein, but also bind to AP-1-Irf consensus elements (AICEs) as a complex
with Irf4 or Irf8. Batf3, induced Batf, or induced Batf2 forms complexes with Irf8 that
induce genes for differentiation of CD8α+ cDCs and CD103+CD11b- cDCs, inducing Ctype lectin domain family 9, member A (Clec9a), chemokine (X-C motif) receptor
(Xcr1), inhibitor of DNA binding 2 (Id2), and Spib83,110. Batf-induced transcription also
plays important roles in cell development in B and some T cell subsets. In B cells, it is
required for the expression of activation-induced cytidine deaminase (Aid) which is
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required for affinity maturation and class-switch recombination (CSR)107. It is important
for differentiation of Th17, Tfh cells, and Th9 by inducing essential genes including
Rorc, IL17A, IL21, IL23R, Map, Bcl6, IL9, IL-10, Furin, Fes, Ets-related gene (Erg), and
IL-1RA71,76,106,111. In Th2 cells Batf or Batf3 both induce GATA3, IL-4, IL-10, and
cytotoxic T-lymphocyte-associated 4 (Ctla4) (Figure 2.2). Like Batf3, the importance of
Batf in these cells is at least in part due to complex formations with Irf4 or Irf8 and
subsequent binding to AICEs86.
Interestingly, Batf3 and Batf can functionally compensate for each other,
suggesting some redundancy in binding to both DNA elements and Irf proteins83,86.
Batf2, on the other hand, can compensate for Batf3 in the cDC subsets, but not Batf or
Batf3 in B cells or T cells, as discussed below. These prior studies clarify that the Batf
family members are partially interchangeable and this interchangeability relies on ternary
complex formation with Irf family members, but that Batf2 has unique activity.

2.3.

Batf2: An AP-1 protein distinct from Batf and Batf3, with roles in cancer

inhibition and immunity
Batf2 is a relatively little-known member of the AP-1 group of the bZIP
transcription factors, but is gaining importance for its roles in tumor suppression and cell
differentiation. Su et al. originally characterized it as an IFNβ -inducible early-response
gene that inhibits tumor-promoting AP-1 activity. Currently, investigation into Batf2’s
value as an indicator of good prognosis as well as potential therapeutic target
continues95,108. Additionally, Batf proteins are emerging as critical cofactors in the
differentiation and function of many immune cells. Batf2 clearly behaves differently
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from Batf and Batf3, and defining its specific contribution to immune cell functions is
advancing our understanding of the transcriptional regulation of immune cells.
Mouse Batf2 shares 63% homology with human Batf2, which is 29.4 kDa. It is
located on chromosome 19 in mice, and 11q13.1 in humans. Batf2 shares the functional
domains characteristic of the AP-1 transcription factors: a basic region that binds DNA
after dimerization and leucine zipper that binds other AP-1 and non-AP-1 proteins. Most
Batfs have a truncated C-terminus compared to cFos, and lack known transactivation
domains (Figure 2.2)83. Batf2, however, contains an extended C-terminus with unknown
function that could encode some transactivation functions. Batf2 protein has 47%
homology to Batf and 43% homology to Batf3. Conservation between Batf2 and the
other Batf proteins is sufficient to allow some functional compensation. Of the other
Batfs, Batf is required for CD103+CD11b+ and CD8α+ cDC development, and Batf3 for
Th2, Th17, and Tfh cell development and function. While DNA-binding assays
demonstrate Batf and Batf3 binding to AICE, Batf2's DNA-binding ability remains
unknown86. Batf2's ability to compensate for Batf3's ability to guide Irf4/8 to DNA in
dendritic cell development suggests DNA-binding activity, but no DNA-binding assays
demonstrating Batf2 binding to the AICE have been published. Further, Roy et al state
that Batf2 has no DNA-binding domain1, Batf2-Jun heterodimers do not bind AP-1
consensus sequences as assessed by electromobility shift assays (EMSAs) and chromatin
immunoprecipitation (ChIP) assays95, and Batf2 inhibits cJun activity by inhibiting its
binding ability95,112. At this time, Batf2's direct interaction with DNA remains unclear
and further experiments are required to determine whether Batf2 binds a yet-unidentified
site, or interacts with other DNA-binding proteins.
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While Batf2-DNA interactions remain unclear, interactions with other proteins are
better characterized. The leucine zipper motif of Batf2 mediates dimerization and ternary
complex formation, and is structurally similar to Batf and Batf376. Batf2 binds in vivo to
cJun and inhibits its activity, and also in vitro to JunB with unexplored functional
consequences95,113. Activity of the Batf subfamily depends largely on ternary complex
formation. Batf and Batf3 guide non-DNA-binding transcription factors Irf4 and Irf8 to
specific consensus sequences to initiate transcription. In some contexts (discussed
below), Batf2 can compensate for a deficiency of Batf3 in a manner dependent upon the
leucine zipper region, supporting the importance of protein-protein interactions for Batf2
activity.
In summary, Batf2 is a member of the bZIP family of transcription factors and the
AP-1 and Batf subfamilies. It contains a DNA-binding domain with unclear function,
and protein-binding domain similar to Batf and Batf3 able to dimerize with AP-1
members and form ternary complexes with other proteins including Irfs.

2.3.1. Batf2 Expression
2.3.1.1. Normal cells and tissues
Batf2 is expressed constitutively in multiple cell types and tissues, and loss tends
to correlate with malignant growth and poor outcomes in vivo. Isolated cell types
expressing Batf2 include common myeloid progenitor cells and macrophages, 'normal'
immortal cell lines including primary human fetal astrocytes, mammary epithelial cells,
prostate epithelial cells, pancreatic mesothelial cells, normal lung, and tongue epithelial
cell lines95,114–116. It is expressed in many immune cells with the exception of T cells76.
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In vivo, Batf2 message is expressed in many normal tissues, although expression is
widely variable between tissues and between samples95,115,117–119. Message levels are
relatively high in colon, spleen, and pancreas; and moderate in heart, kidney, liver, lung,
and prostate95. Low levels were detected in placenta, stomach, small intestine, and
salivary gland. Brain, muscle, and testis do not express Batf295.
IFNs induce Batf2 expression many fold over baseline. In multiple cell lines
including HeLa, IFNβ induces Batf2 within 2 hours, independent of protein
synthesis95,112,114,120. The mRNA half-life under these conditions is 2 hours. IFNβ, IFNγ,
and LPS also induce Batf2 in macrophages 1,109,121. CD8α+ cDCs, and CD11b+CD103+
cDCs express Batf2 in vivo in response to intracellular pathogen Toxoplasma gondii or
IL-1283. Thus, Batf2 is an IFN-inducible transcription factor with basal expression in
multiple cells.

2.3.1.2. Batf2 in Cancers
Although Batf2 is expressed in many normal tissues, expression decreases in
aggressive cancer cell lines and in vivo in tumors. Expression correlates with survival
and inversely correlates with aggressiveness and likely plays a contributing role. Human
leukemia cell lines and malignant counterparts of cell lines including glioma, prostate
cancer, pancreatic cancer, breast cancer, melanoma, lung adenocarcinoma post-EMT, and
oral tongue squamous cell carcinoma (OTSCC), decrease or eliminate Batf2
expression95,114,115,117–119. In general, Batf2 expression appears to generally correlate with
normal cells with loss indicating progression of cancer cells. However, Batf2 may
remain inducible even after basal expression is lost. In multiple cell lines in which Batf2
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is decreased and in the HeLa cell line, IFNβ induces Batf2. Induction occurs within 2
hours, independent of protein synthesis95,109,112,114. The mRNA half-life under these
conditions is 2 hours.
Similarly to cell line studies, Batf2 expression decreases in clinical tumor
samples. Loss tends to correlate with aggressiveness while maintenance correlates with
survival. For instance, the 52% positive expression in normal lung tissue samples
decreases to 50% in paired non-small cell lung carcinoma (NSCLC) tissues96. It's also
decreased in hepatocellular carcinoma (HCC), in OTSCC, and in colorectal cancers
compared to healthy adjacent tissues, as well as in peripheral bone marrow cells
(PBMCs) of leukemia patients compared to PBMCs of normal volunteers117 115 112 122.
Batf2 expression inversely correlates with tumor size, differentiation, and metastasis115–
117,120

. Importantly, expression also correlates strongly with survival when compared to

adjacent non-tumor tissues115–117. Batf2 may well have a causal role in survival,
discussed below.
Mechanisms by which Batf2 decreases in cancers remains unclear. In normal
cells, IFNβ directly induces expression, and Mda7/IL24 increases Batf2 expression by
prolonging detectable mRNA from 1.5 hours to 3.5 hours via p38 MAPK pathway (halflife is 2 hours in HeLa)114. One study in chronic myeloid leukemia (CML) linked Batf2
expression inversely to BCR-ABL, JAK/Stat, and RAS/MAPK pathways122. Inhibition
of BCR-ABL by imatinab mesylate increased Batf2 expression, as did inhibition of
JAK/Stat and RAS/MAPK pathways. Therefore, Batf2 in non-hematopoietic cells is
inducible by IFNs, enhanced by Mda7/IL24, and suppressible in at least some cell types
by BCR-ABL, JAK/Stat, and RAS/MAPK pathways.
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2.3.1.3. Hematopoietic cells
While loss of expression is notable in cancers, gain of expression is notable in
hematopoietic cells of the immune system. Indeed, Batf2 expression increases during
and at least 48 hours after M1 polarization of macrophages, serving important functional
roles discussed below. IFNγ -induced Batf2 is important in cDC subsets, while IFNβ,
IFNγ, and LPS all have roles in Batf2 induction in macrophage cells1,83,109,121. Some
reports suggest LPS enhances Batf2 induction by IFNγ1,83,121, and two reports found that
LPS alone induces Batf2 in murine bone-marrow derived macrophages 1,83. Bone
marrow derived macrophages express minimal Batf2 mRNA in response to heat-killed
Listeria monocytogenes and CpG83. In CD8α+ cDCs and CD11b+CD103+ cDCs in vivo,
Batf2 is inducible with IL-12 or infection with the intracellular pathogen Toxoplasma
gondii83. In vitro, however, purified Flt3L-DC do not produce Batf2 in response to IL-12,
nor in response to GM-CSF or pIC, but rather to LPS. In general, Batf2 is inducible in
macrophages and CD8α+ cDCs or CD11b+CD103+ cDCs by M1-associated stimuli,
especially LPS and IFNγ.

2.3.1.4. Other correlations
Other clinical studies correlating Batf2 with disease outcomes have less clear
connections. Microarray analysis of high-pain versus low-pain fibromyalgia found Batf2
to be among the top 10 most significantly differentially expressed genes in peripheral
blood123 . Increased Batf2 correlates with pain, but any hints at causality remain unclear.
Batf2 is also highly upregulated in cases of common variable immune deficiency with
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inflammation complications compared to cases without, in concert with other IFNresponsive genes. These studies may provide insight into the function of Batf2 or the
mechanisms of these diseases. Although Batf2 may simply be responding to an
inflammatory response involving IFNs, it is possible that Batf2 contributes as well; for
example, by orchestrating macrophage polarization that in turn aggravates inflammation.
Defining the functions of Batf2 paves the way for the development of therapies targeting
Batf2 that may be useful in cancer and other diseases.

2.3.2. Batf2 Function
Initial studies identified Batf2 as an interferon-inducible negative regulator of AP1 activity in transformed cancers. Based on this activity, these studies referred to the
Batf2 protein as suppressor of AP-1, regulated by IFN (SARI). In vitro binding assays
suggest that Batf2 cannot heterodimerize, but can form heterodimers in vitro with other
AP-1 members JunB and cJun, as well as bZIP transcription factors C/EBPG, C/EBPA,
and DNA-damage inducible transcript (Ddit3)113. Batf2 heterodimerizes with cJun in
vivo95. Previous studies on Batf2 have demonstrated roles as a negative regulator of gene
expression by AP-1 inhibition, a negative regulator of gene expression by participating in
dephosphorylation complex, and a positive regulator of gene expression by interacting at
AP-1-Irf consensus elements (AICEs)83,86. Negative gene regulation by AP-1 inhibition
(specifically cJun sequestration) and by dephosphorylation (specifically of glycogen
synthase kinase 3 beta [GSK3β], decreasing β -catenin) occurs in normal cells and is lost
in cancer cells, while positive gene regulation at the AICE occurs in the development of
dendritic cell subsets83,95,124.
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2.3.2.1. Cancer studies: Batf2 negatively regulates AP-1 and aids
dephosphorylation of GSK3β
Studies on Batf2's role as a tumor suppressor lend insights into the mechanisms of
Batf2's activity. As discussed above, decreased expression in vitro occurs post-EMT and
in malignant cells compared to normal counterparts, and decreased Batf2 in vivo
correlates with aggressiveness and survival. The tumor-suppressive activity occurs
through two distinct mechanisms: AP-1 inhibition and β-catenin dephosphorylation.
Batf2's affect as an AP-1 inhibitor appears to be the reason for its cancer-specific effects
on growth and apoptosis and inhibition of proto-oncogenes. In various cancer cells,
forced expression inhibits both anchorage-dependent and -independent cell growth and
induces apoptosis95,112. This selective inhibition seems to arise from the reliance of these
cancer cells on cJun, such that inhibition of cJun by Batf2 prevents gene expression for
growth and survival. Batf2-sensitive cells show elevated cJun, perhaps reflecting
increased reliance on cJun for growth and survival. Moreover, Batf2's growth-inhibiting
activity in cancer cells is most pronounced during by Ras or Src oncogene
transformation, which induces AP-1 activity95.
A great deal of evidence indicates that Batf2 inhibits cJun activity by
sequestration. Fluorescence Resonance Energy Transfer (FRET), immunofluorescence,
and co-immunoprecipitation assays demonstrate Batf2 binding to cJun, and Batf2's
protein-protein interaction motif (the leucine zipper) is required for its activity,
demonstrating that Batf2 heterodimerizes with cJun and that heterodimerization is
necessary for anti-tumor effects95,112,113. Moreover, forced Batf2 expression prevents
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cJun from binding to the AP-1 consensus TRE as demonstrated by reporter assays,
EMSAs, and AP-1-induced gene expression95,112,124. Therefore, little doubt remains that
Batf2 acts as a negative regulator of cJun activity by binding to it and preventing its
binding to AP-1 consensus. Yet, some evidence suggests that Batf2 can in fact drive
transcription in hematopoietic cells, discussed below.
Batf2-inhibited AP-1 can suppress tumor growth by decreasing growth factors,
altering cell cycle regulators, and interfering with communication with and modification
to the extracellular environment. Batf2 inhibits the AP-1 dependent MET in colorectal
cell lines; MET is both a proto-oncogene and a growth factor112. Additionally, Batf2 may
alter cell cycle regulator expression to inhibit cell growth. Forced Batf2 expression
inhibits cyclin D1 and cyclin E expression in HeLa cells84. These AP-1-regualted cyclins
mediate transition into S phase, encouraging cell growth. Batf2 may thus block cell cycle
in part by inhibiting cell cycle progression.
Batf2 also interferes with AP-1-dependent factors promoting invasiveness by
communication with and modification of the extracellular environment, specifically CCN
family member 1 (Ccn1)-induced integrin signaling, and MMP expression. Aggressive
breast and prostate carcinoma cell lines displayed elevated AP-1 activity, elevated
integrin-MAPK signaling, and enhanced invasiveness and anchorage-independent growth
by both AP-1 and integrin-MAPK pathways. Batf2 transduction reduced the feedforward loop of AP-1-induced cJun and Ccn1 expression124. Functionally, this resulted in
reduced growth and invasiveness. Batf2 activity seems to vary between cells, however,
since CCN1 was not affected by Batf2 in colorectal cancers112. Another way Batf2
influences the environment to prevent aggressive cancers is through Mmps. Mmps in
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general contribute to EMT, and can increase growth factor availability by releasing
molecules from the extracellular matrix, but Batf2 inhibits Mmp2 and Mmp7 by
decreasing AP-1 expression125 112. Mmp2 in particular can increase tumor growth by
promoting vascularization, and both Mmp2 and Mmp7 are associated with modulation of
the immune response towards a tumor-promoting environment 125. Therefore, Batf2 may
modulate tumor growth through inhibition of integrin signaling and modification of the
extracellular matrix, in addition to inhibition of cell cycle progression and growth factor
signaling.
In addition to anti-cancer activity by AP-1 inhibition, Batf2 participates in a
dephosphorylation complex that leads to B-catenin inhibition. Wang et al discovered this
activity in lung adenocarcinoma119. Batf2 inhibits the epithelial-mesenchymal transition
(EMT) through activation of GSK3β and subsequent inactivation of β -catenin. During
EMT, cells change morphology, increase migratory ability, lose the adhesion factor and
pre-EMT marker E-cadherin, and increase the intermediate filament vimentin. While
lung adenocarcinoma cell lines pre-EMT express higher levels of Batf2, post-EMT cell
lines lose Batf2 expression. Forced Batf2 in post-EMT cells, however, reverts cells back
to pre-EMT morphology, migratory ability, E-cadherin expression, and vimentin
expression. On the other hand, knockdown of Batf2 in pre-EMT cells increased postEMT morphology, decreased E-cadherin, and increased vimentin. Batf2 therefore plays
an important role in EMT in lung adenocarcinoma. These effects are not due to Batf2's
transcriptional activity; rather, Batf2 inhibits the Wnt/ β-catenin signaling pathway by
activating the β -catenin inhibitor GSK3β. Batf2's mechanistic role in this process
remains unclear, but is required for GSK3β activation by protein phosphatase 2 (Pp2a).
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The interaction involves physical contact between GSK3β, Pp2a, and Batf2. Possibly,
Batf2 acts as a scaffold in this complex. Increased GSK3β activity results in decreased β
-catenin and β –catenin-induced EMT-associated factors. Batf2 expression in post-EMT
lung adenocarcinoma increases active GSK3β and inhibits β -catenin, including that
induced through Wnt pathway activation.
Batf2 manipulation in xenografts demonstrates the importance of Batf2 in vivo as
well as in vitro. Decreasing Batf2 in lung adenocarcinoma tumors with anti-Batf2 with
small interfering RNA increased lymph-node metastases and metastatic sites with
mesenchymal characteristics and reversed severity-associated changes to vimentin and Ecadherin119. In the reverse experiment using colorectal cancer cells, forced Batf2
expression led to decreased tumor size, proliferation, and proto-oncogene MET
expression112. In a similar experiment, Batf2 abrogated Ccn1-induced growth and
aggressiveness114. Therefore, the mechanisms by which Batf2 prevents tumor growth in
vitro do indeed translate to in vivo models.
Clinical data also support Batf2's role as an anti-tumor transcription factor, and
also suggest Batf2 may be a useful diagnostic marker or therapeutic target. Batf2 loss
correlates with tumor aggressiveness in hepatocellular carcinoma, OTSCC, leukemic cell
number in chronic myeloid leukemia, lung adenocarcinoma and lung squamous cell
carcinoma, colorectal cancer, and esophageal squamous cell carcinoma112,115–117,119,122,126.
Although the correlations with differentiation, metastasis, and invasiveness vary
between cancer types, Batf2 may be a predictor of these factors in specific cancers.
Moreover, Batf2 has a much more useful correlation in all cancers previously studied:
survival. Batf2 served as an independent predictor of survival in hepatocellular
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carcinoma, oral tongue squamous cell carcinoma, and colorectal cancer112,115,117.
Therefore, Batf2 may prove useful in the future as a diagnostic marker predicting poor
prognosis of various cancers, depending on the cell type.
Overall, Batf2's ability to inhibit AP-1 activity and β-catenin activity is revealed
through studies on its role as a tumor-suppressor. In vitro, Batf2 inhibits growth factors,
modulates communication and interaction the extracellular environment, suppresses Bcatenin-mediated changes required for aggressiveness, and inhibits EMT. In vivo, Batf2
slows xenograft growth, and loss is associated with increased aggressiveness and
decreased survival in multiple cancer types.

2.3.3. Hematopoietic cell development and function: Batf2 as an AP-1
transcription factor
Although Batf2 has a negative regulatory role in some conditions, studied in
multiple non-hematopoietic cell types, it also has a positive regulatory role, studied in
hematopoietic cell development and function alongside closely related Batf and Batf3.
Batf and Batf3 have been known transcription factors important for multiple immune
cells. Batf3 forms a ternary complex with Irf8 or Irf4 to drive expression of genes for
CD8α+ and related CD103+CD11b- cDCs including CD103 and Xcr76. Normally, these
cells do not produce Batf2, and thus mice deficient in Batf3 lack this population;
however, Toxoplasma gondii infection or IL-12 treatment in vivo induces Batf2, which
can partially compensate for Batf3 deficiency in the development of these CD subsets83.
Table B2 lists the situations in which Batf2 can and cannot compensate for other Batfs.
This suggests that Batf2 does have some transcriptional activation activity.
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Interestingly, Batf2 seems unique among the Batf factors, and its role in activating
transcription remains unclear. Batf and Batf3 are largely interchangeable in the
development of cells, complexing with Irf4 or Irf8 and subsequently binding to the AP1/Irf Composite Element (AICE) (5'-TTTCnnnnTGACTAA-3' or 5'-GAAATGAnTCA3') in regulatory regions of many genes necessary for immune cell development (Figure
2.3). Batf and Batf3 drive Th2 cell development, being necessary for genes including
GATA3, IL-4, IL-10, and Ctla4. Batf or ectopic Batf3 is required for genes involved in B
cell class switching (Aid), Th17 development (Rorc, IL17A, IL21, IL23R), and Tfh
development (Maf, Bcl6) and Th9 development (IL21, IL-10, Furin, Fes, Erg, IL1RA)76,111. Batf2, however, can only compensate for Batf3 in the cDC subsets, and not
Batf3 in Th2 development, or Batf in B cells, Th17, or Tfh cells.
Two components critical for the function of the bZIP transcription factors are the
leucine zipper, critical for protein-protein interaction, and the basic region, critical for
DNA binding. Batf2 presumably binds to Irf4 or Irf8 to compensate for Batf3
development in the cDC subsets, and heterodimerizes with cJun as demonstrated in
cancer cell studies. However, it has not been shown to bind DNA. Fusion of the Batf2
basic region with Batf3 leucine zipper produces a chimera that functions in cDCs but not
Th17, similar to wild-type Batf2. Moreover, Roy et al. in an investigation of Batf2 in
macrophage cells asserts that Batf2 does not contain a DNA-binding domain109.
Recently, Batf2's importance in macrophage polarization was explored in
BMDMs. As in other immune cells, this study suggests the requirement for a cofactor,
specifically the M1-specific Irf1. Batf2 knockdown with small interfering RNA (siRNA)
abolished the expression of several genes important to macrophage polarization. Batf2
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complexed with Irf1, and knockdown of Irf1 mimicked knockdown of Batf2. However,
recognition of a consensus region by Batf2-Irf1 complex was not explored, so it remains
unknown whether this complex indeed recognizes a consensus element, perhaps the
AICE or simply the Irf1 element, in macrophages. Batf2’s function in vivo in regards to
immune function remains only briefly explored. Batf2-/- mice, produced by Tussiwand et
al., appear to possess normal hematopoietic cell populations at homeostasis83. The only
macrophage populations altered significantly in these mice were the lung-resident
CD103-CD11b-, and this deficiency only appeared after Toxoplasma gondii infection.
Whether the macrophages contribute to the increased mortality is unclear. Of note, this
study focused on dendritic cell populations, so macrophage populations were not reported
in detail.
In summary of previous studies, Batf2 has important roles as both a tumorsuppressor and inhibitor of AP-1 activity, as well as a differentiation and polarization
factor in some immune cells as an activator of AP-1 activity. This study complements the
previous and current work on Batf2 by exploring its function in a macrophage cell line
with advantages over BMDMs. The conclusions of Batf2 having an activating role on its
own are contradicted, but the importance of a cofactor or other environmental factor
specific to M1-polarized macrophages is supported.

2.3.4. Studying Batf2’s role as a transcription factor in PUER macrophages
The work in this dissertation adds to this body of research by constitutively
expressing Batf2 in an in vitro macrophage system, the PUER cells. Initial microarray
analysis from our lab found Batf2 highly upregulated in LPS/IFNγ (M1) polarized
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macrophages relative to resting or IL-4 (M2) polarized PUER macrophages, in agreement
with the recent studies in bone marrow macrophages. My hypothesis was that Batf2 is a
master regulator of M1 polarized macrophages. To test this hypothesis, I investigated the
function of Batf2 in the PUER macrophage model.

2.3.4.1. Model system: PUER macrophages
Previous studies have multiple discrepancies due in part to sensitivity and
plasticity of macrophages to a wide variety of stimuli and to variation in animal colonies.
PUER cells uniquely permit study of differentiation of macrophages without the previous
epigenetic programming seen in primary macrophages, macrophage-differentiation
cytokines M-CSF and granulocyte-macrophage colony stimulating factor (GM-CSF),
stress, or polarizing stimuli during purification. All of these can alter gene expression
independently of the experimental stimulus and may account for much of the variability
in the literature that used cells isolated from animals23,127,128. PUER cells are common
myeloid progenitors from fetal liver of PU.1-/- mice constructed in the lab of Harinder
Singh. Homozygous knockout of PU.1 is embryonic or newborn lethal. In the liver, the
development of the myeloid lineages is blocked at the CMP stage. IL-3 dependent fetal
CMPs were cloned and myeloid development potential was restored by inserting a gene
for a chimeric protein containing the PU.1 DNA binding domain with the hormone
binding domain of a modified tamoxifen-sensitive estrogen receptor9. Thus, these
progenitor cells can be differentiated in vitro to multiple cells of the hematopoietic
lineage and provide an attractive tool for studying the factors required for cell
differentiation.
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Our collaborator Dr. Peter Laslo previously used PUER cells for studying factors
for differentiation macrophages and neutrophils129. Differentiation to macrophages can
be induced by treatment with tamoxifen, rather than commonly-used differentiating
cytokines M-CSF and GM-CSF that can alter gene expression of polarization-associated
genes127. Such in vitro polarization results in a highly controllable macrophage
differentiation and polarization model subject to minimal in vivo polarizing stimuli or
accumulation of relevant epigenetic changes, thereby, minimizing environment-induced
factors. We took advantage of this system to build on the differentiation factor studies to
examine transcriptional regulation in M1- and M2-polarized macrophages.

2.3.5. Summary
This project investigates the hypothesis that Batf2 controls M1-specific gene
expression, thus contributing to the inflammatory functions of these cells. To achieve
this end, we use an in vitro model in which CMPs are first differentiated to macrophages
in vitro to avoid potential polarizing stimulation present in in vivo models. We then
polarize them to the M1 phenotype with LPS and IFNγ, producing M1-polarized
macrophages with minimal environment-induced variability. Gene expression analyses
revealed Batf2 as a novel M1-associated transcription factor. The role of Batf2 as a
putative master transcription factor was explored by creating CMPs constitutively
expressing Batf2. Constitutive Batf2 expression alone does not induce M1-specific gene
expression, but it enhances IFNγ/LPS-induced Cxcl10 expression and suppresses IL-4induced Arg1 expression. Further, the study begins to address the possibility of a
required M1-associated cofactor or condition for Batf2's activity, including binding
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partners. In agreement with the recent studies on Batf2, Batf2 is an M1-associated
transcription factor that likely controls gene expression in conjunction with an M1associated cofactor.
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Table 2.1: Select mechanisms of gene expression regulation
Mechanism

References

Protein binding/
Cofactor

AP-1
Dimerization
Partners

Jun/Jun represses
Mmp13, Jun/Fos
activates52

Yes
(Figure 4.17)

Non-AP-1
Dimerization
Partners

Fos/Jun proteins prefer
TREa and ATF/Jun
proteins prefer CREa73

No

Ternary Complex
Members

Batf3/Irf4 activation
complexes

Yes
(Figure 4.19)

Phosphorylation

Phosphorylation of
cFos76

No

SUMOylation

Regulation of AP-1
dimers77

Redox state

Regulation of cFos78

Epigenetic
Modification

PU.1 and Runx1 remodel
chromatin to determine
macrophage
lineage6,7,57,58

Post-translational
modification

Promoter/enhancer
accessibility

a

Tested in this
Study?

Level of Regulation

No

TRE: Phorbol Acetate-Responsive Element; CRE:cAMP-Responsive Element
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Table 2.2: Compensatory ability of Batf2 for other Batf proteins.

Cell Type

Product/
Outcome
Detecteda

Original
Inducer

Means of Batf2
Expressiona

T cells

IL17

BATF

Retroviral
in BATF-/-

No

B Cells

Class Switch
Recombination

BATF

Retroviral
in BATF-/-

No

Development

BATF3

Retroviral
in BATF-/-mice and
bone marrow cells

Yes

CD103+CD11bcDCsa

Development

BATF3

BATF2 DBDc on
BATF LZd

Approx. 50%

Th17

Development

BATF

BATF2 DBDc on
BATF LZd

No

+

CD8α cDCs

a

Compensates? a

________________________________________________________________________
a

Data from Tussiwand, et al.83

b
c

CD8α+cDCs and CD103+CD11b- cDCs are largely the same except for tissue location

The DNA-Binding Domain (DBD) mediates interaction with DNA

d

The Leucine Zipper (LZ) motif mediates interactions with other proteins
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Figure 2.1: Genes associated with various macrophage states.

Figure 2.1: Genes associated with various macrophage states. Common myeloid
progenitor cells (CMPs) are directed to the macrophage lineage and various functional
states by a handful of master transcription factors that induce the largest number of
lineage- or function-specific genes and some major transcription factors the also induce
several critical genes. Many of the transcription factors and key functional genes
defining macrophages and their functional states have been defined, although gaps
remain. Resting macrophages develop from high expression of transcription factors
including SpiB, interferon regulatory factor 8 (Irf8), and runt-related transcription factor
1 (Runx1) and express Cd11b and F4/80 (Emr1). Treatment of resting macrophages with
Th2 cytokine IL-4 leads to induction of master transcription factor Stat6, and major
transcription factors Irf4, Signal Transducer and Activator of Transcription 3 (Stat3),
Kruppel-Like Factor 4 (Klf4). These in turn induce expression of genes including
interleukin 10 (IL-10), transforming growth factor beta (TGF-β), mannose receptor C
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(Mrc), transglutaminase 2 (Tgm2), dectin (C-type lectin domain family 7 member A
[Clec7a]), arginase 1 (Arg1), Ym1 (chitinase 3-like-3 [Chi3l3]), found in inflammatory
zone 1 (Fizz1), and IL1R. These “M2a” polarized macrophages demonstrate decreased
autophagy and increased arginase activity. Treatment of resting macrophages with the
Th1 cytokine IFNγ and bacterial cell wall component LPS, in contrast, polarizes
macrophages to an M1 state. The transcription factors for M1 polarization are less well
defined. Irf5, Irf1, and basic leucine zipper transcription factor, ATF-like 2 (Batf2), all
have roles in broad M1-associated gene expression. Other major transcription factors
include Stat1, nuclear factor kappa B (NF-κB), the cFos and cJun proteins that form
activator protein-1 (AP-1) dimers, and hypoxia inducible factor 1α (Hif1a). M1
macrophages express IFNγ, IL-12, IL-1β, H2-Aa, Cxcl10, and inducible nitric oxide
synthase (iNOS). Functionally, these cells increase pathogen phagocytosis, increased
acidification of phagosomes, increased autophagy, increased nitric oxide (NO)
production, and iron restriction.
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Figure 2.2: Batf2 is a member of the AP-1 group of bZIP transcription factors.

Figure 2.2: Batf2 is a member of the AP-1 group of bZIP transcription factors. The
diagram above shows the alignment of the Batf proteins, centered on the bZIP regions
that mediate protein-protein and protein-DNA interactions. cFos and cJun are included
for reference. The homology between Batf2 and Batf is 47% and between Batf2 and
Batf3 is 43%.
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Figure 2.3: Functions of Batf and Batf3 in immune cell development and function.
A.

B.

C.

Figure 2.3: Functions of Batf and Batf3 in immune cell development and function. A.
Batf, present in B cells, Th17, Tfh, Th2, and Th9 cells, dimerizes with another AP-1
protein, and further complexes with Irf1. This ternary complex recognizes the AICE (5'TTTCnnnnTGACTAA-3' or 5'-GAAATGAnTCA-3') and drives gene expression
including AID (B cells, for class-switching); Rorc (encodes RORγt), IL17A, IL21, IL23R
(Th17, development and function); V-Maf Avian Musculoaponeurotic Fibrosarcoma
Oncogene Homolog (Maf), B cell CLL/lymphoma (Bcl6) (Tfh, development and
function); GATA3, IL-4, IL-10, and Cytotoxic T-lymphocyte associated 4 (Ctla4) (Th2,
development and function); IL9, Furin, Fes, Erg, IL-1RA (Th9, development and
function). B. Batf3, present in CD8α+ cDCs, CD11b+CD103- cDCs, and Th2 cells,
dimerizes with another AP-1 protein and further complexes with Irf4 or Irf8. This ternary
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complex recognizes the AICE and drives gene expression including CD103, Inhibitor of
DNA binding 2 (Id2), chemokine (X-C motif) receptor 1 (Xcr1), Spib, Clec9a (CD8α+,
CD11b+CD103+ cDC, development and function); GATA3, IL-4, IL-10, and Ctla4 (Th2,
development and function). C. In CD8α+ cDCs and CD11b+CD103+cDCs, Batf2 can
compensate for Batf3. Batf3 or Batf2 dimerizes with an AP-1 protein; in vitro, Batf2
binds cJun or JunB. The heterodimer forms a ternary complex with Irf4 or Irf8 that
recognizes the AICE (5'-TTTCnnnnTGACTAA-3' or 5'-GAAATGAnTCA-3'), driving
expression of critical genes for development and function including CD103, Id2, Xcr1,
Spib, and Clec9a. Macrophages express high amounts of Batf2 after M1 polarization;
macrophages simultaneously express cJun, JunB, and Irf8, but Batf2's cofactors remain to
be defined.
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Chapter III
MATERIALS AND METHODS
3.1.

Reagents and antibodies
The following cytokines and reagents were used to differentiate or polarize cells:

4-Hydroxytamoxifen (tamoxifen/4-OHT) (Calbiochem, Billerica, MA), γ-irradiated
lipopolysaccharide (LPS) from E. coli 011184 (Sigma-Aldrich, St. Louis, MO), murine
rIFNγ, murine rIL-10, and murine rIL-4 (Peprotech, Rocky Hill, NJ). PUER cells were
provided by Dr. Harinder Singh (University of Chicago) and maintained in IMDM
without phenol red (GIBCO, Grand Island, NY), supplemented with 10% fetal bovine
serum (Advantage Grade, Atlanta Biologicals) 100 U/ml penicillin, 100 μg/ml
streptomycin, and 28.2 μg/ml L-glutamine (GIBCO). Growth was maintained with the
addition of 12.5ng/ml IL-3 (Peprotech). Cultures were maintained at 37ºC, 5% CO2. For
transfections, Optimem-1 media was used (GIBCO) with TransIT2020 Reagent (Mirus,
Madison, WI). Transductions were perfumed with polybrene solution (Millipore,
Billerica, MA).
The following antibodies were used for Western blots: polyclonal rabbit antihuman Batf2 (Aviva Systems Biology, San Diego, CA), mouse anti-rabbit GAPDH (71.1)
(Sigma-Aldrich), and polyclonal rabbit anti-mouse iNOS/NOS Type II (BD Transduction
Laboratories) and the secondary antibodies used were goat anti-rabbit IRDye680 and goat
anti-mouse IRDye800CW (LI-COR Lincoln, NE).

3.2

PUER macrophage differentiation and polarization
PUER cells are myeloid progenitor cells with PU.1 under the control of the
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estrogen receptor. The cells were originally isolated from fetal liver of PU.1-/- mice, then
transduced with the chimeric construct composed of a PU.1 derivative fused to the
tamoxifen responsive ligand binding domain of the estrogen receptor by Walsh et al 5.
To differentiate the PUER cells to macrophages, PUER were seeded at 0.2x1060.4x106 per cm2 in polystyrene tissue culture flasks. One hundred nM tamoxifen was
added to the IMDM-based growth media described above109 and cells were differentiated
for 4 days. On day 4, one set of flasks was used for analysis. The remainder were treated
with polarizing cytokines or were treated with fresh media as control. At the time of
polarization, cultures consisted of both non-adherent and adherent cells. Non-adherent
cells were pooled, pelleted, washed, and re-distributed evenly to the flasks that contained
the adherent cells. Earlier analysis in our lab and in Dr. Singh’s lab were unable to
identify any differences between adherent and non-adherent cells (data not shown). To
polarize cells to M1 phenotype, 20 ng/ml IFNγ and 100 ng/ml LPS were added. To
polarize cells to M2, 4 ng/ml IL-4 was added. An additional group left unstimulated
served as a negative congrol. For alternative polarizations, recombinant murine IL-10
was added at 1-100ng/ml. Cells were then incubated for 2 days for typical experiments,
or as otherwise described.

3.3.

Cloning and transduction of Batf2 expression vector
Batf2 in the pCMV-SPORT6 plasmid was obtained from Open Biosystems and

cloned into the pMigR1 murine retroviral vector (pMigR1 courtesy of Harinder Singh).
The pMigR1 vector has previously demonstrated high efficiency cloning into
hematopoietic lineage cells130. This vector drives gene expression with a murine stem
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cell virus (MCSV) long terminal repeat (LTR) and allows for GFP selection by following
the MCS with an internal ribosomal entry site for simultaneous expression of GFP130. To
subclone Batf2, EcoRI and XhoI restriction enzyme recognition sequences were
introduced in the flanking regions of the Batf2 open reading frame (ORF) by site-directed
mutagenesis. For site-directed mutagenesis, the QuikChange Lightning kit was used
(Agilent Technologies, La Jolla, CA), following the manufacturer's protocol. The Batf2
ORF was isolated from pCMV-SPORT6 by EcoRI and XhoI digestion followed by gel
purification. At the same time, the vector pMigR1 was prepared by digestion with EoRI
and XhoI and similarly purified by gel purification. pMigR1-Batf2 was made by ligation
of these gel-purified Batf2 ORF and pMigR1 vector. The resulting plasmid (shown in
Figure 3.1) was verified by sequencing and transfected into E. coli for future
experiments.
To create PUER-Batf2 cells, pMigR1-Batf2 viral particles were created with a
packaging cell line and then transduced into PUER at the progenitor (CMP) stage.
Empty vector pMigR1 was transduced in parallel as a control. Purified pMigR1-Batf2
was transfected into the retroviral packaging cell line PLAT-E (Harinder Singh), resulting
in the viral particles used for transduction. At the time of transfection, PLAT-E were at
80-90% confluency in a 15cm2 cell culture plate containing Optimem-1 media with 210
µg of and 63 µg of DNA per 15 ml media. PLAT-E were incubated overnight at 32°C,
then the media was removed and replaced with 14 ml cIMDM as prepared above but
without antibiotics. Transfected PLAT-E cells were then incubated an additional 3 days
at 37 °C. Supernatant containing viral particles was harvested the next day and
immediately used for transduction. PUER cells were transduced with virus by “spin
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transduction.” For the transduction, PUER cells were seeded at 3x106 in 12 mls of viral
supernatant total and 2 mL was placed into each well of a 6-well flat-bottom plates and
spun at 2200 rpm for 2 hours at room temperature. After spin, cells were incubated at 37
°C for 30 minutes, washed, and then seeded in cIMDM supplemented with antibiotics
and IL3 as described above. After two days incubation at 37 °C, transduced cells were
selected by flow cytometry sorting for GFP+ cells. Sorting was done in the Flow
Cytometry Core Facility of the University of Kentucky by Jennifer Strange. After two
rounds of sorting, the transduced cells were greater than 98% GFP+ and used for
experiments. Individual clones were created by sorting the cells a 3rd time for GFP into
98-well plates, 1 cell/well. These clones were used for some experiments, with similar
results to the cells following 2 sorts.
Constitutive expression of Batf2 mRNA is shown in Chapter 4 (Figure 4.12). We
were unable to confirm constitutive Batf2 protein, however, due to inconsistent antibody
quality. Initial Western blots confirming Batf2 protein in M1-polarized PUER were
performed with one lot of AVIVA polyclonal anti-Batf2 antibody. Subsequent batches of
the anti-Batf2 from the same vender and from three other companies did not work with
Batf2 Western blots. I performed extensive troubleshooting with alternative antibody
concentration, protein extraction methods, secondary antibodies, etc. and was unable to
produce usable blots. In these analyses, the M1-specific marker iNOS was clearly
detectable, suggesting the problem lies with the antibodies and not with the methodology,
polarization, or other reagents (Figure 4.13). Thus, I was unable to do further analysis of
Batf2 protein. Recent commentaries suggest that this problem is increasingly
common131. Therefore, we cannot confirm constitutive protein expression in PUER-
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Batf2 cells.

3.4.

RNA extraction and analysis with RT-PCR
After 4 days of differentiation (D4) or 2 additional days of polarization (MØ, M1,

and M2), RNA was extracted for analysis using TriReagent (Molecular Research Center,
Cincinnati, OH) following the manufacturer's instructions. Briefly, both suspended and
adherent cells were collected for analysis: adherent cells were treated with TriReagent,
while suspended cells were pelleted at 1000 xg, washed, and combined with the adherent
cells. RNA was separated by addition of chloroform (Sigma) followed by centrifugation
at 20,000 xg for 15 minutes. RNA was then precipitated by addition of isopropanol
(Fisher), washed with 70% ethanol (maintained at -20 °C), and resuspended in
RNAse/DNAse-free H2O (Ambion, Grand Island, NY). RNA concentration was
measured using a Nanodrop 2000 (Thermo).
cDNA was synthesized from 4ug of extracted RNA using a GE First Strand cDNA
Synthesis Kit (GE Healthcare, Pittsburg, PA) following the manufacturer's instructions,
using random primers. mRNA levels were analyzed using semi-quantitative reversetranscription polymerase chain reaction (RT-PCR). Specific primers shown in Table 3.1
were used for 28-35 amplification cycles, and products were visualized by ethidium
bromide staining and digital photography. For each primer pair the number of cycles
used was based on prior analysis using known template amounts to determine a specific
number of cycles that was near the 50% level on the amplification curve. Band intensity
was calculated using ImageJ and normalized to the average signal of the loading controls
Gapdh, B-actin, and Hprt.
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3.5.

Protein extraction and Western blot analysis
For protein extraction, both suspended and adherent cells were collected.

Adherent cells were removed with a cell scraper. Lysis of cells was performed by
suspension in RIPA buffer (Pierce, Rockford, IL) with protease inhibitors (Sigma) and
passage through a 28 ½ G needle, and 15 minute incubation on ice with occasional
mixing. Protein concentration was determined using BCA assay as per manufacturer's
instruction (Pierce). Forty µg of protein was used for Western blots under reducing
conditions unless otherwise indicated. Protein was mixed with sample buffer (Bio-Rad)
supplemented with 2-mercaptoethanol (Sigma) and incubated at 90 C for 5 minutes.
Samples were then run with appropriate standards on a 4-20% tris-glycine gel (Bio-Rad,
Hercules, CA) at 100V, with buffer containing 0.1% sodium dodecyl sulfate. Proteins
were transferred to 0.2 µm nitrocellulose membrane. The Odyssey Infrared Imaging
System was used to visualize target proteins. Following transfer, the membranes were
blocked in Odyssey PBS blocking buffer (LI-COR) for 1 hour and incubated at 4ºC
overnight with rabbit anti-human Batf2 at 1:200 dilution or iNOS at 1:2000 dilution and
mouse anti-rabbit GAPDH clone 71.1, cross-reactive to mouse GAPDH, at 1:40,000.
Membranes were washed for 3 times with PBS-0.1% Tween for 5 minutes each, then
incubated in blocking buffer with goat anti-rabbit IRDye690 and goat anti-mouse
IRDye800 antibodies at 1:15000. After washing, the membranes were imaged with
Odyssey Infrared Imager.
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3.6.

Cxcl10 and Total Protein Assays
Total protein was used as a correlate of cell number to normalize Cxcl10 that was

measured in the culture supernatants. To verify that total protein correlates with cell
number, a 24-well flat-bottomed cell culture plate was seeded with various concentrations
of PUER-pMigR1 and PUER-Batf2 cells and differentiated for 4 days with tamoxifen.
After differentiation, the plates were spun at 1000 xg, 10 min, then analyzed for total
protein or cell number. For total protein, the cells from two series of aliquots were
harvested, washed with PBS, and lysed in RIPA buffer (Pierce). Total protein was
quantified from lysate with BCA Protein Assay Kit (Pierce) as per manufacturer's
protocol. For cell number, cells were harvested from two parallel series of aliquots,
washed in PBS, and counted using a hemocytometer. As clearly shown in Figure 3.2,
cell number correlates linearly with total protein, validating our use of total protein
concentration to normalize Cxcl10 measurements.
Secreted Cxcl10 was analyzed using the murine IP-10 Mini ELISA Development
Kit (Peprotech), following manufacturer's protocol. Cells in 24-well tissue-culture plates
were differentiated for 4 days and polarized an additional day as described above. Plates
were spun at 1000xg, 10 min. Supernatant was used for Cxcl10 analysis, and cells used
for total protein analysis. For Cxcl10, supernatant was added to 96-well plates coated
with rabbit anti-mIP-10. Biotinylated rabbit anti-mIP-10 were then added, followed by
avidin-HRP conjugate and then ABTS liquid substrate. Absorbance values correlating to
substrate conversion for each kit were detected using a Spectramax M5 plate reader with
SoftMaxPro software. Comparisons between PUER-MigR1 and PUER-Batf2 were done
by 2-tailed Student's T test, 2-tailed (n =3), with equal variance. Statistical significance
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was accepted at P< 0.05.

3.7. shRNA subcloning and transduction
To knock down Batf2 expression, three small-hairpin RNAs (shRNAs) were
designed using a program created by the Hammond lab at RNAi Central
(http://cancan.cshl.edu/RNAi_central/RNAi.cgi?type=shRNA) and subcloned into a
retroviral vector (murine stem cell virus [pMSCV]), resulting in three different
knockdown vectors (shBF2.1, shBF2.2, and shBF2.3). pMSCV containing shRNA
targeting firefly luciferase served as a negative control.
The 22mer shRNAs produced by the Hammond lab’s algorithm for shBF2.1,
shBF2.2, and shBF2.3 contain two regions complementary to each other such that the
resulting transcript forms a short hairpin. These regions are also complementary to the
Batf2 CDS such that the short hairpin, after process by the cell, targets Batf2 message for
degradation. The sequences are as follows:
shRNA1
TGCTGTTGACAGTGAGCGAACTCTCCAGCTGCTCTGGGACTAGTGAAGC
CACAGATGTAGTCCCAGAGCAGCTGGAGAGTCTGCCTACTGCCTCGGA
shRNA2
TGCTGTTGACAGTGAGCGAGTCCATGCTCTCATGAGTCTCTAGTGAAGC
CACAGATGTAGAGACTCATGAGAGCATGGACCTGCCTACTGCCTCGGA
shRNA3
TGCTGTTGACAGTGAGCGCCCACTCATTGGCAGAAGTCATTAGTGAAGC
CACAGATGTAATGACTTCTGCCAATGAGTGGATGCCTACTGCCTCGGA
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Primers complementary to 5’ and 3’ ends containing restriction enzyme sites EcoR1 and
Xho1 were used for amplification to produce oligos for subcloning. Resulting oligos
were purified by electrophoresis on an agarose gel, digested with Ecor1 and Xho1 and
subcloned into the pMSCV vector similarly purified and enzyme-digested. Correct
insertion of the oligos was confirmed by sequencing. The pMSCV vector is useful for
transduction of hematopoietic cells, and contains the Lac operon for selection in bacteria
and hygromycin resistance for selection in eukaryotic cells. pMSCV-shBF2.1, -shBF2.2,
and –shBF2.3 were transfected into E. coli for amplification, with successfully
transfected cells selected by blue-white color selection. Plasmids were later purified
using plasmid purification kits (Qiagen), analyzed for the presence of the shRNA oligo,
and purified using agarose gel purification. Purified plasmids were packaged into
retroviral virions using packaging cell line PLAT-E, and virions were used to transduced
PUER cells by spin transduction as described above for creation of PUER-Batf2 cells.
Unlike PUER-Batf2, successfully transduced cells were selected by growth in
hygromycin-containing cIMDM. Cultures grew from shBF2.2 and shBF2.3 –transduced
cells, but these demonstrated levels of Batf2 equivalent with untransduced PUER after
polarization with LPS/IFNγ (data not shown). shBF2.1-transduced cultures failed to
grow after multiple attempts using the pMSCV retroviral system or a lentiviral vector
system in collaboration with the University of Kentucky Genetic Technology Core
Facility.

3.8. Nitrate detection and arginase activity assays
To determine iNOS activity, supernatants from control and polarized PUER
macrophages were analyzed using a Griess Reaction in a colorimetric assay kit
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(EnzyChrom Nitric Oxide Synthase Assay) as per manufacturer’s instructions (BioAssay
Systems, Hayward, CA.) Briefly, cells were seeded and differentiated to macrophages as
described above in cIMDM with Tamoxifen and IL3. Cells were then polarized with
LPS/IFNγ (M1) or IL-4 (M2), or left unstimulated. After 24 hours, supernatants were
removed and centrifuged at 10,000 x g to remove cells. Nitrate in these supernatants was
analyzed using the kit reagents that employ the Griess reaction, in which nitrate is
reduced to nitrite for 5 min at 60 °C. The reaction generates proportional indicator
product that can be quantified at 540 nm.
To determine arginase activity, conversion of L-arginine to urea in total cell
lysates was analyzed using a kit as per manufacturer’s instructions (Sigma). Briefly, cells
were seeded, differentiated to macrophages, and polarized as described above. After 24
hours, cells were harvested by scraping and washed 1-2 times by pelleting cells at 1000 x
g, 4 C, 10 minutes and resuspension in PBS. Total cell lysates were made using the lysis
buffer suggested in the kit containing 0.4% Triton X-100, pepstatin, and leupeptin at the
recommended concentration of 100 ul per 106 cells. Cells were incubated in the lysis
buffer on ice for 10 minutes. Insoluble material was then removed by centrifugation at
14,000xg at 4 C, 10 minutes, and supernatants were aliquoted onto a 96 well plate for
analysis. The reaction of supernatants with reaction buffer and Mn solution and controls
continued for 2 hours at 37 C, after which the urea detection reagent was added and the
amount of urea was analyzed using a plate reader.
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3.9. BMDM isolation
Bone marrow harvested from BALB/c mouse femurs was suspended in PBS, then
pelleted at 400 x g and resuspended in complete DMEM using a syringe with an 18 G
needle. Cells were then counted on a hemocytometer and 4 x 106 cells were seeded in a
10 cm tissue culture dishes with 50 ng/mL M-CSF (Peprotech). Three days after seeding,
additional complete RMPI media with M-CSF was added. On day 7, cells were washed
with PBS, washed with Ca/Mg free PBS with 0.5 mM EDTA, lifted with Cellstripper
non-enzymateic cell dissociation solution ((Mediatech) pelleted at 450 x g for 5 min, and
resuspended in complete DMEM at 0.5x106 cells/mL. These cultures were polarized and
used for mRNA analysis as described for PUER above.
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Table 3.1: Primers used in RT-PCR analysis.
A.
Arg1
Ccl5
Ccne1
(Cyclin E)
cFos
cJun
Csf1r
Cxcl10
Figf/Vegfd
Fizz1
Fra1
Fra2
H2-Aa
Hdac9
Id2
Bcl6
Ifi204
Ifi205
IL-1β
iNOS

5'- CCCTGGGGAACACTATATAATAAAAA-3'
5'- GTGTTCACAGTACTCTTCACCTCCT-3'
5'- ACCATATGGCTCGGACACCACTCC-3'
5'- AGATGCCCATTTTCCCAGGACCGA-3'
5'- ATTGCCAAGATTGACAAGACTGTG-3'
5'- CGTCTCTCTGTGGAGCTTATAGAC-3'
5'- CCAAACTTCGACCATGATGTTCTC-3'
5'- GATAAAGTTGGCACTAGAGACGGA-3'
5'- CATTTTCTCACCAACTGCTTGGAT-3'
5'- TCTCCCTTTTCTTTACAGTCTCGG-3'
5'- AGGCTAAAGTCCTTGACAGCAATA-3'
5'- TTGAGGATAACGTTGAATCCCACT-3'
5'- CATGAACCCAAGTGCTGCCGTCAT-3'
5'- AAAGGGGAGTGATGGAGAGAGGCT-3'
5'- GAAACAACTGCTTAGTCATCGGTA-3'
5'- CTTGAAGAATGTGTTGGTTGTCTT-3'
5'- TGAGACCATAGAGATTATCGTGGA-3'
5'- ACATTTAAAGGCACATGAGTCAGA-3'
5'- ACAGAGGTTCATCTGGAGAGGT-3'-3'
5'- CAGTGGGTCCCAGGAAATGAG-3'-3'
5'- GAAGAAAACCACCCTGTTTCCTCT-3'
5'- ATAGGGATTGGACATGGAGGTGAT-3'
5'-CAGCCTCTGTGGAGGTGAAGACGA-3'
5'-TTGGGGAACACAGTCGCTTGAGGA-3'
5'-GAGGCAAGAACAGGAAGTAGAGAG-3'
5'-TGAATGAAGTGACAAGATTTCCAT-3'
5'-GAGCTTATGTCGAATGATAGCAAA-3'
5'-ATACTGGGTCCTTCTGGTATTCAC-3'
5'-ACTTCATGTACACATCTAGGCTCAAC-3'
5'-GTATTTCTCAGTGGCATATTGTTCTC-3'
5'-ACCAAAGTTAGTGTGTGGAGAACA-3'
5'-AGGAGTTGCATTAGCTCTTTGTCT-3'
5'-ACTTCCACAGCCCAGAAAAGGAAAG-3'
5'-TCAAACGGGTCTGTTGCAGTGAG-3'
5'-AAGTGATATTCTCCATGAGCTTTGTA-3'
5'-CTTTGCTCTTGACTTCTATCTTGTTG-3'
5'-GATGCTGCCACCTTGGAGTTCACC-3'
5'-GTACCAACCATTGAAGGGGCAGGC-3'
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Table 3.1 (cont.)
Irf1
Irf2
Irf3
Irf4
Irf5
Irf7
Irf9
JunB
JunD
Mmp13
Mrc1
Parp12
Parp14
Prp
Stat1
Stat2
Tcfec
Tgfb1
Tgtp
Ym1

5'-GGAAGTGAAGGATCAGAGTAGGAA-3'
5'-TTCATAAGGTCTTCGGCTATCTTC-3'
5'-AAGAAGATTTTCCAGATCCCCTGG-3’
5'- GGTTCTTGCTTGATGTGCTTAAC-3’
5'- AGTGTATGAGTTTGTGACTCCAGG-3’
5'- GAACTCCCATTGTTCCTCAGCTA-3’
5'-TTCCCTACCCGGACGACAATGGAC-3'
5'-GGAGCGGTGGTAATCTGGAGTGGT-3'
5'-AGCTGCTAGATGTCCTGGACCGTG-3'
5'-ATGCTGTCTGCCGACCAAGAAAGC-3'
5'-AGCGAAGAGGCTGGAAGACCAACT-3'
5'-CTTGGGGTTTGGAGCCCAGCATTT-3'
5'- GTAGAGATTTGGCCCAGTACTTC-3'
5'- ACGGTGATAAGAACCATCACAGAA-3'
5'- GCCTTTCTATCACGACGACTCTTA-3'
5'- CTGATCCCTGACCCGAAAAGTAG-3'
5'- GGGGTACAGAGTGAGATTCTGTTT-3'
5'- TCATATTCCCAAGTGTGGCAGTAA-3'
5'-AAGCAGTTCCAAAGGCTACAACT-3'
5'-AGATAAACATAAGGTCACGGGATG-3'
5'-TCAGAAATGGGAGTGTAAGAATGA-3'
5'-ACAGCTTGTCTTTGTCGTAGTCAG-3'
5'-GGATGTGCCGTGCAGACCACA-3'
5'-GGCCCAAAGAGCATCCCAGACTACT-3'
5'-GCCTCCTGGGGTGGACGAGT-3'
5'-ATGCCAGAGAGCACTGCGGA-3'
5'-CTCTTTGTGACTATGTGGACTGATGT-3'
5'-GCCTGTAGTACACTTGGTTAGGGTAG-3'
5'-TGGACGACCAGTACAGCCGCT-3'
5'-CCTTCTCTGTTCTGAGAGGTTTTGCA-3'
5'-TGGCCCTACCCAGTTGGCTGA-3'
5'-TGGCTCTGATGGGGGTCTGAAGAC-3'
5'-TGCGCTGGAACAAAGGGACCATTC-3'
5'-TTCCTCTCAGGATGGGTCTGCTGC-3'
5'-AAGCGGACTACTATGCTAAAGAGG-3'
5'-ACGCCAGGAATTGTTGCTATATT-3'
5'-TGCCTGGCATTGGGACCACTAACT-3'
5'-GCTTGTGGGCTGGGAGATCCTGTA-3'
5'-AGAATCTGTGGAGAAAGACATTCC-3'
5'-TAGAAGGGTCACTCAGGATAAAGG-3'
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Table 3.1 (continued)
B.
1F
1R
2F
All F
All R
3F
3R

5'- GGGCCTCCATAGGTCACTGG -3'
5'- AAGGATTCGTGCTGGTGCAG -3'
5'- GTCTTGTAGATCTCTTCTGTGCCA -3’
5'- AAGAAGAAGCAGAAGAACCGAGT -3'
5'- CTAGAGGTGTCCTCACCATGAGA -3'
5'- TGACTGAGACATTCTAGGCAGC -3’
5' -CGTGGTTCTGTTTCTCCAAGGATT -3’

A. Sequences of primers used for gene detection.
B. Sequences of primers used for Batf2 isoform analysis.
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Figure 3.1: Vector for constitutive Batf2 expression.

Figure 3.1: Retroviral vector for constitutive Batf2 expression. Batf2 in the pCMVSPORT6 (Open Biosystems) was modified by introducing EcoRI and XhoI restriction
enzyme recognition sequences were introduced in the flanking regions of the Batf2 open
reading frame (ORF) with site-directed mutagenesis. The long terminal repeats (LTRs)
are from the murine stem cell virus (MSCV).
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Figure 3.2: Cell number correlates with total protein.

Figure 3.2: Cell number correlates with total protein. As cell number increases, total
protein extracted also increases linearly. PUER-MigR1 and PUER-Batf2 cells were
seeded at various concentrations in a 24-well plate and polarized with tamoxifen as
described elsewhere in this section. After differentiation, cells were harvested washed
with PBS, then either counted with a hemocytometer or lysed. Lysed cells were analyzed
by BCA analysis for total protein.
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Chapter IV
RESULTS
Transcriptional programs of resting, LPS/IFNγ-activated (M1), and IL-4-activated

4.1.

(M2) PUER macrophages
The overall goal of this project is to understand the mechanisms governing
macrophage polarization to an inflammatory phenotype by describing putative novel
master transcription factors required for key M1 gene expression. In this study, I
investigate and rule out the ability for the highly expressed, M1-associated, and novel
transcription factor Batf2 expression by itself to induce expression of key genes for M1
polarization. I demonstrate a role for Batf2 in enhancing LPS/IFNγ induction of key
inflammatory chemokine Cxcl10 mRNA and suppressing the IL-4 induction of the antiinflammatory effector protein Arginase 1. I further postulate reasons for the failure of
Batf2 alone to induce major M1 gene expression or alter phenotype, the most likely
possibility being a requirement for a cofactor such as an Irf family member.

4.1.1. Differentiation and polarization of the PUER cell line provides an in vitro
system for determining gene changes due to polarization
Macrophage cells have a wide repertoire of functions, from phagocytosis of
pathogens to secretion of growth factors. Macrophages have different functional states
tailored to specific environments, named ‘polarization states.’ During infection,
macrophages can be divided into two polarization states based on the T cell response type
that produces their polarizing cytokines2. M1 polarized macrophages support
inflammatory Th1 type immune responses that function in elimination of microbial
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pathogens. This state is associated with cytokines such as Ccl5 and IL-1β, enzymes such
as iNOS and chemokines such as Cxcl1022. M2 polarized macrophages more often
participate in repair and can counteract M1 responses. These cells secrete cytokines such
as TGF-β1, enzymes such as Arg1 and MMPs, and downregulation of Th1 type
responses. Typically, the bacterial cell wall component LPS and the inflammatory Th1associated cytokine IFNγ are used to imitate an infection and polarize cells to M1, while
Th2-associated cytokine IL-4 or closely-related IL13 are used to imitate an antiinflammatory M2 response in experimental systems2.
Gene expression and thus function in response to polarizing stimuli occurs under
the guidance of transcription factors. Given that a few master transcription factors
govern each stage of development and differentiation of most cells, such as PU.1, Runx
and Irf8 during macrophage development, it follows that macrophages likely require a
master transcription factor for polarization. Our overall goal is to identify these master
transcription factors for M1 polarization. Although master transcription factors have
been determined for development, identification of factors guiding polarization states has
been complicated by the unique plasticity of mature macrophages in that many nonpolarizing stimuli present in the environment alter gene expression. Therefore, my
studies use the PUER cell line, a system which provides a highly controllable
environment.
PUER cells are IL3-dependent common myeloid progenitor (CMP) cells with
PU.1 under the control of the estrogen receptor9. PUER cells uniquely permit study of
macrophages differentiation without the previous epigenetic programming, polarizing
stimulation during purification, or commonly-used differentiating cytokines M-CSF and
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GM-CSF that can alter gene expression, and with controls for time in culture. These are
described in Chapter 3, page 52127,128. Briefly, Walsh et al. created these cells by
isolating fetal liver cells from PU.1-/- mice, then transducing them with a chimeric PU.1
transcription factor attached to a modified estrogen receptor regulatory domain9. These
cells have the ability to differentiate into multiple hematopoietic cell lineages after
treatment with appropriate cytokines. PUER are differentiated to resting macrophages by
tamoxifen with IL-3, then polarized to inflammatory phenotype (M1) with IFNγ/LPS, or
to alternative phenotype (M2, sometimes referred to as M2a) with IL-49,132. This use of
PUER produces polarized macrophages in a highly controlled environment.
Our collaborator, Dr. Peter Laslo (University of Leeds) used the PUER cell
system to study macrophage and neutrophil differentiation and identify factors that
regulate their differentiation129. We extend use of this system to analysis of macrophage
polarization. We first validated the PUER system for studying macrophage polarization
by confirming expression of known key M1- and M2-associated genes and activity of key
M1- and M2-associated enzymes. To do this, PUER cells were differentiated to
macrophages and polarized, and expression of M1 and M2 specific genes was analyzed.
PUER CMPs were first differentiated for 4 days with tamoxifen and IL3, then treated to
produce three groups. Treatments included: i) additional 2 day culture in new media in
parallel with polarized cells (MØ), ii) 2 days in fresh media supplemented with 20ng/ml
IFNγ and 100 ng/ml LPS (M1), and iii) 2 days in fresh media supplemented with 4 ng/ml
IL-4 (M2) (Figure 4.1). An additional control, macrophage differentiated for 4 days and
immediately processed, ruled out any shifts in gene expression due to time in culture.
RNA and protein analyses were performed at the MØ, M1, and M2 state for known
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markers. To analyze RNA, we use semi-quantitative reverse-transcription PCR. This has
the advantage of being a rapid and inexpensive method to roughly quantify gene
expression when the sensitivity of real-time reverse-transcriptase PCR is unnecessary.
This method was used for several known M1- and M2-associated genes.
As shown in Figure 4.2, M1-polarized macrophages expressed high levels of
established M1-associated genes iNOS and Ccl2, and M2-polarized macrophages
expressed high levels of M2-associated genes Arg1 and Fizz1. Our lab extended this
analysis to a wider panel of M1 and M2 specific genes and found that most are
appropriately upregulated in the PUER model systems, including H2-Aa, Irg1, Stat1, and
Mrc1 (data not shown). To confirm that PUER macrophages polarized to M1 or M2
states are functional macrophages, activity of the key enzymes iNOS (M1) and Arg1
(M2) were measured. Nitric oxide production, indicative of iNOS activity, was minimal
in resting or M2-polarized macrophages, but increased in M1-polarized macrophages
(Figure 4.2). Similarly, Arginase activity was undetectable or low in lysates from resting
or M1-polarized macrophages, but increased in M2-polarized macrophages. Taken
together, these results indicate that PUER-derived macrophages polarize to M1 or M2
states after stimulation with LPS/ IFNγ or IL-4, respectively.
To comprehensively survey gene expression changes in polarized PUER
macrophages, a microarray analysis was performed at the UK Microarray Core Facility
using the GeneChip ® Mouse Exon 1.0 ST Array to analyze gene expression in PUER
macrophages in the MØ, M1, and M2 state. Microarray analysis confirmed that PUER
cells express macrophage-specific but distinct transcriptional programs for differentiated
resting, M1-polarized, or M2-polarized macrophages. All states expressed macrophage
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markers Emr1 (F4/80) and Itgam (CD11b) (data not shown) confirming previous studies
using PUER to study macrophages9,129,132. M1-polarized PUER macrophages compared
to unpolarized macrophages revealed an expected increase in M1-associated genes,
including Irf1, Stat1, Cxcl10, and key M1 enzyme iNOS and lack of upregulation of M2associated genes including Mmp13, Fizz1, Mrc1, and the key M2 enzyme Arg1 (Table
4.1). Many were confirmed by semi-quantitative reverse-transcriptase PCR (RT-PCR)
(data not shown). Similarly, M2 -polarized PUER macrophages upregulated M2associated genes Mmp13, Fizz1, Mrc1, and key M2 enzyme Arg1. Likewise, many were
confirmed with RT-PCR including Fizz1 and Arg1. M2-polarized PUER macrophages
did not increase expression of M1-associated genes Irf1, Stat1, Cxcl10, and key M1
enzyme iNOS. Importantly, there were no significant gene expression changes between
the day 4 and the MØ unpolarized macrophages. Therefore, PUER cells differentiate to
macrophages and polarized to M1 and M2 states not only express the appropriate
markers, but also display established M1 and M2 function.
Originally, many investigators thought that macrophage polarization to
M1or M2 states was more stable or permanent. However, macrophages are now
appreciated to be more plastic and exist along a spectrum of idealized polarization states.
For example, adequate stimuli can drive a macrophage cell from an inflammatory state to
an anti-inflammatory state133. To determine whether PUER macrophages also exhibit this
ability, PUER cells were polarized with M1 or M2 stimuli followed by the opposing
stimuli. PUER cells were differentiated to macrophages with tamoxifen and then
polarized for 2 days with LPS/ IFNγ or IL-4 as before. These resulting polarized
macrophages were then treated with the same stimuli or with opposite stimuli for an
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additional 48 hours (M1 with IL-4, M2 with LPS/IFNγ). Lanes 1 to 3 in Figure 4.31
show that tamoxifen-differentiated PUER macrophages strongly express mRNA for the
M1 marker iNOS after 48 hours of polarization with LPS/IFNγ, or strongly expressed
mRNA of M2 marker Arg1 after 48 hours of polarization with IL-4, as expected. To
determine whether polarization was reversible, M1-polarized macrophages were then
treated with IL-4 and M2-polarized macrophages were treated with LPS/IFNγ for an
additional 48 hours. M1 polarized cells treated with IL-4 slightly upregulated Arg1 and
downregulated iNOS, while M2 polarized cells treated with LPS/IFNγ strongly
upregulated iNOS and strongly downregulated Arg1 (Figure 4.3). These results suggest
polarized PUER macrophages exhibit plasticity, with M2-polarized macrophages more
readily reversible than M1- polarized macrophages under the conditions used in this
study.
In summary, our studies provide proof of concept that PUER cells can be used as
a model system to study macrophage polarization. Therefore, PUER-derived
macrophages present a good model for my studies on transcription factors involved in
macrophage polarization. Moreover, PUER macrophage repolarization to M1 and
somewhat to M2, demonstrate a plasticity that is a feature of macrophages in the animal.

4.1.2. Identification of novel transcription factors during sustained M1 or M2
polarization
Many studies on macrophage transcription factors analyze gene expression at
early time points after polarization. We focused on transcription factors altered at 48

The data shown in Figure 4.3 are from an experiment done with the assistance of Mr. Ben Taylor and Dr.
Joe McGillis
1
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hours after stimulation to identify transcription factors involved in long-term maintenance
of polarization. Moreover, transcription factors may be altered briefly due to fresh serum
(such as serum response factors) or serve only a temporary role during initial polarization
while not playing a long-term role maintaining polarization. It is important to distinguish
between these two phases because in vivo inflammatory responses are often beneficial
during initial clearance of infection but damaging to the host in the long term. Having
established the PUER macrophage model as useful for analyzing polarization-associated
gene expression, we used this system to identify transcription factors highly increased or
decreased at 48 hours after polarization. Twenty-three total transcription factors were
increased in M1-polarized macrophages, and 5 were increased in M2-polarized
macrophages (Figure 4.4). M1-associated macrophage transcription factors included the
previously known Irf1 and Stat1, but also novel Ifi204, Id2, and Batf2. M2-associated
transcription factors included known Tcfec and novel Hdac9 and Zpf609. Batf2 was one
of the most highly upregulated transcription factors upon M1 polarization, increasing
nearly 10-fold relative to unpolarized macrophages. Moreover, it belongs to the AP-1
group of transcription factors, interacts with AP-1 signaling in non-immune cells, and
bears close resemblance to key transcription factors important for development of other
hematopoietic cells, Batf and Batf3. These last observations also support the case for
Batf2/s potential as a key M1 transcription factor. We therefore selected Batf2 for further
investigation as a putative master transcription factor during M1 polarization.
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4.2.

Batf2 expression in PUER common myeloid progenitors and macrophages
4.2.1. Batf2 is rapidly upregulated in IFNγ-stimulated macrophages
Our initial hypothesis was that Batf2 is a master transcription factor for LPS/IFNγ

(M1) polarization. The first goal was to confirm the microarray data that Batf2
selectively increases in M1-polarized PUER macrophages. To do this, PUER
macrophages were differentiated and polarized as in the microarray analysis (Figure 4.1).
PUER macrophage progenitors were differentiated to macrophages for 4 days with
tamoxifen, then polarized to M1 with LPS/IFNγ or to M2 with IL-4 for an additional 2
days. Total RNA was extracted and analyzed by semi-quantitative RT-PCR.
Undifferentiated monocytes and unpolarized or IL-4 polarized macrophages express little
or no Batf2, while macrophages stimulated with classical activation stimuli IFNγ and
LPS highly upregulate Batf2 mRNA and protein, shown in Figure 4.5 A and B,
respectively. These results confirm that Batf2 is selectively induced in M1 PUER
macrophages at 48 hours. In our model system we were interested in this later time point
for sustained polarization as explained in the previous section, but it is also important to
know whether Batf2 plays a role in the initial polarization. We therefore stimulated
PUER macrophages with LPS/IFNγ and analyzed Batf2 mRNA expression at various
time points from 0.5 hours to 24 hours. As shown in the representative experiment in
Figure 4.6, Batf2 message appears 1 hour after polarization with LPS/IFNγ, peaks
between 2 and 8 hours, but remains sustained at 48 hours. These results support a role
for Batf2 in both the transition from resting to the M1 polarized state as well as sustained
M1 polarization.
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To confirm that Batf2 expression in the PUER M1-polarized macrophages is
relevant to the induced M1 state in primary macrophages, a study was done with murine
bone-marrow-derived macrophages (BMDMs). BMDMs were purified from mice and
polarized to M1 with LPS/IFNγ, polarized to M2 with IL-4, or left unstimulated for 24
hours. Confirming the results in PUER, M1-polarized cells strongly upregulated Batf2
mRNA as seen in Figure 4.72. In contrast to PUER, the BMDMs also expressed Batf2
after IL-4 stimulation. Batf2 expression by IL-4 polarization was moderate compared to
the strong upregulation by LPS/IFNγ polarization. These cells may have been
epigenetically programmed or primed to M1-associated gene expression in vivo, altering
gene expression, or the stress of purification and stresses in cell culture may have driven
all treatment groups towards M1. The data demonstrates, however, that Batf2 is induced
in macrophages in response to LPS/IFNγ, agreeing with previous reports of Batf2 as part
of an IFN response1,83,95.
For many genes, multiple isoforms exist and may have different functions. The
National Center for Biotechnology (NCBI) database contains sequences for four different
Batf2 mRNA isoforms and proteins, but no studies have reported on the representation of
isoforms in any cell type or the functionality of the different isoforms. To determine
which isoforms are present in macrophages during peak Batf2 mRNA expression and
sustained polarization, cells were polarized for 8 hours (peak Batf2 mRNA expression)
and 48 hours (sustained Batf2 mRNA expression). Total RNA extracts from polarized
cells were analyzed by RT-PCR using isoform-specific primers. Note that no primers can
be made specific to the reference sequence since X1 isoforms include the entire reference

The data shown in Figure 4.7 are from an experiment done with the assistance of Mr. Robert Hayman IV
and Dr. Joe McGillis
2
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sequence (Figure 4.8). Two isoforms were detected: X1 and X3. Since universal Batf2
primers produced a robust product while X1 and X3 are only weakly detectable, it is
likely the reference sequence makes up part of the total isoforms, but this remains to be
conclusively determined. Most differences in message lie outside the reading frame, and
protein products differ only in a brief segment at the C-terminal region. A notable
exception is the truncated isoform “CRA_a” (NCBI accession EDL33225.1). X1 differs
from the reference sequence in a missing Q residue in the bZIP region. No functional
correlations are known. This data provides the first report of the existence of multiple
Batf2 isoforms in any cell type. For protein isoforms, the antibody to Batf2 has not been
tested. The antibody was raised to a region of the human Batf2 overlapping a C-terminal
segment of bZIP region common to all isoforms except the truncated “CRA_a.” The
isoforms share 94% pairwise identity in this region. Therefore, the antibody should
recognize products of the reference, X1, and X3 message present in macrophages.
However, this remains unverified. This data suggests that LPS/IFNγ activation
upregulates multiple isoforms, including X1 and X1, and possibly the reference sequence.
The functional consequences remain unknown.

4.2.2. Batf2 is upregulated in response to IFNγ or IL-10, but not LPS
Typically, LPS and IFNγ are used as in vitro inflammatory stimuli to model M1
polarization, and both are required for full M1 polarization. In vivo, however,
macrophages see a wide variety of stimuli that polarize them to variations of the
inflammatory and anti-inflammatory phenotypes, depending on the environment. In
some contexts, for example, IFNγ may be present without TLR4 agonists like LPS,
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activating different macrophage functions than LPS/IFNγ in combination. IFNγ signals
through JAK/Stat pathways, and LPS signals through MyD88/AP-1 and MyD88/NF-κB.
IFNγ activates a receptor composed of IFNγ-receptor 1 (IFNGR1) and IFNGR2, which
activates JAK2, which then activates Stat1 transcription factor homodimers. TLR4 and
MyD88 activate IKK, PI3K, and MAPKKs, which activate NF-κB and AP-1 transcription
factors. To determine which pathway(s) control Batf2 in PUER macrophages, we tested
for Batf2 mRNA in response to LPS alone, IFNγ alone, or LPS/ IFNγ. Expression was
analyzed at 8, 24, and 48 hours using semi-quantitative RT-PCR with specific primers.
The 8 and 24 hour timepoints were included to account for possible differences in peak
gene expression in response to LPS vs IFNγ. Figure 4.9 shows that IFNγ alone induced
Batf2 at 8, 24, and 48 hours, while LPS did not. Additionally, IFNγ-induced Batf2
message roughly compares to IFNγ /LPS-induced Batf2 message quantitatively. Taken
together, the results suggest that IFNγ induces Batf2 in PUER macrophages, while LPS
does not contribute to Batf2 expression.
Like IL-4, IL-10 also opposes inflammatory stimuli29,33,57. However, the
transcriptional repertoire of IL-10- activated macrophages differs somewhat from IL-4actived macrophages, and overlaps partly with the IFNγ-induced repertoire26,31. IL-4
activated macrophages express IL-10, for example, while IL-10 activated macrophages
express FceRII26. Both induce the mannose receptor (Mrc1) and Arg1. IL-4 stimulates
the IL-4 receptor, resulting in activation of Stat3 and Stat6. IL-10 stimulates the IL-10
receptor, resulting in activation of Stat3 but not Stat629,30,32,33. To determine whether the
IL-10-activated pathway differed from the IL-4 pathway in Batf2 induction, we polarized
PUER macrophages as before with LPS/ IFNγ or IL-4, and in parallel stimulated
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macrophages with 1, 10, or 100ng/ml IL-10. In contrast to the minimal expression of
Batf2 in unstimulated or IL-4-polarized macrophages, all three IL-10-treated
macrophages expressed Batf2 at 48 hours (Figure 4.10). Expression was not dosedependent and not as robust as LPS/IFNγ treatment. It is possible that the minimum dose
used, 1 ng/ml, elicits the maximal response for IL-10. In this case, this suggests that the
maximal LPS/IFNγ response surpasses the maximal IL-10 response.
In summary, LPS/IFNγ induces three isoforms of Batf2 mRNA in PUER
macrophages, although protein products remain unknown. IFNγ and, unexpectedly, IL10 induce Batf2, while LPS does not. After LPS/ IFNγ stimulation, Batf2 mRNA appears
within one hour, peaks before 16 hours, and is maintained for over 48 hours. This data
demonstrates that Batf2 expression in macrophages is controlled by signaling pathways
activated by both IFNγ and IL-10, but not by IL-4 or LPS.

4.2.3. Batf2 expression precedes select M1 genes
If Batf2 is important for generating the M1 phenotype in macrophages, we would
expect that Batf2 expression would proceed expression of genes selectively upregulated
in M1 macrophages. To determine whether Batf2 is induced prior to induction of major
M1-related genes, we compared the timecourse of the expression of various M1associated genes with expression of Batf2. In these studies PUER macrophages were
differentiated with tamoxifen and IL-3 and polarized with LPS/IFNγ or left unstimulated.
Total RNA was extracted at time points from 0 to 24 hours and analyzed by semiquantitative RT-PCR with specific primers.
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Shown in Figure 4.11 are two genes consistently and highly upregulated in our
M1-polarized PUER macrophages, Cxcl10 and interferon-activated protein 204 (Ifi204).
Cxcl10, a chemokine attracting inflammatory cells, is a major marker for M1-polarized
macrophages28,44,51,134 . Ifi204/human myeloid nuclear differentiation antigen (MNDA)
belongs to the p200 family of transcription factors, expressed in response to IFNα, IFNγ,
or LPS in mature granulocytes, in monocytes, and in activated macrophages (reviewed in
Gariglio et al.)135. The p200 family of transcription factors participates in cell cycle
inhibition, apoptosis, and differentiation in some cells including monocytes. While its
specific role in M1 polarization remains unclear, it is consistently and robustly induced
and therefore serves as a good indicator of M1 polarization. Expression of both Cxcl10
and Ifi204 is low or absent in unpolarized PUER macrophages (Figure 4.11). For
Cxcl10, a slight increase was seen at 30 minutes after polarization and peaked from 1 to 8
hours. These kinetics are similar to Batf2, which is expressed at 30 minutes but strongly
expressed at 1 hour. This does not support an argument for Batf2-induced Cxcl10.
However, there is a marked enhancement of Cxcl10 at 1 hour, subsequent to induction of
Batf2, allowing for a role of Batf2 in enhancement of Cxcl10. In contrast, Ifi204
induction occurs much later after polarization, about 2 hours after treatment, after Batf2
induction. Therefore, Batf2 mRNA induction in polarized cells occurs prior to induction
or enhancement of select M1 genes, allowing the possibility that Batf2 lies upstream of
these genes during M1 polarization.

4.2.4. Summary of Batf2 expression data
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To summarize this data on Batf2 expression, Batf2 is highly induced in LPS/IFNγ
(M1) -polarized macrophages within 1 hour of polarization, and expression is dependent
on IFNγ but not LPS. Batf2 induction correlates with expression of Th1-supportive gene
expression, but not IL-4-induced Th2-associated gene expression. Surprisingly, the antiinflammatory cytokine IL-10 also moderately induced Batf2 expression, suggesting Batf2
induction occurs by multiple signals. After LPS/IFNγ, Batf2 induction precedes select
genes important for the M1 phenotype. Overall, mRNA analysis of Batf2 in response to
multiple stimuli and in relation to other M1-associated genes supports the possibility that
Batf2 contributes to M1-associated gene expression.

Constitutive Batf2 expression alone does not drive gene expression, but enhances

4.3.

select M1 genes or suppresses select M2 genes
4.3.1. Constitutive Batf2 expression may enhance select LPS/IFNγ-induced M1
genes in conjunction with other factors
Having established that Batf2 is strongly induced in M1-polarized macrophages,
but not M2-polarized macrophages, and induced prior to at least some M1-associated
genes, we set out to identify genes regulated by Batf2. I therefore created a PUER cell
line that constitutively expresses Batf2, herein called PUER-Batf2. I hypothesized that
genes induced by Batf2 in M1-polarized macrophages would be induced in PUER-Batf2
cells in the absence of cytokine and LPS stimulation. To test this, expression of several
M1-associated genes was analyzed by semi-quantitative RT-PCR. Forced expression of a
single transcription factor in this way has successfully been used to identify genes
downstream of other transcription factors, such as Klf4 overexpression enhancing
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expression of Arg1, Mrc1, Pdcd1lg2, Pparg, and others (reviewed in Liao et al.)136.
Based on the mRNA analyses described in the previous section placing Batf2 within M1associated response, I hypothesized that many key M1-associated genes such as Cxcl10,
iNos, Ifi204, and H2-Aa would be induced PUER cells constitutively expressing Batf2.
To construct cells that constitutively express Batf2, PUER cells were transduced
with a retroviral vector containing a Batf2 cDNA (pMigR1-Batf2). A murine Batf2
cDNA was subcloned in the multiple cloning site of the pMigR1 vector130. The pMigR1
vector drives gene expression with a MCSV LTR, and allows for GFP selection by
following the multiple cloning site with an internal ribosomal entry site for simultaneous
expression of GFP. This vector was transfected into the packaging cell line PLAT-E, and
PUER (at progenitor stage) were treated with the resulting supernatant containing
retroviral particles as described in Chapter 3. Cells then underwent two rounds of
fluorescence-activated cell sorting to select for GFP+ cells. First, expression of Batf2 was
confirmed in these cultures at the common myeloid progenitor stage (undifferentiated)
and unpolarized macrophage stage (tamoxifen and IL-3 treated) by RT-PCR. While
undifferentiated and tamoxifen-differentiated PUER or vector-transduced (PUERpMigR1) cells expressed undetectable to minimal Batf2 message, Batf2-transducaed
(PUER-Batf2 cells) had significant expression of Batf2 message, as shown in Figure 4.I2
B. This suggests that PUER-Batf2 cells constitutively express Batf2 mRNA at levels
surpassing LPS/IFNγ-induced Batf2.
In order to identify genes potentially induced by Batf2, we analyzed expression of
multiple M1-associated genes in PUER-Batf2 compared to the vector-transduced PUERpMigR1 using RT-PCR. Unexpectedly, undifferentiated and tamoxifen-differentiated
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PUER-Batf2 cells did not demonstrate expression of any of the multiple M1-associated
genes, including the key M1 gene Cxcl10 (lane 1 of Figure 4.14 and data not shown).
Table 4.2 contains a list of all genes tested. This suggests that Batf2 alone does not
induce M1 gene expression, as predicted for an M1 master transcription factor.
Although high constitutive Batf2 mRNA expression alone did not drive gene
expression, this does not entirely rule out a role for Batf2 as a part of a transactivating
transcription complex in M1 polarized macrophages. The activity of AP-1 family
members is highly sensitive to context, so activity often requires not only expression of
the factor in question but also a permissive intracellular environment composed of
dimerization partners, cofactors, post-translational modification enzymes, and chromatin
modifications. For example, cFos requires cJun for both activity as activator and as
inhibitor, depending on the cell type and gene examined, and phosphorylation of specific
residues in both cFos and cJun64,87. Moreover, many functions of this family require
additional cofactors for their DNA binding activity. The closely related Batf and Batf3,
for example, requires Irf4 or Irf8 for transactivation of genes necessary for several T cell
subsets including Th17, Tfh, Th2, and Th976,111. Therefore, Batf2 activity may require
necessary cofactors or conditions absent in the CMP stage or resting macrophage stage.
To examine this possibility, we tested gene expression in conditions permissive
for Batf2 activity. Since Batf2 is expressed in M1-polarized macrophages, M1-polarized
macrophages must contain the necessary cofactors and conditions for Batf2 function if
Batf2 is important for M1 polarization. Enhanced Batf2 expression in the M1 state such
as in M1-polarized PUER-Batf2 cells might act with other regulatory factors to increase
downstream gene expression in M1-polarized cells. To determine whether this occurs,
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we next analyzed select M1-associated gene expression in M1-polarized PUER-Batf2
cells compared to controls. PUER, PUER-pMigR1, and PUER-Batf2 were polarized as
in previous gene expression assays. Cells were differentiated with tamoxifen for 4 days
then polarized with LPS/IFNγ to M1 or IL-4 to M2 or left unstimulated. We first
analyzed the protein production of key M1 enzyme iNOS to ensure that cells
constitutively expressing Batf2 polarized normally. iNOS protein was detected in PUERBatf2, demonstrating that these cells functionally polarize to M1 (Figure 4.13). Next, we
asked whether PUER-Batf2 upregulated M1-associated gene expression (see Figure 4.14
for Cxcl10, Figure 4.16 for Csf1r, and Figure 4.19). After polarization, high constitutive
Batf2 mRNA expression enhanced LPS/IFNγ induced Cxcl10 expression, suggesting
there is an additional condition or factor required for Batf2 activity, as clearly shown in
Figure 4.14. However, as also shown in this figure, this increase in message failed to
translate into increased protein. No other M1-associated genes tested demonstrated
consistent enhancement in M1-polarized PUER-Batf2 compared to PUER and vector
controls, including key M1-associated genes Irf1 and iNOS and (refer to Table 4.2 for the
list of all genes tested). Interestingly, Batf2 does not seem to enhance Cxcl10 mRNA
except in the context of M1 polarization, when the cellular environment expresses
multiple different factors, shifts in metabolism, different enzymes, etc. This suggests that
Batf2 requires an additional condition such as a dimerization partner, cofactor, posttranslational modification, or chromatin modification for its activity. These data show
that constitutive high levels of Batf2 expression alone does not induce expression of key
M1-associated genes, but in M1-polarized cells enhances select LPS/IFNγ-induced
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expression of select M1-associated genes, suggesting that Batf2 requires a cofactor or
condition.

4.3.2. Constitutive Batf2 expression may downregulate select IL-4-induced
genes in conjunction with other factors
Based on the data in the previous sections, the modified hypothesis is that Batf2
induces M1-associated gene expression in concert with a necessary cofactor or condition
present only in M1-polarized cells. However, constitutive Batf2 expression only
enhanced Cxcl10 in M1 state out of the genes tested. This could be due to Cxcl10 being
very sensitive to Batf2 induction. Another explanation, however, could be that Batf2's
main activity is as a repressor of M2 functions rather than an activator of M1 functions.
In cancer studies, for example, Batf2 suppresses activity at the AP-1 element by
sequestering cJun into an inactive dimer, suppressing transcription of genes including
Cyclin E in HeLa cells95 (see Chapter 2 page 34 for more detail).
To determine if Batf2 suppresses M2-associated genes, we analyzed gene
expression in IL-4-polarized M2 PUER-Batf2 macrophages compared with PUER and
PUER-pMigR1 cells. Cells were differentiated for 4 days with tamoxifen and IL3, then
polarized with IL-4 or left unstimulated. M2-associated genes as defined in this study
refers to either absent/minimal in PUER macrophages and upregulated upon IL-4
treatment, or expressed in resting state and downregulated in M1 stimuli but upregulated
or maintained in M2 state. This is shown in Figures R2 for Arg1 and Fizz1 and Irf4 in
Figure 4.19 A. It is worth noting that resting macrophages are more similar in many
respects to M2-polarized macrophages, and M2-associated genes are sometimes
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expressed in the resting stage to a lesser extent than M2-polarized macrophages. As
shown in Figure 4.15, PUER-Batf2 cells failed to upregulate Arg1 mRNA after IL-4
stimulation compared to PUER and PUER-pMigR1. This effect was consistent across
three experiments. Thus, Batf2 expression reduces IL-4-induced Arg1 mRNA
expression.
Of note, an experiment suggested that unpolarized macrophage PUER cells with
forced Batf2 expression also express higher levels of the M2-associated gene Mmp13
(discussed further in the context of AP-1 activity below, see Figure 4.16). This may give
hints to pathways Batf2 interacts with in macrophages, but is not useful to our goal of
identifying factors involved in the M1 polarization since Mmp13 is absent in M1 state.
Overall, constitutive high levels of Batf2 message as seen in PUER-Batf2 suppresses IL4-induced Arg1 message but does not significantly suppress multiple other IL-4-induced
gene expression. This data does not support the hypothesis that Batf2 alone promotes M1
polarization by suppressing M2-associated gene expression, but Batf2 might suppress
M2-associated gene expression with a necessary cofactor or condition.

4.3.3. Constitutive Batf2 expression does not alter expression of genes that are 1)
Batf2-regulated in non-immune cells, 2) cJun-regulated in macrophages, 3)
compensatorally regulated by Batf2 in DC subsets
We initially hypothesized that Batf2 by itself promotes M1 polarization as a
master transcription factor inducing M1-associated gene expression. Alternatively, since
this does not seem to be the case, Batf2 could promote M1 polarization as a factor
downregulating M2-associated genes such as Arg1, Tcfec, and Mrc1. However, while
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Batf2 alone enhances Cxcl10 and suppresses Arg1 mRNA, it fails to cause the broad
changes we expected. Most of the M1 or M2-associated genes I examined support other
immune cells or are involved in microbicidal activity. Another possibility is that Batf2
controls genes that encode more supportive functions such as stress responses to the
microbicidal reactive species released during inflammation, or structural changes
supporting chemotaxis, etc.92,93,137,138. AP-1 has well described roles in cellular stress
responses in other cells, responding to stimuli such as intracellular oxidative stress92,93.
Moreover, Batf2 exhibits anti-tumorigenic activity through integrin signaling and
anchorage-independent cell growth124. Based on this information, Batf2 might
reasonably play a critical role in M1 polarization by regulating antioxidants, extracellular
matrix, cell cycle, etc. We therefore explored whether Batf2 impacted three categories of
non-immune genes: 1) genes regulated by Batf2 in non-immune cells, 2) genes regulated
by cJun (which Batf2 represses) in macrophages, 3) genes regulated by Batf and Batf3,
with which Batf2 shares function in some situations. These three categories of genes
were investigated in tamoxifen-differentiated PUER, PUER-pMigR1, and PUER-Batf2 in
unpolarized, LPS/IFNγ (M1)-polarized, and IL-4 (M2)-polarized cells at 48 hours after
stimulation.

4.3.3.1. Genes directly regulated by Batf2
Batf2 suppresses Ccne1 (encoding Cyclin E protein) in non-hematopoietic cells
by sequestering cJun95. Cyclin E is needed for cell cycle progression from the G1 to S
phase139,140. Macrophages undergo cell cycle arrest upon activation with LPS or IFNγ141.
Thus, Batf2 might support polarization in part through inhibiting Cyclin E and
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subsequent cell cycle progression. Cyclin E expression was therefore compared in
PUER, PUER-pMigR1, and PUER-Batf2. M1-polarized and M2-polarized cells were
also compared to resting macrophages, to determine whether Batf2-mediated cJun
enhancement or suppression requires an M1-associated cofactor or condition. In this
case, suppression would occur in M1-polarized PUER-Batf2 but not resting macrophages
and possibly not M2-polarized macrophages. As seen in Figure 4.16 A, high constitutive
Batf2 mRNA expression did not markedly suppress levels in unpolarized, M1-polarized,
or M2-polarized cells. This data demonstrates that Batf2 expression alone does not
regulate Cyclin E in macrophages. Moreover, the failure of Batf2 to suppress Cyclin E
here, in contrast to previous studies on non-hematopoietic cells, suggests that Batf2 has
differential activity in different cell types.

4.3.3.2. Genes regulated by Batf2’s dimerization partner cJun
Because Batf2 suppresses cJun activity in some cells and transactivates genes as a
heterodimer with another AP-1 member (possibly cJun or JunB) in CD8α+ and
CD103+CD11b- cDCs, Batf2 could be acting as an inhibitor or an activator in
macrophages. That constitutive Batf2 expression alone failed to activate expression of
major M1-associated genes was not necessarily surprising given the literature suggesting
that Batfs requires cofactors. Batf2's suppressive activity, however, has not been reported
to require a cofactor, and forced expression of Batf2 does suppress AP-1 activity in prior
studies 95,124. Therefore, I expected constitutive Batf2 expression to suppress genes
downstream of cJun in macrophages. Three genes regulated by cJun in macrophages
were specifically tested for induction or suppression by Batf2: Csf1r, IL-1β, and Mmp13.
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Behre et al. demonstrated that cJun/PU.1 complexes induce M1-associated Csf1r in M1polarized macrophages87. PUER macrophages contain PU.1, so it is reasonable to expect
that PU.1/cJun complexes drive Csf1r expression in our cells and that Batf2 might
suppress cJun and thus Csf1r expression. However, Batf2 expression did not markedly
alter Csf1r expression in M1 PUER macrophages (Figure 4.16 B). Grondin et al.
demonstrated that cJun/PU.1 also regulates IL-1β, but in complex with the additional
factor C/EBP that is also present in PUER macrophages 80. Therefore, Batf2 might also
suppress IL-1β message expression by suppressing cJun. PUER-Batf2 did not, however,
express markedly different levels of IL-1β in the M1 state compared to control cells in
the resting MØ state (Figure 4.16 A). Finally, cJun also regulates Mmp13 in
macrophages by a mechanism more complex than simple transactivation, described in
Ogawa, et al. and Glass, et al. For Mmp13 regulation, unphosphorylated cJun (inactive)
normally negatively controls Mmp13 through recruitment of the corepressor NCoR1 and
subsequent silencing histone modifications. TLR signaling leads to phosphorylated
(active) cJun in macrophages63,98. Like Csf1r and IL-1β, M1-polarized PUER-Batf2 did
not display markedly suppressed Mmp13 expression compared to M1-polarized controls
(Figure 4.16 B). Interestingly, PUER-Batf2 cells display markedly increased basal IL-1β
and Mmp13. This may provide insight into pathways with which Batf2 interacts, but
requires further studies to identify binding partners. With relevance to our study, failure
of high constitutive Batf2 mRNA expression to alter these three representative cJunregulated genes suggests that Batf2 does not alter cJun's activity in M1-polarized
macrophages.
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4.3.3.3. Genes regulated by Batf2 in compensation of Batf2 deficiency
Batf2 or Batf compensate for Batf3 in CD8α cDCs and the related
CD103+CD11b- cDCs by forming complexes with Irf4/Irf8 that transactivate transcription
at AP-1-Irf Composite Elements (AICE)110 (see Figure 2.2, page 48). Irf8 is present in
macrophages under all conditions, and Irf4 is present in M2-polarized macrophages (see
Irf discussion on page 148 for further analysis, as well as Figure 19 A). Constitutive
expression of Batf2 might therefore support M1 polarization by enhancing expression of
genes controlled by these Batf-Irf complexes, including Id2 142. Id2 plays a role in fetal
liver macrophage differentiation by countering differentiation-promoting Retinoblastoma
protein (Rb)143 and is expressed in PUER macrophages as shown in Figure 4.16 C
although its function in polarization has not been described. This figure shows that
PUER-Batf2 cells do not show enhanced expression of Id2 in unpolarized, M1-polarized,
or M2-polarized states, suggesting that Batf2 expression alone does not enhance the same
genes as Batf-Irf complexes in the cDC subsets. Additionally, although Batf2 cannot
compensate for loss of Batf in Tfh cells, macrophages may contain factors necessary for
Batf2 and absent from Tfh cells. We therefore tested the Batf-induced T cell gene Bcl6
83

. Bcl6 induction might assist macrophage polarization by promoting the necessary

structural changes needed for cytokinesis, cell motility, and other functions138. However,
high constitutive Batf2 mRNA expression Batf2 expression fails to enhance Bcl6
expression in unpolarized, M1-polarized, or M2-polarized macrophages (Figure 4.16 C).
Therefore, Batf2 expression alone in macrophage cells does not regulate genes
downstream of Batf2 in CD8α and CD103+CD11b- cDCs, nor does it induce expression
of genes controlled by Batf or Batf3 in T cells.
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In this survey of select genes, Batf2 did not induce genes regulated by Batf2 in
non-hematopoietic cells (Cyclin E), by cJun in non-hematopoietic cells or macrophage
cells (Csf1r, IL-1β, and Mmp13), by Batf2 compensationally in CD8α and
CD103+CD11b- cDCs (Id2) or Tfh cells (Bcl6). These results suggest that Batf2
regulation differs between cell types and that BAT2 function differs in macrophages from
other cell types. However, whether Batf2 functions overlap in macrophages and other
cells requires a much more extensive analysis.

4.3.4.

Possibility that Batf2 plays a role in growth or survival

Batf2 appears to require a cofactor or condition present in M1-polarized cells to
enhance gene expression, but in these cells Batf2 activity from naturally-induced protein
may be at maximum. This could account for the lack of changes to the array of M1 genes
tested here. Therefore, we attempted to examine genes induced by Batf2 by knocking
down Batf2 using small-hairpin RNA (shRNA). Three different shRNA constructs were
transduced into PUER cells using the retroviral vector pMSCV. Although all three
shRNA constructs were successfully transduced into PUER as well as the control plasmid
encoding shRNA against firefly luciferase, two of the resulting shBatf2-transduced
cultures displayed normal Batf2 expression and one failed to grow (data not shown).
Batf2 mRNA is normally only minimally detectable in healthy PUER cells (see Figure
4.5). However, Batf2 amounts in newly-transduced cultures remain unknown. Batf2
expression may be important for growth and survival shortly after transduction.

4.4.

Regulation of Batf2 activity: Requirement for additional M1-associated factors
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Based on the survey of gene expression in the previous sections, high constitutive
Batf2 mRNA expression alone does not appear to suppress cJun activity (Csf1r, IL-1β,
and Mmp13) as in other cells, or enhance transcription at the AICE (Id2) as in subsets of
cDCs143. This does not rule out a role for Batf2 protein in macrophage polarization,
however, given the many layers regulation of gene expression in general and AP-1
activity in particular (Table 4.2). The complex requirements for activity of the AP-1
related transcription factors provide a means of fine control over transcription for any
given downstream gene. Some of the mechanisms for regulation include: presence of a
positively-regulating dimerization partner (although appropriate cofactors may
compensate), absence of any negatively regulating dimerization partners, non-AP-1
cofactors (if necessary), post-translational modifications, mainly phosphorylation but also
avoidance of SUMOylation, and redox potential64–66,77,80,92,93,144,145. Moreover, gene
expression in general requires correct epigenetic landscape through modification of the
DNA or chromatin, exemplified by PU.110. If our PUER cells or PUER-Batf2 cells lack
activating factors or have an overabundance of repressive factors, then this could prevent
us from detecting any changes in genes that are usually regulated by Batf2 in vivo.
Using gene expression studies, we began to explore possible restrictions of Batf2
activity by analyzing the presence or absence of factors that interact with AP-1. AP-1
proteins interact with a complex network of factors. These interactions include multiple
categories, including dimerization with AP-1 proteins, dimerization with more distantly
related bZIP proteins, ternary complex formation with DNA-binding transcription factors,
and complex formation with non-DNA binding transcription factors. Our preliminary
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study examined select representative genes from two categories: 1) other AP-1
dimerization partners, and 2) ternary complex members.

4.4.3. Other AP-1 members are present and may dimerize with Batf2 or a Batf2
partner
AP-1 family members require dimerization with another AP-1 member which
provides an opportunity to regulate DNA binding specificity and activity63,73,75,80–83.
Some members, such as cJun, recognize the AP-1 consensus elements when in a dimer
and contain transactivation domains, and thus more often activate than repress gene
expression79,81,82 . Other members, such as cFos, activate transcription in a heterodimer
with a DNA-binding member but cannot bind DNA as a homodimer. Other members,
such as JunB, lack a transactivation domain and may decrease activity. Still other
members may prevent DNA recognition entirely at some consensus elements. Batf2
itself, for example, prevents cJun from binding to the AP-1 consensus95,112,124. Which
homo- or hetero-dimers form is in part determined by relative levels of possible partners.
Therefore, Batf2 activity in macrophages could be limited by available activating partners
or overabundance of repressive partners.
We first looked for the presence or absence of known in vitro Batf2 partners cJun
and JunB. Multiple studies support Batf2-cJun dimerization95,112,113,124. JunB binds Batf2
FRET assays but lacks direct evidence in the cell. Expression of AP-1 family members
was analyzed as above by RT-PCR in unpolarized, LPS/IFNγ (M1)-polarized, or IL-4
(M2)-polarized PUER, PUER-pMigR1, and PUER-Batf2. Unlike previous analyses, the
important data here is the presence or absence of the binding partner rather than the effect
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of Batf2 expression on the relative levels: either the factor is absent and unavailable for
Batf2 interaction, or the factor is present and Batf2 could interact. Additionally, gene
expression was assessed for M1 or M2 association: an M1-associated gene may be more
likely to be the dimerization partner for Batf2. Both cJun and JunB message are
detectable in macrophages, but are not associated with M1 polarization at 48 hours
(Figure 4.17). Therefore, Batf2 activity in the M1 state does not appear to result from
increased Batf2/cJun or Batf2/JunB dimers. However, the activity of these proteins may
be regulated in ways not detectable by message analysis. First, they may be bound up by
another dimerization partner and thus be unavailable to Batf2. Second, they may be
regulated post-transcriptionally. To explore whether cJun or JunB might be dimerizing
with another AP-1 member in the M1 state, shifting dimer balance to Batf2/cJun or
Batf2/JunB, we tested many other AP-1 members. JunD, Batf, cFos, and Fra2 were all
present in macrophages under all conditions at 48 hours, and were not altered by
polarization (Figure 4.17). This does not support a role for these factors in macrophage
polarization, but they also may be regulated post-transcriptionally or through
dimerization with other bZIP proteins. Batf3, on the other hand, is M2-associated.
Figure 4.17 shows that Batf3 message is downregulated in M1-polarized cells and
upregulated in M2-polarized cells. Fra1, in contrast, was not detected at 48 hours, but is
upregulated in M1 polarized macrophages at 8 hours. Batf3 and Fra1, at early time
points, may have a role in macrophage polarization. None of the patterns of expression
change in PUER-Batf2 cells.
Fra1, which transiently increased in M1-polarized macrophages, binds both cJun
and JunB and so could potentially sequester a dimerization partner of Batf2 in PUER-
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Batf2, thus limiting activity at early time points. Other interactions may also exist in vivo
that are not predicted by in vitro screening, and a homo- or hetero-dimer with activity in
one context may have different activity in another. Therefore, downstream genes were
examined as a better correlate of activity. High constitutive Batf2 mRNA expression
does not alter Figf/Vegfd, a gene reportedly regulated by Fra1, suggesting no change in
Fr-1 activity (Figure 4.18)146. Although constitutive Batf2 expression might be predicted
to inhibit cJun activity as in other cells, Csf1r , reportedly regulated by PU.1/cJun 87, also
did not change, suggesting no significant negative interaction of Batf2 with PU.1-cJun
complexes. Interestingly, a cJun-regulated genes IL-1β and Mmp13 appear to be
upregulated in M2-polarized PUER-Batf2 (Figure 4.16 B). IL-1β and Mmp13 are not
normally expressed simultaneously with Batf2, being M2-associated genes. Future
investigation into the pathways by which Batf2 enhances Mmp13 expression under these
conditions might be helpful in defining the activity of Batf2.
Overall, analysis of AP-1 factors reveals that only Batf3 and Fra1 message change
with polarization. In vitro Batf2 binding partners cJun and JunB remain stable, but could
interact with Fra1. Figf/Vegfd and Csf1r, reportedly controlled by Fra1 and PU.1-cJun,
respectively, remain unaltered by high constitutive Batf2 mRNA expression. This
suggests that Batf2 may not interact significantly with these proteins in macrophages.
However, Batf2 might interact with cJun/cFos pathways in non-physiologically relevant
context, as suggested by derepression of cJun/cJun-repressed Mmp13 in unpolarized
macrophages.
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4.4.2. Presence of possible ternary cofactors
In addition to dimerization, transcriptional activation by AP-1 at some sites
requires ternary complex formation. AP-1 consensus TREs were the first AP-1 target
sites to be defined and AP-1 heterodimers alone possess high affinity for these sites;
however, this transcriptional repertoire expands when AP-1 dimers complex further with
cofactors important for immune cell development and function such as Irf4/8, Ets,
nuclear factor of activated T cells (NFAT) family, SMAD family, C/EBPB and PU.1 62,87.
These complexes expand the transcriptional repertoire to genes with AP-1-Irf composite
elements (AICE) Ets-Irf composite elements (EICE), C/EBPB promoter sequences, and
PU.1 promoter sequences, respectively. Defining the Batf2 cofactors present in
macrophages allows predictions of which ternary complexes form and which genes can
be activated by those complexes. Moreover, lack of a Batf2 cofactor might explain the
failure of constitutive high Batf2 expression to activate genes.
To begin to explore which cofactors are present in M1-polarized PUER
macrophages, we began with expression analysis of the Irf family members. Irf1, 4, and
8 bind to Batf2. Batf2/Irf1 complexes have been tested directly by immunoprecipitation
assays in mouse-derived macrophages, while Batf2-Irf4 and Batf2-Irf8 interactions can
be implied by its ability to compensate for Batf3 deficiency in CD8α/CD103+CD11bcDC development in vivo, described in Chapter 2, Table B21,83. Moreover, Irf1 is
important for macrophage polarization and the induction of inflammatory genes including
iNOS, in part by complexing with cJun and NF-κB (see Gunthner et al. for a review of Irf
functions in macrophages)1,4,99,147–149. Irf5 has previously been proposed as a master
regulator of M1 polarization, but not reported to interact with AP-1 factors 70. Irf7
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contributes to M1 polarization in microglia1,150. Irf2, 3, and 9 were also tested, although
there are no reports of these interacting with AP-1 or playing a large role in M1
macrophage polarization. As before, PUER macrophages were differentiated for four
days with tamoxifen, then polarized an additional 8 or 48 hours with LPS/ IFNγ to
inflammatory/M1 phenotype or with IL-4 to alternative/M2 phenotype or left
unstimulated (Figure 4.1). Following polarization, mRNA was extracted and analyzed
using semi-quantitative RT-PCR for the presence or absence of the binding partners using
specific primers.
The results shown in Figure 20 indicate that Irf4 and Irf8 are not associated with
long-term M1 polarization. Irf4 message is strongly associated with M2 polarization in
both PUER-Batf2 and control cells at 8 hours and 48 hours (Figure 4.19 A). Irf8, on the
other hand, is only minimally expressed in polarized cells. Irf1, in contrast, is highly
associated with M1 polarization, confirming previous reports. Irf7 appears to be M1associated, but in 2 out of 4 experiments PUER cells expressed similar levels of Irf7
mRNA in M1-polarized state as in resting state (data not shown). Unexpectedly, Irf5 was
not expressed. Irf2, 3, and 9 expression does not vary markedly between conditions.
This data supports the recent suggestion that Irf1 plays a role in macrophage
polarization, suggests Irf7 might also support polarization, and contradicts reports of
Irf5's importance for macrophage polarization. Irf1 and Irf7 may both function in part by
binding to Batf2, although more study is needed. Moreover, other non-Irf proteins may
well serve as cofactors for Batf2. Future protein-protein and protein-DNA binding
studies are needed to further define interactions.
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Summary: Batf2 is an M1-associated transcription factor not regulating select

4.5.

genes alone, but requiring additional factors
In this study, we describe Batf2 as an LPS/IFNγ-induced, M1-specific
transcription factor with activity likely dependent on additional M1-associated factors or
processes. Constitutive high Batf2 expression alone enhanced LPS/IFNγ-induced Cxcl10
message but not protein, and suppressed IL-4-induced Arg1 message. Since AP-1
proteins in general require additional factors for activity, including proper dimerization
partners, non-AP-1 cofactors, adequate chromatin modifications, and post-translational
modifications, Batf2 also likely requires a necessary cofactor that is limiting Batf2
activity in our cells. An Irf, possibly Irf1, may play this role, especially considering
recent reports showing Batf2 interaction with Irf1 in macrophages.
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Table 4.1: Microarray analysis of select novel and established M1 or M1 associated genes
in polarized PUER macrophages.
A.
Type

Gene

Established or Novel M1
or M2-Associated

Fold change
M1/MØ

Pa

Transcriptional
Regulator

Irf1

Established M11,109,151,152

21.8

6.76e-9

Stat1

Established M1151,153

15.4

6.44e-7

Batf2/SARI

Novel

10.0

8.28e-7

Ifi204/p204

Novel

8.3

2.67e-7

Id2

Novel

3.5

6.54e-5

Ccl5/Rantes

Established M1154,155

68.8

4.4e-10

Cxcl10/IP-10

Established M144,109,134,151

101

4.3e-9

CXCL9

Established M1 109,151,156

28.0

6.1e-8

Cytokine

IL-1β

Established M1151,157–159

4.5

6.4e-7

Enzyme

iNOS/NOS2

Established M1 55,57,109,160

55.4

1.7e-10

T-Cell Ligand

H2-Aa

Conflicting109,161

36.6

1.2e-7

Transcriptional
Regulators

Hdac9

Novel

0.94

5.9e-3

ZFP609

Novel

0.96

2.9e-3

Tcfec/Tfec

Established M2162

0.34

2.7e-4

Arg1

Established M257,160

0.99

1.9e-3

Mmp13/Collagenase 3

Conflicting

1.0

3.0e-4

Mitogen

Figf /Vegfd

Novel

1.1

2.3e-8

Regulator Protein

Myc

EstablishedM2163

0.27

9.6e-5

Receptor

Mrc1/Mmr

Established M2164

0.11

1.7e-7

Secreted Proteins

Ym1/Chil3

Established M2160,165,166

0.71

4.5e-6

Fizz1/Retnlb

Established M2160,165

0.89

2.6e-4

Chemokine

Enzymes
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Table 4.1 (continued)
B.
Type

Gene

Established or Novel M1
or M2-Associated

Transcriptional
Regulator

Irf1

Established M1 1,109,151,152

Stat1

Established M1151,153

0.94

6.44e-7

Batf2/SARI

Novel

0.82

8.28e-7

Ifi204/p204

Novel

0.84

2.67e-7

Id2

Novel

1.1

6.54e-5

Ccl5/Rantes

Established M1154,155

1.1

4.4e-10

Cxcl10/IP-10

Established M144,109,134,151

1.1

4.3e-9

CXCL9

Established M1 109,151,156

1.3

6.1e-8

Cytokine

IL-1β

Established M1151,157–159

0.74

6.4e-7

Enzyme

iNOS/NOS2

Established M1 55,57,109,160

1.2

1.7e-10

T-Cell Ligand

H2-Aa

Mixed109,161

1.1

1.2e-7

Transcriptional
Regulator

Hdac9

Novel

3.9

5.9e-3

ZFP609

Novel

2.4

2.9e-3

Tcfec/Tfec

Established M2162

2.0

2.7e-4

Arg1

Established M257,160

1.4

1.9e-3

Mmp13/Collagenase 3

Mixed

0.79

3.0e-4

Mitogen

Figf /Vegfd

Novel

29.8

2.3e-8

Regulator Protein

Myc

Established M2163

1.13

9.6e-5

Receptor

Mrc1Mmr

Established M2164

0.42

1.7e-7

Secreted Proteins

Ym1/Chil3

Established M2160,165,166

1.65

4.5e-6

Fizz1/Retnlb

Established M2160,165

3.97

2.6e-4

Chemokine

Enzymes

a

Fold change
M2/MØ

P
6.76e-9

P-value determined by ANOVA for comparison of day 4, MØ, M1, and M2 groups (n=3)

A. M1-polarized gene changes compared to MØ.
B. M2-polarized gene changes compared to MØ.
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Table 4.2: Genes tested by microarray and RT-PCR analyses

Gene

Relevance

Microarray
M1/MØa
M2/MØb

RT-PCR
M1/ MØc

Ccne1
(Cyclin E)

Decreased by forced Batf2
in HeLa cells

Var1 NC
Var1e NCf
Var2 ND/NC Var2 ND/NC

NCe 8hr
↓ e 48hr

NC 8hr
NC 48hr

Csf1r

M1-associated cytokine
receptor
Induced by PU.1-AP-1 in
macrophages

3.2

0.2

NT 8hr
↑ e 48hr

NT 8hr
NC 48hr

IL-1β

Induced by cJun/PU.1CEBPB in macrophages

4.5

0.7

NT 8hr
↓/↑ e 48hr

NT 8hr
↓/ND 48hr

Mmp13

Induced by cJun in
macrophages

1.2

5.9

NT 8hr
↓/NC 48hr

NT 8hr
↑ 48hr

Figf

Induced by Fra1

1.1

29.8

NC 8hr
↓/↑ 48hr

↑ 8hr
↑ 48hr

cJun

AP-1 family member, binds 0.9
Batf2 in vitro
Batf2 suppresses activity

0.7

NC 8hr
NC 48hr

NC 8hr
NC 48hr

JunD

AP-1 family member

NC

0.6

NC 8hr
NC 48hr

NC 8hr
NC 48hr

JunB

AP-1 family member, binds NC
Batf2 in vitro

NC

↑ 8hr
NC 48hr

NC 8hr
NC 48hr

Fra1

AP-1 family member
Induces Figf expression

NC

NC

↑ 8hr
↓/↑ 48hr

↓ 8hr
↓/↑ 48hr

Fra2

AP-1 family member

0.8

0.4

NC 8hr
NC 48hr

NC 8hr
NC 48hr

cFos

AP-1 family member

0.3

0.2

NC 8hr
↓/↑ 48hr

↓ 8hr
↓/↑ 48hr

M2/MØd
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Table 4.2 (Continued)
Microarray
M1/MØa M2/MØb

RT-PCR
M1/ MØc

NC/ND

NC/ND

NC 8hr
↓ 48hr

NA 8hr
↑ 48hr

101
M1-associated cytokineg
LPS/IFNγ-induced message
enhanced in pMigR1-Batf2

NC

NT 8hr
↑ 48hr

NT 8hr
ND4 8hr

Batf family members76

NC

NC

NC 8hr
NC 48hr

NC 8hr
NC 48hr

NC/ND

1.4

NT 8hr
ND/NC 48hr

NT 8hr
↑ 48hr

3.4

NC

NC 8hr
NC 48hr

↑ 8hr
NC 48hr

2.8

NC

NT 8hr
NC 48hr

NT 8hr
NC 48hr

21.8

NC

↑ 8hr
↑ 48hr

NC 8hr
NC 48hr

ND

ND

ND 8hr
ND 48hr

ND 8hr
ND 48hr

Irf7

7.7

1.2

↑ 8hr
↑ 48hr

↑ 8hr
NC 48hr

Irf9

3.2

0.7

NC 8hr
NC 48hr

NC 8hr
NC 48hr

NC/ND

NC/ND

↑ 8hr (minor) ↑ 8hr
ND 48hr
↑ 48hr

NC/ND

NC/ND

↑ 8hr
NC/ND 8 hr
NC/ND 48 hr NC/ND 48 hr

1.8

0.9

NC 8hr
NC 48hr

NC 8hr
NC 48hr

NC

NC

NC 8hr
↓/↑ 48hr

NC 8hr
NC 48hr

Gene

Relevance

Arg1

M2-associated enzymeg
IL-4-induced message
suppressed in pMigR1Batf2

Cxcl10

Batf

Batf3

Id2

Potential Batf2-inducible
genes

Bcl6

Irf1
Irf5

Irf4

M1-associated Irfg
transcription factors
Potential Batf2
cofactors76,83,86

Known Batf2 cofactors83,86

Irf4

Irf2

Irf3

Potential Batf2
cofactors76,83,86

M2/MØd
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Table 4.2 (continued)

Gene
Ccl5

Relevance

RT-PCR
M1/ MØc

M2/MØd

68.1

1.1

NT 8hr
↑ 48hr

NT8hr
NC 48hr

36.6

1.1

NT 8hr
↑ 48hr

NT 8hr
NC 48hr

Id2

3.4

NC

NT 8hr
↑ 48hr

NT 8hr
NC 48hr

Ifi204

8.3

0.8

NT 8hr
↑ 48hr

NT 8hr
NC 48hr

Ifi205

8.8

NC

NT 8hr
↑ 48hr

NT 8hr
NC 48hr

iNOS

5.4

1.2

NT 8hr
↑ 48hr

NT 8hr
ND 48hr

Tgtp

97.8

1.2

NT 8hr
↑ 48hr

NT 8hr
NC 48hr

Parp12

7.8

0.9

NT 8hr
NC 48hr

NT 8hr
NC 48hr

Parp14

12.8

NC

NT 8hr
NC 48hr

NT 8hr
NC 48hr

Stat1

12.7

9.8

NT 8hr
NC 48hr

NT 8hr
NC 48hr

Stat2

6.6

0.9

NT 8hr
NC 48hr

NT8hr
NC 48hr

H2-Aa

M1 or inflammatory-stimulus
associated cytokine,
established or tentativeg

Microarray
M1/MØa M2/MØb
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Table 4.2 (continued)

a

Microarray
M1/MØa M2/MØb

PUER
M1/ MØc

0.9

4.0

NC 8hr
↓ or ND 48hr

↑ 8hr
↑ 48hr

Hdac9

0.9

3.2

NT 8hr
↓ 48hr

NT 8hr
↑ or NC 48hr

Mmp13

1.2

5.9

NT 8hr
↓ or NC 48hr

NT 8hr
↑ 48hr

Mrc1

0.1

0.4

NT 8hr
↓ 48hr

NT 8hr
NC 48hr

Prp

1.1

1.6

NT 8hr
↓/↑ 48hr

NT 8hr
↓/↑ 48hr

Tcfec

0.3

2.0

NT 8hr
↓ 48hr

NT 8hr
NC 48hr

Tgfb1

NC

NC

NT 8hr
NC 48hr

NT 8hr
NC 48hr

Ym1

0.7

1.6

NT 8hr
↓ or NC 48hr

NT 8hr
↓ or NC 48hr

Gene

Relevance

Fizz1

M2-associated proteins,
established or tentativeg

M2/MØd

M1/MØ for microarray data: Fold change in signal of M1 over MØ 48 hours after

polarization
b

M2/MØ for microarray data: Fold change in signal of M2 over MØ 48 hours after

polarization
c

M1/MØ for RT-PCR data: Direction of change in signal from MØ to M1 8 or 48 hours

after polarization
d

M2/MØ for RT-PCR data: Direction of change in signal from MØ to M2 8 or 48 hours

after polarization
e

Cyclin E has two variants
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f

NC=No change (includes slight changes that not clearly significant); ND=Not detected;

NT=Not Tested; ↑=Increased; ↓=Decreased; ↓/↑ = Variable across multiple experiments
and cell types
g

References for established M1/M2 markers or novel M1/M2-associated genes are

included in Table 4.1
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Figure 4.1: Schematic of macrophage differentiation and polarization.

Figure 4.1: Schematic of macrophage differentiation and polarization. To differentiate
the PUER cells to macrophages, PUER were seeded at 2x105-4x105 cells per cm2 in
polystyrene tissue culture flasks and tamoxifen was added to media supplemented with
5ng/ml IL-3 for 4 days. On day 4 cells were treated with fresh control media (M0 group)
or fresh media with cytokines for an additional 48 hours, or at times indicated in
individual experiments. In some cases, experiments lasting 24 hours or less did not
receive fresh media in order to minimize the short-term effects of adding fresh media. To
polarize cells to M1 phenotype, 20 ng/ml IFNγ and 100 ng/ml LPS were added. To
polarize cells to M2, 4 ng/ml IL-4 was added. Cells were analyzed after 2 days, or as
otherwise described.
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Figure 4.2: PUER macrophages polarize to M1 or M2.
A.

B.

Figure 4.2: PUER macrophages polarize to M1 or M2. M1/M2 polarization of PUER
macrophages was confirmed by expression of M1 and M2 specific genes and enzyme
activities. Briefly, PUER cells at the common myeloid progenitor stage (CMP) or
differentiated to macrophages and polarized by treatment with 100 ng/ml LPS and 20
ng/ml IFNγ (M1) or 4 ng/ml IL-4 (M2) for 48 hours, or left unstimulated (MØ), were
analyzed as described in Chapter 3. A. Expression of M1 and M2 specific genes was
measured by RT-PCR. Total cellular RNA was isolated 48 hours after treatment, reverse
transcribed and specific genes for M1 (iNOS and Ccl2) or M2 (Arg1 and Fizz) were
amplified by PCR using the primers listed in the materials and methods. The PCR
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products were separated on agarose gels, stained with ethidium bromide and
photographed. The images were inverted for clarity. LPS/IFNγ or IL-4 treatment
resulted in the expected upregulation of M1 specific genes iNOS and Ccl2 and M2
specific genes Fizz1 and Arg1. B. Enzyme activities of the M1 specific enzyme iNOS or
M2 specific enzyme Arginase 1 were measured in PUER cells 24 hour after treatment
with LPS/IFNγ or IL-4. For iNOS activity, nitrate concentration in the culture
supernatants was measured using the Griess reagent, which measures nitrate in the
supernatant. For Arginase 1 activity cell extracts were prepared and arginase activity was
measured by urea production, a product of arginase activity. LPS/IFNγ treatment caused
an approximately 23 fold selective upregulation of iNOS activity, whereas IL-4 treatment
selectively upregulated arginase activity by about 6 fold.
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Figure 4.3: PUER macrophage polarization is reversible.

Figure 4.3: PUER macrophage polarization is reversible. PUER cell re-polarization after
initial polarization and repolarization was measured by gene expression of iNOS or Arg1.
100 ng/ml LPS and 20 ng/ml IFNγ (M1) or 4 ng/ml IL-4 (M2) for 48 hours, or left
unstimulated (MØ), as described in Chapter 3. For baseline comparison, cells in the first
three lanes were polarized for 48 hrs as in Figure 4.2, RNA was extracted and iNOS and
Arg1 expression were detected by RT-PCR. The products were separated on agarose
gels, stained with ethidium bromide and photographed. The images have been inverted
for clarity. The cells in lanes 4 to 8 were polarized for an additional 48 hours with the
same stimuli (lanes 4, 5 &7) or the opposing stimuli (lanes 6 & 8). iNOS and Arg1
expression in PUER cells repolarized from M1 to M2 or M2 to M1 shows an almost
complete reversal for M2 to M1 and a partial reversal of M1 to M2. (credit: B. Taylor
and J. McGillis)
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Figure 4.4: Transcription factors upregulated in M1 or M2 polarized PUER macrophages.

Figure 4.4: Transcription factors upregulated in M1 or M2 polarized PUER macrophages.
Transcription factors upregulated in M1 or M2 polarized macrophages were identified by
microarray analysis. Cells were treated with100 ng/ml LPS and 20 ng/ml IFNγ (M1) or 4
ng/ml IL-4 (M2) for 48 hours, or left unstimulated (MØ), as described in Chapter 3. At
48 hours, mRNA was extracted and a microarray analysis performed in the UK
Microarray Core Facility using the GeneChip® Mouse Exon 1.0 ST Array. Transcription
factors upregulated or downregulated more than two fold were selected. Numbers
indicate fold increase compared to unstimulated. Irf1 and Stat1 were previously reported
to be upregulated in M1 and Tcfec found to be upregulated in M2. Batf2, Ifi204, and Id2
are novel transcription factors in M1 polarized macrophages. Hdac9 and ZFP609 are
novel transcription factors in M2 polarized macrophages. A full list of genes in the
microarray is found in Table 4.1.
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Figure 4.5: Classical activation upregulates Batf2 mRNA and protein.
A.

B.

Figure 4.5: Classical activation upregulates Batf2 mRNA and protein. Batf2 mRNA (A)
and protein (B) were confirmed in PUER macrophages by RT-PCR (A) and Western blot
(B). PUER cells were polarized with 100 ng/ml LPS and 20 ng/ml IFNγ (M1) or 4 ng/ml
IL-4 (M2) for 48 hours, or left unstimulated (MØ), then analyzed as described in Chapter
3. A. Total RNA was extracted and analyzed using RT-PCR with specific primers. The
products were separated on agarose gels, stained with ethidium bromide and
photographed. The images have been inverted for clarity. B. Total protein extracts were
analyzed by Western blot with fluorescence detection methods. Standards denoting 37
kDa and 20 kDa are marked on the right, and Batf2 and Gapdh bands are marked on the
left. Batf2 expression is unique to M1-polarized macrophages.

110

Figure 4.6: Kinetics of Batf2 induction by LPS/IFNγ.

Figure 4.6: Kinetics of Batf2 induction by LPS/IFNγ. Batf2 mRNA at various time
points was confirmed in PUER macrophages by RT-PCR. PUER cells were polarized
with 100 ng/ml LPS and 20 ng/ml IFNγ (M1) or 4 ng/ml IL-4 (M2) for 48 hours, or left
unstimulated (MØ), then analyzed as described in Chapter 3. Total RNA was extracted
and analyzed using RT-PCR with specific primers. The products were separated on
agarose gels, stained with ethidium bromide and photographed. The images have been
inverted for clarity. Batf2 message appears 1 hour after polarization and seems to peak
around 8 hours. Marked expression above baseline is shown here up to 26 hours.
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Figure 4.7: Classical activation upregulates Batf2 mRNA in BMDM.

Figure 4.7: Classical activation upregulates Batf2 mRNA in BMDM. Batf2 expression in
bone marrow derived macrophages (BMDM) was determined by RT-PCR. BMDM were
polarized with 100 ng/ml LPS and 20 ng/ml IFNγ (M1) or 4 ng/ml IL-4 (M2) for 48
hours, or left unstimulated (MØ), then analyzed as described in Chapter 3. Total RNA
was extracted and analyzed using RT-PCR with specific primers. The products were
separated on agarose gels, stained with ethidium bromide and photographed. The images
have been inverted for clarity. Both M1 and M2 polarization induced Batf2 expression;
however, Batf2 expression in M2 polarized cells did not reach the amounts in M1
polarized cells. Moreover, additional gene analysis suggested that BMDMs were
partially M1 polarized, even after M2 stimulus (data not shown). (Credit: R. Hayman IV
and J. McGillis).
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Figure 4.8: Classical activation upregulates multiple Batf2 mRNA isoforms.
A.

B.

C.

Figure 4.8: Classical macrophage activation upregulates multiple Batf2 mRNA isoforms.
A. Known and predicted mRNA isoforms and protein variants in the National Center for
Biotechnology (NCBI) database. Four mRNA isoforms are predicted to exist for Batf2:
the reference sequence NM_028967, isoform X1, isoform X2, and isoform X3. Colors of
the RNA correspond to sequence similarities (for example, the dark blue is shared by all
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isoforms). These translate into four protein variants: the reference sequence, variant X1
(which differs from the reference sequence by a glutamine residue in the bZIP region),
variant X2, and variant X3. The isoform specificity of the antibody used in Figure 4.5 is
unknown, but was raised to the indicated region (**) that is conserved in all full-length
products with 94% identity. B. Detection of Batf2 isoforms X1 and X3. PUER cells
were polarized with 100 ng/ml LPS and 20 ng/ml IFNγ (M1) or 4 ng/ml IL-4 (M2) for 8
or 48 hours, or left unstimulated (MØ), then analyzed as described in Chapter 3. Total
RNA was extracted and analyzed using RT-PCR with isoform-specific primers. The
products were separated on agarose gels, stained with ethidium bromide and
photographed. The images have been inverted for clarity. Isoforms were confirmed by
sequencing (data not shown). The product indicated as “X3” could be produced from
both X2 and X3; however, reactions using primers “1 F” and “All R” yielded no product
the length of isoform X2. C. Alignment of primers to the three mRNA isoforms detected
in M1-polarized PUER cells: X1, X2, X3, and the reference sequence. Dark areas
indicate regions of variation between isoforms. Triangles indicate the primers used to
detect the isoforms and correspond to the primers on the left in (B).
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Figure 4.9: IFNγ, but not LPS, induces Batf2 expression
A.

B.

Figure 4.9: IFNγ, but not LPS, induces Batf2 expression. Batf2 expression in response to
LPS or IFNγ alone (A) or compared to LPS/IFNγ combination (B). PUER cells were
polarized with 100 ng/ml LPS and/or 20 ng/ml IFNγ for 8, 24, or 48 hours, or left
unstimulated (MØ), then analyzed as described in Chapter 3. Total mRNA was extracted
and analyzed using RT-PCR with specific primers. The products were separated on
agarose gels, stained with ethidium bromide and photographed. The images have been
inverted for clarity. Unstimulated and LPS-stimulated cells had minimal Batf2 mRNA,
while cells treated with IFNγ by itself expressed Batf2 at roughly comparable levels to
cells treated with LPS and/IFNγ.
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Figure 4.10: Both LPS/IFNγ and IL-10 induce Batf2 expression.

Figure 4.10: Both LPS/IFNγ and IL-10 induce Batf2 expression. IL-10-induced Batf2
expression vs LPS/IFNγ-induced Batf2 expression. PUER cells were polarized with 100
ng/ml LPS and 20 ng/ml IFNγ (M1), 4 ng/ml IL-4 (M2), or IL-10 at the listed
concentrations for 48 hours, or left unstimulated (MØ), then analyzed as described in
Chapter 3. Total RNA was extracted and analyzed using RT-PCR with specific primers.
The products were separated on agarose gels, stained with ethidium bromide and
photographed. The images have been inverted for clarity. Concentrations of IL-10 from
1-100 ng/ml induce Batf2 expression.
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Figure 4.11: Induction of select M1-associated genes occurs subsequent to Batf2
induction.

Figure 4.11: Induction of select M1-associated genes occurs subsequent to Batf2
induction. Two M1-associated genes, Cxcl10 and Ifi204, increase markedly subsequent
to Batf2 induction. PUER cells were polarized with 100 ng/ml LPS and 20 ng/ml IFNγ
(M1) or 4 ng/ml IL-4 (M2) for 48 hours, or left unstimulated (MØ), then analyzed as
described in Chapter 3. Total RNA was extracted and analyzed using RT-PCR with
specific primers. The products were separated on agarose gels, stained with ethidium
bromide and photographed. The images have been inverted for clarity. Chemokine
Cxcl10 and transcription factor Ifi204 are induced by IFNγ and LPS in macrophages with
slightly different kinetics.
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Figure 4.12: PUER-Batf2 constitutively express Batf2 mRNA.
A.

B.

Figure 4.12: PUER-Batf2 cells constitutively express Batf2 mRNA. PUER cells were
transduced with retroviral vector pMigr1-Batf2 to create cells that constitutively express
Batf2 (PUER-Batf2).To control for off-target effects due to the retroviral vector, PUER
cells were also transduced with the empty vector pMigr1 (PUER-pMigR1). Batf2 and
Gapdh expression were also analyzed as described in Chapter 3. Total RNA was
extracted and analyzed using RT-PCR with specific primers. The products were
separated on agarose gels, stained with ethidium bromide and photographed. The images
have been inverted for clarity. A. PUER, PUER-pMigR1, and PUER- Batf2 were
analyzed at common myeloid progenitor stage (D0) or differentiated to resting
macrophages with tamoxifen for the 1 or 4 days. In contrast to unpolarized PUER cells
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or macrophages that express little Batf2 message in resting state, PUER-Batf2
constitutively express abundant Batf2 message at all stages. B. PUER-Batf2 comparison
to resting or M1-polarized PUER. Batf2 message is highly expressed even compared to
M1-polarized PUER levels.
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Figure 4.13: PUER-Batf2 cells polarize to M1 phenotype after LPS/IFNγ.

Figure 4.13: PUER-Batf2 cells polarize to M1 phenotype after LPS/IFNγ. M1
polarization was verified by detection of the M1-associated iNOS protein. PUER cells
and Batf2-transduced cells (PUER-Batf2) were analyzed in cells differentiated for 4 days
and analyzed immediately (MØa) or differentiated to macrophages with tamoxifen
treatment and then were polarized with 100 ng/ml LPS and 20 ng/ml IFNγ (M1) or 4
ng/ml IL-4 (M2) for 48 hours, or left unstimulated (MØb). iNOS protein in cell extracts
was analyzed by Western blot with fluorescence detection as described in Chapter 3.
Gapdh was used as a loading control. M1-polarized PUER and PUER-Batf2 produce
iNOS, indicating proper M1 polarization.
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Figure 4.14: Constitutive expression of Batf2 enhances LPS/IFNγ-induced Cxcl10 gene
mRNA expression.
A.

B.

Figure 4.14: Constitutive expression of Batf2 enhances LPS/IFNγ-induced Cxcl10
mRNA expression. M1-associated chemokine Cxcl10 mRNA and protein in
macrophages constitutively expressing Batf2 compared to controls was detected by RTPCR and Western blot, respectively. A. Cxcl10 mRNA. PUER cells, vector-transduced
cells (PUER-pMigR1) and Batf2-transduced cells (PUER-Batf2) were polarized with 100
ng/ml LPS and 20 ng/ml IFNγ (M1) or 4 ng/ml IL-4 (M2) for 48 hours, or left
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unstimulated (MØ), then analyzed as described in Chapter 3. Total RNA was extracted
and analyzed using RT-PCR with specific primers. Gapdh was included as a loading
control. The products were separated on agarose gels, stained with ethidium bromide and
photographed. The images have been inverted for clarity. Similar results were observed
in 3 out of 4 independent experiments. While there was a clear trend, the enhancement of
Cxcl10 message in PUER-Batf2 M1-polarized macrophages from these three
experiments pooled was not significant after quantitation with Image J due to high
standard deviation. B. Cxcl10 protein. Vector-transduced cells (PUER-pMigR1) and
Batf2-transduced cells (PUER-Batf2) were polarized for 24 hours with 100 ng/ml LPS
and 20 ng/ml IFNγ or left unstimulated (MØ), then Cxcl10 levels in the medium were
analyzed as described in Chapter 3. Supernatant was removed for Cxcl10 analysis and
the cells were harvested for total protein quantification for normalization. Cxcl10 protein
in supernatant was assayed by ELISA, and total protein was extracted from cell fraction
and used as a correlate of cell number (see Chapter 3) for the correlation of protein and
cell number). The difference between PUER-MigR1 and PUER-Batf2 is not statistically
significant (p=0.204) demonstrating that Batf2-enhanced LPS/IFNγ-induced Cxcl10
mRNA does not translate into enhancement of Cxcl10 protein secretion.
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Figure 4.15: Constitutive expression of Batf2 downregulates IL-4 induced Arg1 mRNA.

Figure 4.15: Constitutive expression of Batf2 downregulates IL-4 induced Arg1 mRNA.
Arginase 1 (Arg1) in macrophages constitutively expressing Batf2 compared to controls
was determined by RT-PCR. PUER cells, vector-transduced cells (PUER-pMigR1) and
Batf2-transduced cells (PUER-Batf2) were polarized with 100 ng/ml LPS and 20 ng/ml
IFNγ (M1) or 4 ng/ml IL-4 (M2) for 48 hours, or left unstimulated (MØ), then analyzed
as described in Chapter 3. Total RNA was extracted and analyzed using RT-PCR with
specific primers. Gapdh was analyzed as a loading control. The products were separated
on agarose gels, stained with ethidium bromide and photographed. The images have
been inverted for clarity. Similar suppression of Arg1 expression compared to
unpolarized macrophages was observed in 3 out of 4 independent experiments. PUERBatf2 cells suppress Batf2-induced Arg1 expression relative to PUER and PUERpMigR1. While there was a clear trend, the suppression by Batf2 from these three
experiments combined was not significant after quantitation with ImageJ due to high
standard deviation.
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Figure 4.16: High constitutive Batf2 mRNA expression does not alter known or potential
genes downstream of Batf2 in macrophages.
A.

B.
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Figure 4.16 (continued)
C.

Figure 4.16: High constitutive Batf2 mRNA expression does not alter known or potential
genes downstream of Batf2 in macrophages. PUER cells, vector-transduced cells
(PUER-pMigR1) and Batf2-transduced cells (PUER-Batf2) were polarized with 100
ng/ml LPS and 20 ng/ml IFNγ (M1) or 4 ng/ml IL-4 (M2) for 48 hours, or left
unstimulated (MØ), then analyzed as described in Chapter 3. Total RNA was extracted
and analyzed using RT-PCR with specific primers. Either Gapdh or Hprt were included
as a loading control. The products were separated on agarose gels, stained with ethidium
bromide and photographed. The images have been inverted for clarity. A. Expression of
cJun-suppressible Ccne1 (Cyclin E). Batf2 suppression of cJun suppresses expression of
expression of Ccne1 (encoding the Cyclin E cell cycle protein) in multiple cell types.
Expression in PUER-Batf2 cells compares to control cells, suggesting Batf2 does not
interfere with cJun-driven gene expression. Lack of induction in PUER-Batf2 was
observed in 2 out of 2 independent experiments. B. Expression of cJun-inducible Csf1r,
Il1b, and Mmp1.3 Csf1r, Il1b, and Mmp13 are induced in macrophages by cJun and the
cofactors pictured to the right of the gel. cJun homodimer induces Il1b in conjunction
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with macrophage transcription factors PU.1 and C/EBP, cJun and an undefined AP-1
dimerization partner to induce Csf1r in conjunction with PU.1. Phosphorylated
cJun/cFos activates Mmp13 transcription while unphosphorylated cJun/cJun represses
Mmp13. Basal expression of Mmp13 is increased in PUER-Batf2 cells but not enhanced
by LPS/IFNγ treatment, suggesting Batf2 does not enhance these genes in M1-polarized
macrophages. Lack of suppression in PUER-Batf2 was observed in 3 out of 3
experiments for Csf1r and Mmp13, and 2 out of 2 experiments for Il1b. C. Expression
of Batf2-inducible Id2. Id2 is induced by forced Batf2 in compensation for a deficiency
of Batf3 in cDC subsets. Bcl6 is induced by Batf in Tfh cells, but Batf2 cannot
compensate in these cells. PUER-Batf2 express Id2 and Bcl6 comparably in PUERBatf2 and controls, suggesting Batf2 activity differs in macrophages and the cDC subsets
and that Batf2 does not have similar activity in macrophages as Batf3 or Batf in other
cells. Lack of enhancement in PUER-Batf2 relative to controls was observed in 3 out of 4
experiments for Id2 and 2 out of 2 experiments for Bcl6.
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Figure 4.17: Dimerization partners are present in PUER cells.
A.

B.

C.
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Figure 4.17: Dimerization partners are present in PUER cells. Presence of mRNA for
other AP-1 proteins was determined by RT-PCR. PUER cells, vector-transduced cells
and Batf2-transduced cells (PUER-Batf2) were polarized with 100 ng/ml LPS and 20
ng/ml IFNγ (M1) or 4 ng/ml IL-4 (M2) for 48 hours, or left unstimulated (MØ), then
analyzed as described in Chapter 3. Total RNA was extracted and analyzed using RTPCR with specific primers. Either Gapdh or Hprt was included as a loading control. The
products were separated on agarose gels, stained with ethidium bromide and
photographed. The images have been inverted for clarity. One representative experiment
out of three to four (for the 48-hour polarizations) or two (for 8 hour polarization) is
shown for clarity. A. Summary of the representation of AP-1 proteins in PUER
macrophages, determined by RT-PCR at 8 and 48 hours. cJun dimerizes with Batf2
functionally in vivo, and JunB dimerizes with Batf2 in fluorescence resonance energy
transfer (FRET) assays by Reinke et al.113. The remaining AP-1 proteins did not bind to
Batf2 in FRET assays. B. Batf, cFos, Fra2, and JunD are not associated with any
polarization state. Batf3 is associated with M2 polarized cells during sustained M2
polarization. The presence of the AP-1 factors leave open the possibility that Batf2
interacts with their activity either directly by dimerization with them or indirectly by
sequestering a binding partner. C. Fra1 is associated with M1-polarized cells at 8 hours
but not during long-term maintenance of polarization (data not shown). This suggests
Fra1 may be involved with early M1 polarization, either in conjunction with Batf2 or
alone, but does not necessarily suggest involvement during sustained polarization. It is
worth noting that AP-1 proteins are highly regulated by post-translational modifications
and therefore activity may not correlate to mRNA expression.
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Figure 4.18: Constitutive Batf2 expression does not appear to interfere with Fra1
signaling.

Figure 4.18: High constitutive Batf2 mRNA expression does not appear to interfere with
Fra1 signaling. The Fra1-inducible gene Figf was detected in PUER cells constitutively
expressing Batf2 compared to controls by RT-PCR. PUER cells, vector-transduced cells
(PUER-pMigR1) and Batf2-transduced cells (PUER-Batf2) were polarized with 100
ng/ml LPS and 20 ng/ml IFNγ (M1) or 4 ng/ml IL-4 (M2) for 48 hours, or left
unstimulated (MØ), then analyzed as described in Chapter 3. Total RNA was extracted
and analyzed using RT-PCR with specific primers. Gapdh was included as a loading
control. The products were separated on agarose gels, stained with ethidium bromide and
photographed. The images have been inverted for clarity. Similar results were observed
in 3 independent experiments. Figf is induced by Fra1 in macrophage cells, and Fra1
dimerizes with Batf2 in vitro. Figf expression was not suppressed in PUER-Batf2 cells
that highly express Batf2 constitutively compared to controls in 3 out of 3 experiments,
suggesting Batf2 does not interfere with Fra1 activity.
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Figure 4.19: mRNA expression of known and potential Batf subfamily cofactors, the Irf
transcription factors.
A.

B.

C.

Figure 4.19: mRNA expression of known and potential Batf subfamily cofactors, the Irf
transcription factors. Expression of Irf family members in PUER, PUER-pMigR1, and
PUER-Batf2 cells. PUER cells, vector-transduced cells (PUER-pMigR1) and Batf2130

transduced cells (PUER-Batf2) were polarized with 100 ng/ml LPS and 20 ng/ml IFNγ
(M1) or 4 ng/ml IL-4 (M2) for 48 hours, or left unstimulated (MØ), then analyzed as
described in Chapter 3. Total RNA was extracted and analyzed using RT-PCR with
specific primers. Gapdh was included as a loading control. The products were separated
on agarose gels, stained with ethidium bromide and photographed. The images have
been inverted for clarity. Similar results were observed in 3 independent experiments for
the 48 hour timepoints. A. Expression of known Batf family cofactors Irf4 and Irf8. Irf4
and Irf8 form a ternary complex with AP-1 dimers containing Batf family members and
subsequently bind to the AP-1/Irf Composite Element (AICE) (5'-TTTCnnnnTGACTAA3' or 5'-GAAATGAnTCA-3'). At 8 hours, Irf8 and Irf4 are both expressed in M1polarized macrophages, although Irf4 is more strongly expressed in M2-polarized
macrophages. At 48 hours, Irf8 is minimally expressed and Irf4 is not detectable in M1polarized macrophages. Therefore, Irf4 and Irf8 may interact with Batf2 at 8 hours but
not 48 hours in M1-polarized PUER macrophages. B. Expression of M1-associated Irf1,
Irf7, Irf9, and Irf5. Irf1 binds to Batf2 in macrophages and plays a role in expression of
M1associated genes. Irf7 and Irf 9 have no demonstrated interactions with Batf2. Irf1
and Irf7 are expressed in M1-polarized macrophages at 48 hours, while Irf5 is not
detectable. Therefore, Irf1, Irf7, and Irf9 could potentially interact with Batf2 at 48 hours
in M1-polarized PUER macrophages. C. Irf2 and Irf3 are not M1-associated. Irf2 and
Irf9 are expressed in M1-polarized macrophages at 48 hours, while Irf3 is not detectable.
Therefore, Irf2 could potentially interact with Batf2 at 48 hours in M1-polarized PUER
macrophages, but not Irf3.
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Chapter V
DISCUSSION
5.1.

Summary
The major question addressed in this project is how specific genes affect

macrophage polarization; more specifically, the role of the transcription factor Batf2 in
sustained inflammatory (M1) polarization. My initial hypothesis was that Batf2 alone is
a master regulator of M1 polarization. However, this was not the case. Constitutive high
Batf2 expression alone did not drive expression of M1-associated genes, but did
moderately enhance LPS/IFNγ-induced Cxcl10 mRNA and suppress IL4-induced Arg1
mRNA. Additionally, Batf2 activity in macrophages does not appear to be similar to its
roles in other cells. These results considered alongside the previously established
importance of cofactors to the activity of Batf subfamily members activity suggests that
Batf2 activity requires a necessary cofactor, and lead the way for future studies
investigating the cofactors that interact with Batf2 and the genes regulated by Batf2cofactor complexes in sustained M1 polarization state.
In this discussion I address first the evidence suggesting Batf2 drives M1-specific
gene expression. Next, I address the moderate polarization-dependent effects of Batf2
and extrapolate those results to hypothesize functions of Batf2 during immune responses.
I then present possible implications of the inability of Batf2 alone to drive M1-associated
gene expression, as well as differences in Batf2 activity between other cells and
macrophages. Finally, I consider several potential factors that might contribute to the
lack of Batf2 activity from constitutive high expression alone, and focus in on the most
likely solution: that Batf2 requires a necessary cofactor. Based on previous studies, I
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focus on the Irf family members, discussing the potential of each for being the necessary
cofactor of Batf2.

5.2.

Batf2 is rapidly induced in M1-polarized macrophages
Several pieces of evidence strongly support Batf2 as a master transcription factor

in sustained M1 polarization. First, Batf2 expression is specific to the M1 state. Second,
Batf2 is highly expressed relative to other M1-specific transcription factors. Third, Batf2
mRNA appears early after LPS/IFNγ stimulation. Finally, Batf2 subfamily members
have established roles as master transcription factors in development and function of
other immune cells.
Batf2's specificity to the M1 polarization state in the PUER model system
supports the hypothesis that it regulates genes important for M1 functions. In general,
LPS/IFNγ-activated M1 functions support a type 1 inflammatory response involving the
production of effector proteins such as nitric oxide, activation of effector functions such
as phagocytosis, and recruitment and support of Th1-type T cells. In our PUER cells,
Batf2 correlated with upregulation of the anti-microbial and phagocytosis-supporting
enzyme iNOS, inflammatory cell-recruiting chemokine Cxcl10, and multiple genes
consistently associated with multiple models of M1 macrophages including Irf1, Irf7 and
Ccl5. In contrast, Batf2 was not expressed in IL-4-activated M2 polarization (denoted
specifically by some authors as M2a). M2 polarization supports type 2 inflammatory
responses with effector proteins such as NO-antagonizing Arg1 and with proteins
supporting Th2-type T cells. Batf2 expression inversely correlated with multiple M2aassociated genes including Arg1, Fizz1, and Irf4. In PUER cells, resting macrophages
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displayed only minimal amounts of Batf2, if any. On the other hand, bone marrow
derived macrophages (BMDMs) did express Batf2 mRNA in the M2-polarized state.
This could be due to previous in vivo influences, the isolation procedures, or stresses
from cell culture partially polarizing the highly plastic macrophage partially to M1.
Although we use a reductionist model with discrete M1/M2 subsets for study, in reality
macrophages fall on a spectrum. Some M2 subsets, such as BMDM in our study, may be
closer to M1 on the spectrum. In vivo, macrophages likely exist in states with some M1
functions and some M2 functions. Roy et al. and Tussiwand et al. examined
macrophages and dendritic cells ex vivo and found low basal Batf2 expression compared
to infected mice or in vitro stimulated cells1,83. Whether this compares to the level in our
BMDMs is not clear. Batf2 expression in basal levels or M2-associated macrophages in
vivo requires further exploration. The analyses in human cancer studies and IFNassociated diseases (see Background section) suggest that Batf2 is indeed somewhat
variable in vivo. As future studies define the genes induced or repressed by Batf2, the
consequences of Batf2 expression in macrophages exposed to M2 stimuli such as IL-4
will become clearer. For the purposes of this study, we are focusing on the fact that Batf2
associates highly with IFNγ but not IL-4 activation in our reductionist and highly
controllable model, and this agrees with previous reports on Batf2’s correlation with
inflammatory responses1,83,95,108,109,119.
Typically, LPS and IFNγ are the model in vitro inflammatory stimuli for the M1
state. In vivo, macrophages see a wide variety of stimuli that polarize them to variations
of the inflammatory phenotype depending on the environment. In some contexts, for
example, IFNγ may be present without TLR4 agonists such as LPS, activating different
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macrophage functions than LPS/IFNγ in combination. IFNγ signals through IFNGR1/2
and activates the JAK1/2 and Stat1/1 pathway, while TLR4 signals through MyD88,
which then activates the MAPK pathway and transcription factor AP-1, or activates the
transcription factors NF-кB or Irf3. Our study began to address the potential for Batf2
activity in multiple environments by assessing differential induction by LPS or IFNγ.
TLR4 stimulation by LPS was not necessary for Batf2 expression in PUER macrophages,
so Batf2 may have activity in contexts where TLR4 stimulation is minimal but IFNγ is
high. This is consistent with the developing understanding on Batf2 expression. Batf2
was initially discovered as an IFNβ -inducible gene in multiple cell types, and IFNβ has
continued to be the main stimulus in studies on Batf2's tumor-suppressing effect95,112,114.
These studies demonstrate that Batf2 has a role in functions outside of bacterial infections
and TLR4-stimulating damage, and open the possibility that IFN-induced Batf2 might
drive damaging inflammatory genes in situations when inflammation is inappropriate.
For example, Batf2 is highly upregulated in common variable immune deficiency patients
with autoimmune complications versus those without, and in fibromyalgia with high pain
versus low pain123,167. In these cases, Batf2 might be a good target for anti-inflammatory
therapeutics.
Two previous studies have examined Batf2 expression in macrophages in
response to LPS and/or IFNγ, in part agreeing and in part disagreeing with our results.
Tussiwand et al. found that IFNγ alone can induce Batf2 in BMDM, similar to our PUER
cells83. Contrary to our results, however, Batf2 was also induced by LPS, although this
experiment was in peritoneal macrophages. Roy et al. has recently done further studies
on the effects of Batf2 in macrophages. As in our study and in Tussiwand et al., Batf2
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was induced by IFNγ alone. Contrary to our results but agreeing with Tussiwand et al.’s
experiments with BMDM cells, Batf2 was also inducible by LPS1,109. Further, a genomewide association study by Chmielewski et al. found synergism between IFNγ and TLR4
for Batf2 induction in vascular smooth muscle cells121. It is possible that the
macrophages in the Roy et al. and Tussiwand et al. studies, being isolated from mice or
human patients, experienced some mildly polarizing stimuli in vivo or during the
isolation procedure that primed them for Batf2 expression in response to LPS, or were
epigenetically programmed. One of the advantages of PUER cells is the ability to
differentiate and polarize the cells with minimal polarizing stimulation. Future studies
could examine these pathways with a wider variety of macrophage cells to determine the
consistency of LPS-induced Batf2 expression. Regardless, Batf2 clearly belongs to in an
LPS/IFNγ-induced M1 and not an IL-4-induced M2 transcriptional program in PUER
cells.
Interestingly, Batf2 also increased in response to IL-10 stimulation, demonstrating
that Batf2 may also be induced by factors more often associated with M2 phenotypes.
IL-10 in combination with TGF-β and glucocorticoids activates macrophages to an
alternative phenotype. IL-10/TGF-β/glucocorticoids-induced macrophages produce IL10, TGF-β, and Ccr2. This polarization state functions in wound healing and cell debris
scavenging, and has more in common with the IL-4-induced M2 state than the LPS/IFNγinduced M1 state31,33,34,128. LPS/IFNγ activates Stat1, while both IL-4 and IL-10 activate
Stat3, so Batf2 induction by IL-10 was unexpected. Nevertheless, IL-10-activated
macrophages do express some overlapping genes with IFNγ and LPS31,33. Therefore,
Batf2 may be induced by an IL-10-activated pathway distinct from Stat3. Additionally,
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IL-10-induced Batf2 was not dose-dependent in the experiment shown in Figure 4.10,
suggesting that all three concentrations of IL-10 (1, 10, and 100ng/ml) elicited maximal
Batf2 expression on the plateau of the dose-response curve. Therefore, the pathway
inducing Batf2 in response to IL-10 may have a lesser maximal response than LPS/IFNγ,
or the maximal response in response to LPS/IFNγ may be from a combination of the IL10-induced pathway and an LPS/IFNγ-exclusive pathway. Our study and those of other
support an important role for Batf2 in polarization to an M1 phenotype, but Batf2induced gene expression may also have functions in other contexts (as discussed in the
Background section on Batf2’s role in cancers). IL-10-induced Batf2 may induce some
functions needed in specific environments containing IL-10 as well as environments
containing LPS and IFNγ. Future studies may seek to confirm IL-10 induction of Batf2
and examine the pathways inducing Batf2, as well as the role of IL-10-induced Batf2 in
the context of wound healing and debris scavenging. Batf2 may serve in this context to
activate phagocytic abilities during scavenging, or receptors detecting foreign molecules
such as bacterial mannose by the mannose receptor (Mrc1).
In addition to its association with the LPS/ IFNγ-induced M1 state, the rapid
induction of Batf2 message and high expression levels at later time points support a role
for Batf2 in the MØ to M1 transition and sustained M1 polarization. Batf2's appearance
as early as 1 hour after stimulation suggests it may be an immediate-early gene as well
for M1 polarization. This would mean that the factor inducing Batf2 is constitutively
present and rapidly activated upon stimulation, allowing Batf2 among other immediateearly genes to activate downstream gene expression early after stimulation when
macrophages are shifting out of a resting state and into an inflammatory state. The
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approximately10-fold increase in Batf2 after polarization approaches the major
inflammatory transcription factor Stat1, which was increased 12.7-fold. This robust
expression of Batf2 may support our hypothesis that Batf2 is important for sustained M1
polarization. It is worth considering, however, that Batf2 does not necessarily need to be
an immediate-early gene to be critical for sustained M1 polarization. Several
transcription factors are expressed early but transiently such as Fra1168. Another
transcription factor could have conceivably fulfilled Batf2's role initially, with Batf2
being a critical factor only later. Instead, the data suggest that Batf2 seems to be
important for initial polarization as well as long-term polarization. Once genes
downstream of Batf2 are identified, studies knocking down Batf2 and examining early
expression of these genes could clarify the timeframe of Batf2 importance and confirm
whether it indeed is important for initial polarization, as this data suggests.
The hypothesis that Batf2 is important for M1 polarization, sustained in
particular but likely also immediate, is backed by a large body of research demonstrating
the importance of Batf subfamily members in immune cell differentiation and function.
Batf3 drives genes for the differentiation of CD8α+ cDCs and CD103+CD11b- cDCs,
inducing Clec9a, Xcr1, Id2, and Spib. Batf induces genes for CSR in B cells (Aid), and
genes for differentiation of Th17, Tfh cells, and Th9 including Rorc, Il17A, Il21, Il23R,
Maf, Bcl6, ILl9, Il21, Il10, Furin, Fes, Erg, and IL-1RA. In Th2 cells Batf or Batf3 both
induce GATA3, Il4, Il10, and Ctla4. Batf, Batf2, and Batf3 all share homology and have
partially overlapping functions in some cells 76,111. Batf2's ability to compensate for
Batf3 is discussed more in depth below. Based on Batf2's association to M1 polarized
macrophages, rapid and robust expression, and prior knowledge of the Batf subfamily
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members, it is reasonable to predict that Batf2 could function as an inducer of an array of
M1-associated genes in macrophages.

5.3.

Constitutive Batf2 expression alone enhances select M1 genes or suppresses
select M2 genes
If Batf2 was a master transcription factor for M1 macrophage polarization as

initially predicted, similar to the Th1 master transcription factor Tbet, then constitutive
Batf2 expression in resting macrophages should have induced expression of M1-specific
genes. This turned out not to be the case. On the other hand, Roy et al. recently
uncovered a role for Batf2 in a broad array of M1-associated genes using knockdown
studies 1. This apparent contradiction, as well as our mild polarization-exclusive
changes, can be most simply explained as a requirement for a necessary cofactor
(discussed in more detail below). In spite of the lack of broad changes, constitutive Batf2
expression enhanced LPS/IFNγ-induced Cxl10 and suppressed IL-4-induced Arg1.
Neither Cxcl10 nor Arg1 was mentioned in the knockdown studies by Roy et al. These
results, along with prior studies on Cxcl10 and Arg1 regulation, provide a starting point
for future studies on Batf2 control of these genes. Batf2 is known to inhibit cJun activity
at the AP-1 consensus by preventing DNA binding95. The murine Cxcl10 promoter
contains an AP-1 consensus site although it is not required for Cxcl10 expression in some
contexts. For example, Cxcl10 was not inducible by the AP-1 activator PMA40,51.
Moreover, AP-1-mediated enhancement contradicts Batf2's known role as an inhibitor of
cJun activity by preventing cJun binding to these sites95. This would not contradict our
results if Batf2 or a Batf2-containing complex recognizes and activates from a consensus
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other than the AP-1 site. In contrast to Cxcl10, Arg1 contains an AP-1 consensus on the
promoter that significantly drives Arg1 expression in macrophages via cFos in response
to macrophage stimulating protein (MSP), and another that drives expression in rat aortic
endothelial cells via cJun/ATF2 in response to thrombin47,169. Thus, Batf2 could inhibit
Arginase 1 expression via the AP-1 consensus site in M2 associated genes.
Another explanation for our results that Batf2 message itself may be preventing
Cxcl10 message degradation through RNA interference. Currently, there is substantial
interest in the importance of small interfering RNAs (siRNAs) in macrophage
polarization170 (siRNA)-mediated gene knockdown is now standard in mice and has
potential for human therapies as well. In consultation with Dr. Penni Black (College of
Pharmacy, University of Kentucky) we asked whether it might be possible that the
presence of Batf2 mRNA itself could regulate Cxcl10. Interestingly, analysis using
miRDB (http://www.mirdb.org) found that miR-296 is both predicted to bind both Cxcl10
message and Batf2 message3. Batf2 may, therefore, sequester and act as a sink for Cxcl0degrading miR-296. This could contribute to the enhanced Cxcl10 mRNA induction in
our cells, especially given the lack of enhancement of any other genes tested. This type
of regulation, by sequestering a regulatory miRNA, presents a novel mechanism of gene
regulation and requires experimental verification. An interesting further experiment
would be to transduce a translation-defective Batf2 mRNA to analyze whether this can
enhance Cxcl10. Future studies could evaluate further the interaction of miR-293 with
Cxcl10 and Batf2, and determine whether this interaction occurs in vivo. This avenue of
research, although departing from studies on Batf2, could lead to a deeper understanding

3
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of the ramifications of overexpression vectors in research, and to helpful therapeutics
using miRNAs to decrease Cxcl10 and therefore decrease T and NK cell influx in
inflammatory diseases.
One approach to confirm a role for Batf2 in enhancing LPS/IFNγ-induced Cxcl10
and suppressing IL-4-induced Arg1 is to knock down Batf2 and analyze the changes in
these genes. Roy et al. successfully knocked down Batf2 and found decreased expression
of an array of M1-associated genes1. This study did not mention Cxcl10 or M2associated genes. We did attempt to create PUER cells constitutively expressing smallhairpin RNAs (shRNAs) to downregulate Batf2 message (see Section 4.3.3 on page 85).
However, transduced cells from two shRNA sequences did not demonstrate decreased
Batf2, and a third did not grow (data not shown). Batf2 is minimally expressed in healthy
PUER cells prior to polarization, but Batf2 levels have not been tested in newly
transduced cells. It is possible that Batf2 suppression by our specific shRNA strategy or
vector system is toxic or growth-prohibitive in PUER cells. This contrasts with the study
by Roy et al. that successfully stably transduced BMDMs with shRNA knocking down
Batf2, and with Batf2’s known role as a growth suppressant in cancer cells1,95. Further
studies could determine the lethality or growth inhibition of Batf2 in PUER cells by
treatments with small interfering RNA treatments, which permit transient knockdowns.

5.4.

Possible cofactor proteins or processes required for Batf2 activity
Surprisingly, constitutively high Batf2 expression in the common myeloid

progenitor stage did not drive multiple M1-associated genes. This approach has
successfully uncovered other master regulators in particular in T cells such as Tbet (Th1
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cells) Foxp3 (Treg), Bcl6 (Tfh), GATA2 (Th2) and RORγt (Th17)14–20. Recently, Roy et
al. confirmed the importance of Batf2 for the expression of multiple M1-associated genes
and repression of multiple M2-associated genes in murine macrophages using
knockdown studies1. While constitutively high Batf2 expression in our study did
enhance Cxcl10 mRNA expression and suppress Arg1 expression, this effect was
moderate and specific to polarized cells. Therefore, Batf2 must be undergoing some level
of post-transcriptional regulation. Transcription factors undergo multiple posttranscriptional regulatory mechanisms (see Table 2.2 in Chapter 1). In particular, the
ubiquitous AP-1 proteins undergo many layers of regulation that provide fine control of
transcription of any given downstream gene. These layers include: presence of a
positively-regulating dimerization partner (although appropriate cofactors may
compensate80); absence of any negatively regulating dimerization partners; non-AP-1
cofactors (if necessary); post-translational modifications, including phosphorylation,
avoidance of SUMOylation, ubiquitination, and redox potential.
Based on our data and previous studies on Batf members, the simplest and most
likely explanation is that a necessary cofactor, also upregulated upon polarization, is
required for Batf2 activity. First, Batf2 enhances Cxcl10 message only in the polarized
state, when the cofactor would also be elevated. Second, Batf proteins exert their known
activities in other immune cells via protein-protein binding, presumably to a coregulatory
factor. Third, knockdown of Batf2 leads to changes in gene expression not seen in
constitutive Batf2 mRNA expression1,76. Cofactor binding also provides a mechanism for
Batf2's cell specific activity and might explain why Batf2 suppresses Cyclin E in cancer
cells and Id2 in CD103+CD11b- cDCs but suppresses neither in our macrophages (Figure
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4.16A). This evidence suggests not only that Batf2 functions in conjunction with a
necessary cofactor, but that Batf2 target genes differ between different cell types. This
could be due to unique cofactors that modify Batf2 activity, or differences in gene
accessibility through chromatin modification. Finally, Batf2 must associate with Irf4/Irf8
in order to compensate for Batf3 deficiency in CD103+CD11b- cDCs development and
function83. This evidence suggests that a cofactor is probably required for Batf2 activity
in macrophages. However, other mechanisms could also be at play. Although Batf2
sequesters cJun away from DNA binding, constitutive expression of excess Batf2 did not
seem to seem to affect cJun activity, since the PUER-Batf2 cells expressed equal amounts
of three genes downstream of cJun in macrophages (Csf1r, IL-1β, Mmp13). This might
be due to post-translational regulation of the Batf2 protein, cJun, or both. Thus, it is
worth considering other mechanisms that might alter the activity of Batf2.
In this study, we began to explore two of the likely mechanisms regulating Batf2
activity by examining the presence, absence, and polarization state association of known
or likely proteins with which Batf2 interacts and that lie downstream of pathways with
which Batf2 interacts. Two categories of interactants tested include a) dimerization
partners and b) ternary complex cofactors.

5.4.1. Dimerization partners
The balance of AP-1 proteins present in a cell may be a key factor regulating
Batf2 activity. Dimerization is necessary for activity of bZIP proteins
ontranscription81,82. Thus, the balance of binding partners present could regulate gene
expression by shifting the predominant heterodimers, which have different transactivation
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activity. Activity of AP1 activity depends on relative ratios of binding partners,
demonstrated in several instances by altering cJun, cFos, Fra2, and Batf
proteins63,73,75,79,83,171,172. cJun/cJun versus cJun/cFos dimers at the Mmp12 and Mmp13
locus provide an example of the importance of correct partners. cJun/cJun heterodimers
repress transcription by recruiting repressors, while cJun/cFos heterodimers activate
transcription through their transactivation domains63. Batf2 itself provides another
example of the influence of relative levels of dimerization partners; low levels of Batf2 in
multiple cancer cell lines allow cJun to bind DNA and activate transcription, while high
expression of Batf2 in those cells sequesters cJun from DNA binding and thereby inhibits
transcription 95,124. Based on these observations, I expect that Batf2 dimerization could
alter activity of a dimerization partner in two ways, depending on interacting proteins or
complexes present. This could occur by 1) assisting a dimerization partner in DNA
binding, directly activating or repressing of the downstream gene, or 2) preventing a
dimerization partner binding to DNA, indirectly preventing activation or derepressing the
downstream gene. The former occurs when Batf2 replaces Batf3 (which heterodimerizes
with cJun, JunB, or JunD) in Batf3-Irf4 ternary complexes driving CD103+CD11b- cDC
development83. The latter occurs when Batf2 sequesters cJun in multiple non-immune
cells, preventing activation of tumor promoting genes 95. Predicting the effect of Batf2
on other AP-1 proteins in macrophages is complicated by the lack of in vivo information
on Batf2's possible dimerization partners. Batf2 binds to cJun in vivo and JunB in
fluorescence resonance energy transfer (FRET) protein-protein binding assays, while
none of the other AP-1 proteins bound Batf2 strongly in FRET assays95,113. cJun and
JunB expression is not associated with M1 polarization, but either could be Batf2 binding
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partners in PUER macrophages since they were both detectable at 48 hours, Batf2
interacts with cJun, and JunB has been implicated previously in macrophage activation
159

. However, the mRNA kinetics does not support a role for either in maintaining long-

term M1 polarization with Batf2, since neither cJun nor JunB increased in M1-polarized
cells at 8 or 48 hours. A previous study on BMDMs observed an increase in cJun at 24
hours after IFNγ polarization109. It is possible that these proteins play a transient role at
early time points in PUER macrophage polarization. Further, cJun message does not
necessarily indicate activity, since post-translational modifications, largely
phosphorylation, commonly regulate cJun activity. Constitutive Batf2 expression even at
the high levels in our PUER-Batf2 cells does not appear to be functionally sequestering
cJun protein, however, as three genes downstream of cJun (Ccne1 [Cyclin E], Csf1r, and
IL-1β) were comparable in control cells and in cells highly and constitutively expressing
Batf2 mRNA.
In contrast to cJun and JunB, cFos, Fra1, Fra2, JunD, Batf, and Batf3 do not
dimerize significantly to Batf2 in large-scale binding assays113. Batf2 is more likely to
interact with these by sequestering another binding partner. Like cJun and JunB,
expression of these factors is not M1-associated at later time points but mRNA levels do
not necessarily correlate with activity. cFos message was elevated transiently hours after
IFNγ polarization in a separate study109, which might suggest a transient role at early time
points, but not long-term maintenance of M1 polarization state. Fra1 was the only factor
increased markedly after M1 polarization, but at 48 hours was detected sporadically in
unpolarized as well as polarized cells, with no correlation to any specific treatment.
Constitutive, high Batf2 expression does not appear to interact with Fra1 activity since
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PUER-Batf2 do not exhibit enhanced expression of Figf, a gene induced by Fra1
transfection in mouse mammary epithelial carcinoma cells146. Therefore, the AP-1
proteins that do not likely dimerize with Batf2 but may be indirectly regulated by Batf2
are not associated with sustained M1 polarization by mRNA analysis, and unlikely to
play a significant role in M1-promoting gene expression changes mediated by Batf2.
Overall, mRNA analysis alone does not suggest either of the putative (JunB) or
verified (cJun) Batf2 dimerization partners as a partner in long-term Batf2 activity.
However, mRNA analysis at 8 and 48 hours alone may not be a good indication of
activity. In spite of a lack of significant message increase, the recent study mentioned
above by Roy et al. reports that the kinetics of JunB most closely match the kinetics of
enriched cJun/cFos consensus-driven message in IFNγ-polarized BMDMs at 2-24 hours,
and the authors suggest that JunB plays a role in polarization 1. This agrees with previous
studies implicating JunB in macrophage polarization159. JunB may well be the most
likely candidate for Batf2 heterodimers, although this raises the question of how it
continues to drive M1-associated gene expression after expression returns to baseline at
later time points. Future studies on the Batf2 activity must analyze the heterodimers that
form in vivo at various time points after polarization and the activity of these
heterodimers.

5.4.2. Ternary complex cofactors
Alongside dimerization, ternary complex formation may also regulate Batf2
activity during M1 polarization. As mentioned above, the simplest interpretation of the
evidence supports the existence of a necessary cofactor for Batf2. Further, precedents in
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other systems suggest that the cofactor is a ternary complex cofactor. Ternary complex
cofactors guide Batf proteins to specific consensus sites in other immune cells including
T cells, B cells, and some subsets of DCs (reviewed in Murphy et al.76). Cofactor
binding also provides a mechanism for Batf2's cell specific activity and might explain
why Batf2 suppresses Cyclin E in cancer cells and Id2 in CD103+CD11b- cDCs but does
neither in macrophages.
Batf provides an example of the manner by which cofactors dictate different roles
for Batf subfamily members in T cells and B cells (reviewed in Li et al.173). In B cells,
Batf is important for class-switch recombination107; while in T cells it is important for
differentiation of various T cell subsets and for expression of various cytokines and
transcription factors such as Rorc, Rora, and Ahr. The major difference between these
two cell lineages is the presence of the Irf4-binding proteins PU.1 and Spib in B cells.
Irf4 monomers have autoinhibitory activity preventing DNA binding at the concentrations
found in T and B cells, but PU.1, Spib, and Batf bind and disinhibit Irf4. In B cells, Irf4
binds PU.1 or Spib, and guides the complex to ETS-Irf consensus elements (EICEs) (5'GGAAnnGAAA-3'), leading to gene expression. T cells, however, lack these factors so
Irf4 binds instead to Batf-cJun heterodimers, and the complex subsequently binds AP-1Irf composite elements (AICEs) (TGAnTCAnnnnGAAA or GAAATGAnTCA). AICE
binding by Batf-cJun-Irf4 complexes also occurs in B cells, but to a much lesser extent,
possibly due to relative abundance of each complex, or possibly due to another factor yet
to be identified. Thus, Batf2 activity in M1-polarized macrophages likely depends on the
unique cofactor repertoire in these cells relative to other cells that use Batf2 and other
Batfs.
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Irf family members are candidates for being Batf2 cofactors in PUER cells. Irf1
and Irf7 are most likely to have a role in long-term polarization based on mRNA
expression analysis, since both are elevated during sustained M1 polarization. Irf8 is
associated with early M1 polarization, so potentially plays a role during early shift from
resting to M1. Previous studies suggest that Irf9 and Irf5 induce M1-associated gene
expression, but Irf9 is not M1-associated in our study and Irf5 is not expressed. Irf2, Irf3,
and Irf4 are not likely to support M1 polarization. Irf2 was constitutively expressed, Irf3
was somewhat decreased upon M1 polarization, and. Irf4 was associated with sustained
M2 polarization. Prior studies do not report roles for either of them in M1 polarization

5.4.2.1. Irf4 and Irf8: Hematopoietic-specific known Batf subfamily cofactors
Irf4 and Irf8 are hematopoietic-specific Irf family members that bind with Batfsubfamily proteins, including Batf2, and are therefore candidates for Batf2 cofactors in
macrophages. Batf-Irf4/Irf8 complexes are critical for development of other immune
cells by driving transcription at AICEs. Although no DNA-binding assays have been
published demonstrating Batf2-Irf4/Irf8 complexes binding to AICE elements, previous
data suggests Batf2 does have transactivation activity through DNA binding. For
example, the protein-protein interaction domain (the leucine zipper) allows Batf2 to
functionally compensate for Batf3 deficiency in CD103+CD11b-cDC/CD8α+ cDC
development. This suggests that it either activates gene expression from AICEs or an
alternative site located in most of the same promoter or enhancer regions83. Therefore,
Irf4 has the potential to drive gene expression in PUER cells in concert with Batf2.
However, Irf4 is M2-associated in our study and in previous reports, acting as an
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antagonist in TLR signaling4,8. Irf4 has known activity in macrophages both at the
interferon stimulated response element (ISRE) by interacting with other Irf family
members as well as at the Ets/Irf composite elements (EICE) by interacting with PU.1,
but has no activity alone due to an autoinhibitory domain174–177. In contrast, Irf8 is
associated with M1 polarization in our study at earlier time points but expressed equally
in unpolarized and polarized PUER macrophages at 48 hours. Irf8 is induced by LPS
and/or IFNγ and in turn induces M1-specific cytokines including IL-1β, TNFα, IL-12,
IL-6, and iNOS 178. Irf8 contains a similar protein-binding domain to Irf4, and also
interacts with other Irf family members to transactivate at ISRE or with PU.1 at EICE175–
177,177

. Notably, transactivation tends to be weaker than Irf4, and it seems to lack

transactivation activity alone179,180. If that is the case, then how Batf-Irf8 complexes
activate transcription requires clarification, since Batf also lacks transactivation activity
on its own83,180. Unlike Irf4, Irf8 is IFNγ -inducible and associated with M1-polarized
macrophages181. It is important for FcgR1, LPS/IFNγ-induced IL-12p40, and iNOS, as
well as directing myeloid progenitors to the macrophage instead of granulocyte
lineage182. In vivo Irf8 is important for proper development and response of macrophage
populations in bone marrow183. In PUER, we find Irf8 expressed under all conditions at
48 hours, but it is M1-associated at early timepoints. Irf8 may be important for initial
polarization, and then sustained expression continues to contribute to maintenance of M1associated gene expression. Therefore, although Irf4 is not M1-associated, Irf8 is an
early M1-associated Batf-subfamily cofactor that may be a cofactor for Batf2.
Overall, although initially promising, the evidence does not suggest a role for the
hematopoietic Irf family members Irf4 and Irf8 as Batf2 cofactors with roles in sustaining
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M1 macrophage polarization. Batf2 and Irf4 or Irf8 expression do not coincide, since
CMPs, mature macrophages, and M2-polarized macrophages lack Batf2, while M1polarized macrophages cells lack Irf4 and do not upregulate Irf8 throughout sustained
polarization. Moreover, previous studies have detected Irf8 significantly upregulated at 2
hours after IFNγ polarization, so it may be a factor at earlier time points, but Batf2 must
interact with another cofactor for activity during sustained M1 polarization109.

5.4.2.2. M1-associated Irf1 and Irf7 may interact with Batf2 and play a role in
M1 polarization
Although not supported as a Batf/Irf cofactor by the initial studies described
above, Irf1 has recently become a likely candidate for driving gene expression in concert
with Batf2 in macrophages. Recent studies demonstrate that Irf1 interacts with Batf2 in
M1-polarized macrophages. Moreover, Irf1 is induced by IFNγ and TLR stimulation,
strongly and consistently associates with M1 polarization, and is known to act in concert
with cofactors including NF-кB and cJun1,4,109,184. Roy et al made the discovery that Irf1
binds to Batf2 in M1-polarized macrophages, and further demonstrated that loss of Irf1
recapitulates many of the same changes as loss of Batf21. Irf1 still lacks confirmation as
a necessary cofactor of Batf2 in macrophages, however, and has some important
differences with known Batf subfamily cofactors Irf4 and Irf8. Irf1 binds to ISREs and
drives gene expression without the necessity of a Batf member, while Batf-Irf complexes
were originally found because Irf4 and Irf8 are necessary for cell development or
function but do not drive gene expression alone. In dendritic cells, Irf4/8 guides the Batfs
preferentially from the conventional AP-1 consensus sequence to an AP-1/Irf consensus
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element, termed the AICE83,86. Glasmacher et al's study defining the AICE did explore a
role for Irf1 along with Irf3, since they are structurally similar to Irf4 and Irf8. They
found that these factors did not assemble on AICE sites with Batf-JunB complexes as did
Irf4 and Irf8. Moreover, Irf1 is also found in B cells but Batf2 cannot compensate for
Batf in these cells, suggesting Batf2-Irf1 complexes do not function like Batf-Irf4/8
complexes83. This evidence taken together suggests that Batf-Irf1 complexes do not have
the same activity as Batf-Irf4/8 complexes.
However, if Irf1 can bind ISREs on its own and does not bind to AICEs in
conjunction with Batfs, why does knockdown of Irf1 and Batf2 result in similar
transcriptional profiles? One possibility is that Batf2-Irf1 complexes may recognize an
alternative consensus. In theory, this alternative consensus might be present in the
critical promoters for DC development and macrophage polarization (where Batf2 has
activity and interacts with Irfs), but not critical genes in T cell development and function
and B cell activation. There may also be another cofactor required to stabilize Batf2-Irf1
complexes that is not present in T and B cells.
Our finding that Irf1 increases selectively in M1-polarized macrophages contrasts
with other reports of Irf1 increased in M2-polarized cells, but agrees with Irf1's consistent
association with M1 polarization4,109. Irf1 could drive M1 associated genes in M1polarized but not M2-polarized cells if Batf2 mediates Irf1's effects, or if M1-specific
post-translational modification activates Irf1184. Future studies must examine the
promoters of genes for Batf-Irf1 consensus binding, as well as exploring other potential
cofactors that may be part of a larger transcriptional activation complex.
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Irf7 is also M1-associated at 48 hours in our PUER macrophages, and may have
relevance to M1 polarization. Unlike Irf1, Irf4, and Irf8, Irf7 is not specific to
hematopoietic cells, but nonetheless is involved in macrophage differentiation and type I
interferon induction, as well as M1-like polarization in microarray 4,150. Interestingly,
Irf7 basal expression is increased in PUER cell constitutively expressing Batf2. Irf7interacting pathways would provide a reasonable start for future studies examining Batf2interacting pathways.

5.4.2.3. M1-associated Irf5 and Irf9, and M1-unassociated Irf2 and Irf3
Irf5 and Irf9 both are notable as previously proposed master regulators of M1
polarization and mediators of LPS-activated transcription4,70. However, Irf5 was not
detected in our PUER macrophages in resting or polarized states, suggesting this factor is
dispensable for macrophage polarization. In our study, Irf9 was not exclusive to M1
state. Irf9 might still have M1-promoting roles under some conditions by propagating
type 1 IFN signaling and inducing Cxcl10 in concert with Stat1 homodimers185. It might
also be active selectively in M1-polarized macrophages without a change in mRNA
expression by post-translational regulation or cofactor interaction.
Based on the literature, other ubiquitously-expressed Irf family members have
activity in macrophages, but are unlikely to serve a broad role. Irf2 and Irf3 were
constitutively expressed under all conditions. Irf2 is not a likely contributor to M1
polarization because expression is not M1-associated and because it can inhibit Irf1101,186.
Irf3 may promote either M1- or M2- associated cytokines. On the one hand, Irf3 induces
Ccl5; on the other, Irf3 suppresses IL-1A and IL-23187,188. These Irf family members
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provide examples of a minor importance of Irf family members and Irf-containing
complexes inducing macrophage genes, but other Irf family members are more likely to
play a role
In summary, studies on the Batf subfamily suggest that Irf family members
present the most likely candidates for being cofactors for Batf2. Irf1, Irf4, and Irf8 are
established Batf2-interacting factors, but only Irf1 is strongly M1-associated.
Batf2manipulation by itself may fail to alter genes in our cells simply due to limited
availability of Irf1 or another Irf. Still, Batf2's interaction with a cofactor or multiple
cofactors has not been definitively determined. Batf2-Irf1 has not yet been evaluated for
DNA-binding. Batf2's putative cofactor remains to be definitively determined. Future
studies should examine complexes formed with Batf2 in macrophages. Knock-out and
restoration methods could examine the ability of each of these complexes to drive
macrophage polarization.

5.4.3. Other regulatory mechanisms: Chromatin state and post-translational
modification
Two more major regulatory mechanisms that likely regulate Batf2 activity merit
some discussion: epigenetic modifications and post-translational modification.
Chromatin modification regulates gene accessibility to multiple transcription factors,
while post-translational modification regulate individual transcription factors.
Phosphorylation is of particular importance to AP-1 proteins64–66,66,145. Other regulatory
modifications for AP (reviewed by Foletta et al.74,77) include SUMOylation of cFos,
ubiquitination of cJun in Xia et al., and oxidation or reduction of cJun77,91–93. Both
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chromatin state and post-translational mechanisms likely mediate to a major extent some
of the differences seen in Batf2 activity in various cell types.
Chromatin structure is an important determinant of cell specificity that presents an
avenue of research for future studies on the differences in Batf2's activity in macrophages
relative to other cells. Chromatin structure refers to the modifications and tightness of
the collective bundle of DNA-wrapped protein histones called nucleosomes. Remodeling
enzymes modify DNA or histones, tightening or loosening interactions of DNA with the
proteins. Tightening blocks access to transcription factors, and loosing permits access
and transcription. The pattern of closed and open chromatin is to some extent determined
by lineage-specific 'pioneer factors' that can access regions inaccessible to other
transcription factors and recruit remodeling enzymes that open specific regions. This
results in linage-specific gene, reviewed in Smale et al.6. Additionally, external stimuli
can to some extent cause remodeling, providing a means of environment-specific gene
expression. In macrophages, Runx1 transiently permits PU.1 transcription. Macrophage
lineage-determining pioneer factor PU.1 along with Runx1 mediate gene accessibility by
facilitating H2K4me1 deposition via remodeling enzymes expression10,11,68,69. Thus,
chromatin structuring during development by factors like PU.1 may open up different
sets of enhancers and promoters to Batf2 in macrophages, CD103+CD11b-cDCs, and
cancer cell lines. It is also interesting to note that Hdac proteins also seem to be playing
roles cell differentiation and our lab has strong evidence that Hdac9 is important for the
M2 state (McGillis, unpublished data). Thus interaction with chromatin modifying
proteins and complexes may be another potential binding partner for Batf2 mediated
regulatory activities.
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Not only may lineage-specific epigenetic modifications mediate differences in
Batf2-induced or suppressed genes between different cells, it may also contribute to the
differences in Batf2 expression in response to LPS stimulation seen in PUER cells
compared to bone-marrow derived macrophages in the Roy et al study1. LPS stimulation
of PUER does not induce Batf2 expression, while Roy et al reported that LPS
synergistically with IFNγ as well as independently induces Batf2 expression in murine
BMDMs. Green and Kerr et al. reported that epigenetic modifications control LPSresponsive genes, so primary macrophages may be primed in vivo or during isolation to
express inflammatory genes189. PUER macrophages, in contrast, undergo minimal
epigenetic programming compared to primary cells derived from animals. Gene
expression in PUER cells may more closely reflect a truly naïve macrophage seeing
polarizing stimuli for the first time, whereas gene expression in primary cells may be
partially due to epigenetic programming from stimuli in vivo, during isolation, or during
growth in vitro. On the other hand, PUER notably contain a modified PU.1 element:
PU.1 attached to an estrogen receptor (ER) regulatory domain190. This artificial PU.1
may differ in remodeling ability; however, there has been no reason to suspect significant
differences. PUER macrophages have been successfully used for prior studies and found
to exhibit similar gene expression as macrophages from other models 129,132,191.
Therefore, Batf2 expression in other studies in response to LPS may result from external
insults in vivo or during isolation. Further studies on LPS responsiveness of Batf2 are
required to further define the regulatory pathways controlling Batf2 expression.
Post-translational modifications including phosphorylation and SUMOylation
strongly regulate AP-1 family members77. M1-specific activating modifications may also
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partially explain Batf2's M1-specific effects. cJun and cFos must undergo appropriate
phosphorylation at specific residues for transactivation activity64–66,144,145. The antibody
to Batf2 we used is a polyclonal antibody, raised to a peptide from human Batf2, and so
the phosphorylation state of Batf2 remains unknown. AP-1 factors are also regulated
through ubiquitination and SUMOylation90,91. These modifications tend to lead to
degradation and thus reduce rather than enhance activity, and so are unlikely to mediate
Batf2's M1-specific effects. Redox state also mediates cJun92,93. This regulation provides
a mechanism for these proteins to mediate stress responses. Batf2, in contrast, is not
associated with stress response, so is less likely to be influenced by oxidation. Of the
post-translational modifications, phosphorylation state most likely regulates Batf2
function. Phosphorylation sites and their activities should be further explored in future
studies to better understand post-translational regulatory mechanisms of Batf2 activity.
In summary, Batf2 likely undergoes regulation by a number of mechanisms
including through cell-specific chromatin state and post-translational modifications.
Thus, in contrast to our initial simple hypothesis, the mechanisms by which Batf2
influences macrophage functions is complex and will require in-depth mechanistic
studies to fully understand its role in M1 macrophages. Our study did not explore these
mechanisms, but they offer promising avenues of future research. Chromatin states differ
between cell types and may mediate part of Batf2's cell specificity. PUER cells offer a
good model for future Batf2 studies since they are relatively free of in vivo epigenetic
modification. Phosphorylation very likely mediates Batf2 activity. Future studies could
determine activating and repressing phosphorylation of Batf2, and the pathways
mediating both.
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5.5.

Batf2 as a therapeutic target
One reason to define master transcription factors in inflammation is to manipulate

them therapeutically. However, this study suggests that the effect of constitutively Batf2
expression alone such as could be delivered through adenovirus treatments may not
produce changes robust enough for clinical benefit. For Cxcl10 in this study, the
moderate enhancement of message failed to significantly increase protein levels
(p=0.204). Functional studies are required to determine whether constitutive Batf2
expression alone has therapeutic applications. However, simultaneously inducing Batf2
and the limiting factor would likely induce more M1-specific genes than we detected in
our study, including the genes inhibited by Batf2 knockdown. This remains to be tested.
With our current knowledge, we can speculate that in vivo transduction of Batf2 with the
required factor might enhance Cxcl10 significantly and suppress Il4-induced Arg1
significantly.
On the other hand, if our modified hypothesis is correct and Batf2 interacts with a
cofactor, Batf2 knockdown with siRNA may prove effective for modulating M1
polarization. Roy et al.'s knockdown study demonstrating broad suppression of M1associated genes supports this possibility1,108. Further support of the use of Batf2
suppression in inflammatory conditions arises from Tussiwand et al.’s report of Batf2-/mice, which display abnormal phenotype after inducing IFNγ and IL-12-induced immune
function after T. gondii infection83. These mice possessed both fewer lung-resident
CD103+CD11b- cDCs and CD103-CD11b- macrophages after infection, but not during
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homeostasis, suggesting that Batf2 knockdown might have minimal off-target effects
when used as a target for excess inflammation. This study did not report macrophage
responses in depth, so further analyses are required to define the macrophage
inflammatory phenotype in Batf2-/- mice.
In spite of Batf2’s associating with inflammatory stimuli IFN and LPS in multiple
studies, it is possible that Batf2 plays a role in a response that occurs in IFNγ/LPSactivated M1 as well as some subsets of M2. Macrophages in vivo exist on a spectrum,
so it is indeed likely that Batf2 is expressed in in vivo macrophages that have seen M2associated stimuli such as IL-4. Batf2’s expression in our BMDMs and IL-10 activated
macrophages support this, as well as the highly variable expression of Batf2 isolated
human cells and tissues in cancer studies115,116,119,120. As further studies elucidate the
functions of Batf2, the significance of Batf2 expression in vivo will become clearer.
Batf2-mediated manipulation of Cxcl10 would most likely impact local
inflammatory cell influx. Cxcl10, enhanced by Batf2 in our study, binds to CXCR3 that
is found mainly on polarized Th1 cells and NK cells but also on macrophages, microglia,
and dendritic cells128,192. Cxcl10 activates chemotaxis to attract cells to the origin of
infection. To a lesser extent, it is associated with T cell development, T cell function, T
cell adhesion to endothelial cells, NK cell cytolysis, angiogenesis inhibition, tumor
growth inhibition, mitogenesis and chemotaxis on smooth muscle cells, inhibition of
development of bone marrow progenitor cells, and apoptosis and cell growth 51,193.
Batf2-enhanced Cxcl10 production could therefore contribute to immune cell influx and
function at sites of inflammation, and more rapid responses to infection. Conversely,
Batf2 suppression could reduce immune cell influx and function, and mitigate damaging
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inappropriate inflammatory responses. This might be useful in cases of high-pain
fibromyalgia and common variable immune deficiency (CVID), where Batf2 is highly
expressed but inflammation is inappropriate123,167.
Argininase 1 (Arg1), in contrast to Cxcl10, generally associates with antiinflammatory macrophages. Arginase activity shuttles L-arginine into the pathway for
ornithine, a cell growth promoter and building block for tissue repair, and urea54, away
from its potential conversion to the inflammatory nitric oxide by iNOS in M1-polarized
cells. Thus, it not only provides metabolites for growth and repair but also actively
counters inflammatory responses. Arginase competes with iNOS for arginine, and low
arginine pools do indeed decrease iNOS activity as well as arginase activity. During
infection, arginase prevents excess inflammation and fibrosis in the case of some
pathogens such as S. mansonii56. Batf2 transduction with the limiting cofactor may
suppress Arg1 induction and thus increase inflammation by blocking the shunting of
arginase into alternative pathways, allowing its use in the iNOS pathway. Alternatively,
Batf2 knockdown could enhance Arginase 1 activity, promoting tissue repair with
ornithine production and decreasing tissue damage from nitric oxide production. Thus,
manipulation of Batf2 may have therapeutic potential.

5.6.

Conclusions
Batf2, a bZIP transcription factor in the AP-1 family of proteins, is highly and

rapidly upregulated in LPS/IFNγ-polarized macrophages. This dissertation initially
hypothesized that Batf2 was a master regulator of LPS/ IFNγ-stimulated (M1)
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polarization, driving expression of several M1-associated genes. However, constitutive
high Batf2 expression did not induce or enhance expression of most of the M1-associated
genes tested. Batf2 also did not broadly suppress IL-4-induced (M2-associated) genes,
nor enhance or suppress potential downstream genes based on Batf2 activity in other cell
types. Batf2 did mildly enhance LPS/IFNγ-induced M1 chemokine Cxcl10 mRNA and
mildly suppress IL-4-induced M2 enzyme Arginase 1 mRNA expression. Based on this
data and previous Batf2 studies, Batf2 likely requires a necessary cofactor for its role in
M1 macrophages, which remains largely undefined. An Irf family members, especially
Irf1, is one of the most likely candidates for a Batf2 interacting factor. More research is
needed to determine the factors that interact with Batf2. Clearly the evidence from my
studies and others suggest that Batf2 plays a role in M1 polarization. Defining the
mechanisms of Batf2 induction and activity may offer in the future ways to approach
therapies targeting macrophage inflammatory responses.
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